<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN"  "JATS-archivearticle1-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.2"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">73245</article-id><article-id pub-id-type="doi">10.7554/eLife.73245</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Biochemistry and Chemical Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Cancer Biology</subject></subj-group></article-categories><title-group><article-title>Metabolic requirement for GOT2 in pancreatic cancer depends on environmental context</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-252734"><name><surname>Kerk</surname><given-names>Samuel A</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-9786-2245</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund3"/><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-252735"><name><surname>Lin</surname><given-names>Lin</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-252736"><name><surname>Myers</surname><given-names>Amy L</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-284227"><name><surname>Sutton</surname><given-names>Damien J</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-252757"><name><surname>Andren</surname><given-names>Anthony</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-252744"><name><surname>Sajjakulnukit</surname><given-names>Peter</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-115879"><name><surname>Zhang</surname><given-names>Li</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-85949"><name><surname>Zhang</surname><given-names>Yaqing</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="fund16"/><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-285845"><name><surname>Jiménez</surname><given-names>Jennifer A</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund13"/><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-252745"><name><surname>Nelson</surname><given-names>Barbara S</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund14"/><xref ref-type="other" rid="fund15"/><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-252746"><name><surname>Chen</surname><given-names>Brandon</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-252747"><name><surname>Robinson</surname><given-names>Anthony</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con12"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-252748"><name><surname>Thurston</surname><given-names>Galloway</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con13"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-252749"><name><surname>Kemp</surname><given-names>Samantha B</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="other" rid="fund17"/><xref ref-type="other" rid="fund18"/><xref ref-type="fn" rid="con14"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-252750"><name><surname>Steele</surname><given-names>Nina G</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="other" rid="fund15"/><xref ref-type="other" rid="fund19"/><xref ref-type="fn" rid="con15"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-252751"><name><surname>Hoffman</surname><given-names>Megan T</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con16"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-252752"><name><surname>Wen</surname><given-names>Hui-Ju</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con17"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-252753"><name><surname>Long</surname><given-names>Daniel</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con18"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-252754"><name><surname>Ackenhusen</surname><given-names>Sarah E</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="con19"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-252755"><name><surname>Ramos</surname><given-names>Johanna</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con20"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-252756"><name><surname>Gao</surname><given-names>Xiaohua</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con21"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-252758"><name><surname>Nwosu</surname><given-names>Zeribe C</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con22"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-252759"><name><surname>Galban</surname><given-names>Stefanie</given-names></name><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="fn" rid="con23"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-252760"><name><surname>Halbrook</surname><given-names>Christopher J</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund20"/><xref ref-type="other" rid="fund21"/><xref ref-type="fn" rid="con24"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-48368"><name><surname>Lombard</surname><given-names>David B</given-names></name><xref ref-type="aff" rid="aff9">9</xref><xref ref-type="other" rid="fund22"/><xref ref-type="other" rid="fund23"/><xref ref-type="fn" rid="con25"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-252761"><name><surname>Piwnica-Worms</surname><given-names>David R</given-names></name><xref ref-type="aff" rid="aff10">10</xref><xref ref-type="fn" rid="con26"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-104811"><name><surname>Ying</surname><given-names>Haoqiang</given-names></name><xref ref-type="aff" rid="aff11">11</xref><xref ref-type="fn" rid="con27"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-14008"><name><surname>Pasca di Magliano</surname><given-names>Marina</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-9632-9035</contrib-id><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="fn" rid="con28"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-85968"><name><surname>Crawford</surname><given-names>Howard C</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="fn" rid="con29"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-44774"><name><surname>Shah</surname><given-names>Yatrik M</given-names></name><email>shahy@umich.edu</email><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="aff" rid="aff12">12</xref><xref ref-type="other" rid="fund4"/><xref ref-type="other" rid="fund5"/><xref ref-type="fn" rid="con30"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" corresp="yes" id="author-284938"><name><surname>Lyssiotis</surname><given-names>Costas A</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-9309-6141</contrib-id><email>clyssiot@umich.edu</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="aff" rid="aff12">12</xref><xref ref-type="other" rid="fund6"/><xref ref-type="other" rid="fund7"/><xref ref-type="other" rid="fund9"/><xref ref-type="other" rid="fund10"/><xref ref-type="other" rid="fund11"/><xref ref-type="other" rid="fund12"/><xref ref-type="other" rid="fund24"/><xref ref-type="other" rid="fund8"/><xref ref-type="fn" rid="con31"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00jmfr291</institution-id><institution>Doctoral Program in Cancer Biology, University of Michigan-Ann Arbor</institution></institution-wrap><addr-line><named-content content-type="city">Ann Arbor</named-content></addr-line><country>United States</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00jmfr291</institution-id><institution>Department of Molecular and Integrative Physiology, University of Michigan-Ann Arbor</institution></institution-wrap><addr-line><named-content content-type="city">Ann Arbor</named-content></addr-line><country>United States</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00jmfr291</institution-id><institution>Department of Surgery, University of Michigan-Ann Arbor</institution></institution-wrap><addr-line><named-content content-type="city">Ann Arbor</named-content></addr-line><country>United States</country></aff><aff id="aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00jmfr291</institution-id><institution>Department of Cell and Developmental Biology, University of Michigan-Ann Arbor</institution></institution-wrap><addr-line><named-content content-type="city">Ann Arbor</named-content></addr-line><country>United States</country></aff><aff id="aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00jmfr291</institution-id><institution>Molecular and Cellular Pathology Graduate Program, University of Michigan-Ann Arbor</institution></institution-wrap><addr-line><named-content content-type="city">Ann Arbor</named-content></addr-line><country>United States</country></aff><aff id="aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00jmfr291</institution-id><institution>Program in Chemical Biology, University of Michigan-Ann Arbor</institution></institution-wrap><addr-line><named-content content-type="city">Ann Arbor</named-content></addr-line><country>United States</country></aff><aff id="aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00jmfr291</institution-id><institution>Department of Radiology, University of Michigan</institution></institution-wrap><addr-line><named-content content-type="city">Ann Arbor</named-content></addr-line><country>United States</country></aff><aff id="aff8"><label>8</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00jmfr291</institution-id><institution>Rogel Cancer Center, University of Michigan</institution></institution-wrap><addr-line><named-content content-type="city">Ann Arbor</named-content></addr-line><country>United States</country></aff><aff id="aff9"><label>9</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00jmfr291</institution-id><institution>Department of Pathology and Institute of Gerontology, University of Michigan</institution></institution-wrap><addr-line><named-content content-type="city">Ann Arbor</named-content></addr-line><country>United States</country></aff><aff id="aff10"><label>10</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04twxam07</institution-id><institution>Department of Cancer Systems Imaging, University of Texas MD Anderson Cancer Center</institution></institution-wrap><addr-line><named-content content-type="city">Houston</named-content></addr-line><country>United States</country></aff><aff id="aff11"><label>11</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04twxam07</institution-id><institution>Department of Molecular and Cellular Oncology, University of Texas MD Anderson Cancer Center</institution></institution-wrap><addr-line><named-content content-type="city">Houston</named-content></addr-line><country>United States</country></aff><aff id="aff12"><label>12</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00jmfr291</institution-id><institution>Department of Internal Medicine, Division of Gastroenterology and Hepatology, University of Michigan</institution></institution-wrap><addr-line><named-content content-type="city">Ann Arbor</named-content></addr-line><country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Finley</surname><given-names>Lydia WS</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02yrq0923</institution-id><institution>Memorial Sloan Kettering Cancer Center</institution></institution-wrap><country>United States</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>White</surname><given-names>Richard M</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02yrq0923</institution-id><institution>Memorial Sloan Kettering Cancer Center</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><pub-date publication-format="electronic" date-type="publication"><day>11</day><month>07</month><year>2022</year></pub-date><pub-date pub-type="collection"><year>2022</year></pub-date><volume>11</volume><elocation-id>e73245</elocation-id><history><date date-type="received" iso-8601-date="2021-08-21"><day>21</day><month>08</month><year>2021</year></date><date date-type="accepted" iso-8601-date="2022-07-09"><day>09</day><month>07</month><year>2022</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint at .</event-desc><date date-type="preprint" iso-8601-date="2020-08-07"><day>07</day><month>08</month><year>2020</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2020.08.07.238766"/></event></pub-history><permissions><copyright-statement>© 2022, Kerk et al</copyright-statement><copyright-year>2022</copyright-year><copyright-holder>Kerk et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-73245-v2.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-73245-figures-v2.pdf"/><abstract><p>Mitochondrial glutamate-oxaloacetate transaminase 2 (GOT2) is part of the malate-aspartate shuttle, a mechanism by which cells transfer reducing equivalents from the cytosol to the mitochondria. GOT2 is a key component of mutant KRAS (KRAS*)-mediated rewiring of glutamine metabolism in pancreatic ductal adenocarcinoma (PDA). Here, we demonstrate that the loss of GOT2 disturbs redox homeostasis and halts proliferation of PDA cells in vitro. GOT2 knockdown (KD) in PDA cell lines in vitro induced NADH accumulation, decreased Asp and α-ketoglutarate (αKG) production, stalled glycolysis, disrupted the TCA cycle, and impaired proliferation. Oxidizing NADH through chemical or genetic means resolved the redox imbalance induced by GOT2 KD, permitting sustained proliferation. Despite a strong in vitro inhibitory phenotype, loss of GOT2 had no effect on tumor growth in xenograft PDA or autochthonous mouse models. We show that cancer-associated fibroblasts (CAFs), a major component of the pancreatic tumor microenvironment (TME), release the redox active metabolite pyruvate, and culturing GOT2 KD cells in CAF conditioned media (CM) rescued proliferation in vitro. Furthermore, blocking pyruvate import or pyruvate-to-lactate reduction prevented rescue of GOT2 KD in vitro by exogenous pyruvate or CAF CM. However, these interventions failed to sensitize xenografts to GOT2 KD in vivo, demonstrating the remarkable plasticity and differential metabolism deployed by PDA cells in vitro and in vivo. This emphasizes how the environmental context of distinct pre-clinical models impacts both cell-intrinsic metabolic rewiring and metabolic crosstalk with the TME.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>tumor metabolism</kwd><kwd>pancreatic cancer</kwd><kwd>tumor microenvironment</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000060</institution-id><institution>National Institute of Allergy and Infectious Diseases</institution></institution-wrap></funding-source><award-id>T32AI007413</award-id><principal-award-recipient><name><surname>Kerk</surname><given-names>Samuel A</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000054</institution-id><institution>National Cancer Institute</institution></institution-wrap></funding-source><award-id>F31CA24745701</award-id><principal-award-recipient><name><surname>Kerk</surname><given-names>Samuel A</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000054</institution-id><institution>National Cancer Institute</institution></institution-wrap></funding-source><award-id>1F99CA264414-01</award-id><principal-award-recipient><name><surname>Kerk</surname><given-names>Samuel A</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000054</institution-id><institution>National Cancer Institute</institution></institution-wrap></funding-source><award-id>CA148828</award-id><principal-award-recipient><name><surname>Shah</surname><given-names>Yatrik M</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000054</institution-id><institution>National Cancer Institute</institution></institution-wrap></funding-source><award-id>CA245546</award-id><principal-award-recipient><name><surname>Shah</surname><given-names>Yatrik M</given-names></name></principal-award-recipient></award-group><award-group id="fund6"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100001784</institution-id><institution>Pancreatic Cancer Action Network</institution></institution-wrap></funding-source><award-id>13-70-25-LYSS</award-id><principal-award-recipient><name><surname>Lyssiotis</surname><given-names>Costas A</given-names></name></principal-award-recipient></award-group><award-group id="fund7"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100001368</institution-id><institution>V Foundation for Cancer Research</institution></institution-wrap></funding-source><award-id>V2016-009</award-id><principal-award-recipient><name><surname>Lyssiotis</surname><given-names>Costas A</given-names></name></principal-award-recipient></award-group><award-group id="fund8"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100011034</institution-id><institution>Sidney Kimmel Foundation</institution></institution-wrap></funding-source><award-id>SKF-16-005</award-id><principal-award-recipient><name><surname>Lyssiotis</surname><given-names>Costas A</given-names></name></principal-award-recipient></award-group><award-group id="fund9"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000043</institution-id><institution>American Association for Cancer Research</institution></institution-wrap></funding-source><award-id>17-20-01-LYSS</award-id><principal-award-recipient><name><surname>Lyssiotis</surname><given-names>Costas A</given-names></name></principal-award-recipient></award-group><award-group id="fund10"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000054</institution-id><institution>National Cancer Institute</institution></institution-wrap></funding-source><award-id>R37CA237421</award-id><principal-award-recipient><name><surname>Lyssiotis</surname><given-names>Costas A</given-names></name></principal-award-recipient></award-group><award-group id="fund11"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000054</institution-id><institution>National Cancer Institute</institution></institution-wrap></funding-source><award-id>R01CA248160</award-id><principal-award-recipient><name><surname>Lyssiotis</surname><given-names>Costas A</given-names></name></principal-award-recipient></award-group><award-group id="fund12"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000054</institution-id><institution>National Cancer Institute</institution></institution-wrap></funding-source><award-id>R01CA244931</award-id><principal-award-recipient><name><surname>Lyssiotis</surname><given-names>Costas A</given-names></name></principal-award-recipient></award-group><award-group id="fund13"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000054</institution-id><institution>National Cancer Institute</institution></institution-wrap></funding-source><award-id>F31CA254079</award-id><principal-award-recipient><name><surname>Jiménez</surname><given-names>Jennifer A</given-names></name></principal-award-recipient></award-group><award-group id="fund14"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000062</institution-id><institution>National Institute of Diabetes and Digestive and Kidney Diseases</institution></institution-wrap></funding-source><award-id>T32-DK094775</award-id><principal-award-recipient><name><surname>Nelson</surname><given-names>Barbara S</given-names></name></principal-award-recipient></award-group><award-group id="fund15"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000054</institution-id><institution>National Cancer Institute</institution></institution-wrap></funding-source><award-id>T32-CA009676</award-id><principal-award-recipient><name><surname>Nelson</surname><given-names>Barbara S</given-names></name><name><surname>Steele</surname><given-names>Nina G</given-names></name></principal-award-recipient></award-group><award-group id="fund16"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000054</institution-id><institution>National Cancer Institute</institution></institution-wrap></funding-source><award-id>R50 CA232985</award-id><principal-award-recipient><name><surname>Zhang</surname><given-names>Yaqing</given-names></name></principal-award-recipient></award-group><award-group id="fund17"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000057</institution-id><institution>National Institute of General Medical Sciences</institution></institution-wrap></funding-source><award-id>T32-GM11390</award-id><principal-award-recipient><name><surname>Kemp</surname><given-names>Samantha B</given-names></name></principal-award-recipient></award-group><award-group id="fund18"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000054</institution-id><institution>National Cancer Institute</institution></institution-wrap></funding-source><award-id>F31-CA247076</award-id><principal-award-recipient><name><surname>Kemp</surname><given-names>Samantha B</given-names></name></principal-award-recipient></award-group><award-group id="fund19"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000048</institution-id><institution>American Cancer Society</institution></institution-wrap></funding-source><award-id>PF-19-096-01</award-id><principal-award-recipient><name><surname>Steele</surname><given-names>Nina G</given-names></name></principal-award-recipient></award-group><award-group id="fund20"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000054</institution-id><institution>National Cancer Institute</institution></institution-wrap></funding-source><award-id>K99CA241357</award-id><principal-award-recipient><name><surname>Halbrook</surname><given-names>Christopher J</given-names></name></principal-award-recipient></award-group><award-group id="fund21"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000062</institution-id><institution>National Institute of Diabetes and Digestive and Kidney Diseases</institution></institution-wrap></funding-source><award-id>P30DK034933</award-id><principal-award-recipient><name><surname>Halbrook</surname><given-names>Christopher J</given-names></name></principal-award-recipient></award-group><award-group id="fund22"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000057</institution-id><institution>National Institute of General Medical Sciences</institution></institution-wrap></funding-source><award-id>R01GM101171</award-id><principal-award-recipient><name><surname>Lombard</surname><given-names>David B</given-names></name></principal-award-recipient></award-group><award-group id="fund23"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000054</institution-id><institution>National Cancer Institute</institution></institution-wrap></funding-source><award-id>CA253986</award-id><principal-award-recipient><name><surname>Lombard</surname><given-names>David B</given-names></name></principal-award-recipient></award-group><award-group id="fund24"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100003645</institution-id><institution>National Cancer Center</institution></institution-wrap></funding-source><award-id>P30 CA046592</award-id><principal-award-recipient><name><surname>Lyssiotis</surname><given-names>Costas A</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Inhibition of GOT2 drives growth inhibitory reductive stress that can be rescued by electron acceptors in vitro, whereas GOT2 inhibition in endogenous or transplanted tumor models is tolerated without consequence, highlighting the importance of context when studying tumor metabolism.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Cancer cells depend on deregulated metabolic programs to meet energetic and biosynthetic demands (<xref ref-type="bibr" rid="bib44">Pavlova and Thompson, 2016</xref>; <xref ref-type="bibr" rid="bib66">Vander Heiden and DeBerardinis, 2017</xref>; <xref ref-type="bibr" rid="bib38">Martínez-Reyes and Chandel, 2021</xref>). Metabolic therapies aim to preferentially target these dependencies (<xref ref-type="bibr" rid="bib65">Vander Heiden, 2011</xref>). This approach has shown promise in preclinical models of pancreatic ductal adenocarcinoma (PDA) – one of the deadliest major cancers, notoriously resistant to anti-cancer therapies (<xref ref-type="bibr" rid="bib49">Ryan et al., 2014</xref>; <xref ref-type="bibr" rid="bib15">Halbrook and Lyssiotis, 2017</xref>). Pancreatic tumors are poorly vascularized and nutrient dysregulated (<xref ref-type="bibr" rid="bib30">Kamphorst et al., 2015</xref>). Therefore, cancer cells commandeer metabolic pathways to scavenge and use nutrients (<xref ref-type="bibr" rid="bib15">Halbrook and Lyssiotis, 2017</xref>; <xref ref-type="bibr" rid="bib9">Encarnación-Rosado and Kimmelman, 2021</xref>). A wealth of recent literature has identified that this is mediated predominantly by mutant KRAS (KRAS*), the oncogenic driver in most pancreatic tumors (<xref ref-type="bibr" rid="bib6">Commisso et al., 2013</xref>; <xref ref-type="bibr" rid="bib70">Ying et al., 2012</xref>; <xref ref-type="bibr" rid="bib55">Son et al., 2013</xref>; <xref ref-type="bibr" rid="bib67">Viale et al., 2014</xref>; <xref ref-type="bibr" rid="bib52">Santana-Codina et al., 2018</xref>; <xref ref-type="bibr" rid="bib25">Humpton et al., 2019</xref>). The KRAS* has also been implicated in shaping the pancreatic tumor microenvironment (TME; <xref ref-type="bibr" rid="bib62">Tape et al., 2016</xref>; <xref ref-type="bibr" rid="bib31">Kerk et al., 2021</xref>). The PDA tumors exhibit a complex TME (<xref ref-type="bibr" rid="bib58">Storz and Crawford, 2020</xref>; <xref ref-type="bibr" rid="bib72">Zhang et al., 2019</xref>) with metabolic interactions between malignant, stromal, and immune cells enabling and facilitating tumor progression (<xref ref-type="bibr" rid="bib37">Lyssiotis and Kimmelman, 2017</xref>). Recent successes in drug development have provided KRAS* selective inhibitors, and these are in various stages of preclinical and clinical testing. However, consistent with other targeted therapies, resistance inevitably occurs (<xref ref-type="bibr" rid="bib28">Janes et al., 2018</xref>; <xref ref-type="bibr" rid="bib29">Jänne, 2022</xref>). Therefore, disrupting downstream metabolic crosstalk mechanisms in PDA is a compelling combinatorial or alternative approach (<xref ref-type="bibr" rid="bib7">Cox et al., 2014</xref>).</p><p>In support of this idea, previous work from our lab described that PDA cells are uniquely dependent on KRAS*-mediated rewiring of glutamine metabolism for protection against oxidative stress (<xref ref-type="bibr" rid="bib55">Son et al., 2013</xref>). Mitochondrial glutamate-oxaloacetate transaminase 2 (GOT2) is implicated in this rewired metabolism in PDA. In normal physiology, GOT2 functions in the malate-aspartate shuttle (MAS), a mechanism by which cells transfer reducing equivalents between the cytosol and mitochondria to balance the two independent NADH pools and maintain redox balance (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). The PDA cells driven by KRAS* divert metabolites from the MAS and increase flux through malic enzyme 1 (ME1) to produce NADPH (<xref ref-type="bibr" rid="bib55">Son et al., 2013</xref>). Since this pathway is critical for PDA, we set out to evaluate GOT2 as a potential therapeutic target. Using metabolomics analyses and manipulation of the redox state in PDA cells, we discovered that loss of GOT2 in vitro induces intracellular NADH accumulation and reductive stress. These metabolic changes impair cellular growth, which can be rescued with chemical or genetic interventions that oxidize NADH. However, loss of GOT2 had no effect on tumor growth or initiation in immunocompromised or immunocompetent mouse models of PDA. Cancer cells use a complex cell-intrinsic rewiring and crosstalk with the TME to maintain redox homeostasis in vivo. These data emphasize an underappreciated role for GOT2 in pancreatic tumor redox homeostasis and illustrate the differential biochemical pathways and metabolic plasticity deployed by cancer cells in vivo.</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Glutamate-oxaloacetate transaminase 2 (GOT2) knockdown (KD) impairs in vitro pancreatic ductal adenocarcinoma (PDA) proliferation.</title><p>(<bold>A</bold>) The metabolic roles of mitochondrial GOT2. OAA: oxaloacetate; Glu: glutamate; Mal: malate; Asp: aspartate; αKG: α-ketoglutarate; ME1: malic enzyme 1; TCA: tricarboxylic acid. (<bold>B</bold>) Immunoblot of GOT2 and VINCULIN loading control in PaTu-8902 cells after 1 µg/mL doxycycline (DOX) induction of two independent GOT2 (sh1, sh2) and non-targeting (NT) shRNAs for 3 days. (<bold>C</bold>) Representative images from colony formation assays in ishRNA PaTu-8902 cells −Dox (n=3) or +Dox (n=3). (<bold>D</bold>) Heatmap summarizing the relative colony formation ishRNA PDA cell lines −Dox (n=3) or +Dox (n=3), normalized to −Dox for each indicated shRNA. Representative images from colony formation assays and western blots presented in <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>. (<bold>E</bold>) Relative abundances of Asp and αKG in PaTu-8902 (left) and MIAPaCa-2 (right) ishGOT2.1 −Dox (n=3) or +Dox (n=3). (<bold>F</bold>) Relative proliferation of PaTu-8902 (left) and MIAPaCa-2 (right) ishGOT2.1 −Dox (n=3) or +Dox (n=3) cultured in normal media (Dulbecco’s modified Eagle medium, DMEM) or supplemented with 20 mM Asp and 1 mM dimethyl-αKG (dmαKG). For all panels, data represent mean ± SD. *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001, and ****p&lt;0.0001.</p><p><supplementary-material id="fig1sdata1"><label>Figure 1—source data 1.</label><caption><title>Full western blot images for <xref ref-type="fig" rid="fig1">Figure 1B</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-73245-fig1-data1-v2.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-73245-fig1-v2.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>GOT2 knockdown (KD) impairs in vitro colony formation and proliferation of pancreatic cancer cell lines.</title><p>(<bold>A</bold>) Immunoblots of glutamate-oxaloacetate transaminase 2 (GOT2) and VINCULIN loading control in pancreatic ductal adenocarcinoma (PDA) cell lines after 1 µg/mL doxycycline (Dox) induction of the indicated shRNAs (ishRNA) for 3 days. NT: non-targeting shRNA. Westerns for data in <xref ref-type="fig" rid="fig1">Figure 1D</xref>. (<bold>B</bold>) Immunoblot of GOT1, GOT2, and VINCULIN in PaTu-8902 ishRNA −Dox or +Dox after 3 days. (<bold>C</bold>) Representative images from colony formation assays in PDA ishRNA cell lines −Dox (n=3) or +Dox (n=3) for the data in <xref ref-type="fig" rid="fig1">Figure 1D</xref>. (<bold>D</bold>) Relative proliferation of PDA ishRNA cell lines −Dox (n=3) or +Dox (n=3), normalized to Day 0 cell number for each condition. (<bold>E</bold>) Immunoblots of GOT2 and VINCULIN in human cancer-associated fibroblast cell line human pancreatic stellate cells (hPSC) and human pancreatic nestin expressing cells (HPNE) ishRNA cells. (<bold>F</bold>) Relative proliferation of hPSC (left) and HPNE (right) ishRNA −Dox (n=3) or +Dox (n=3). For all panels, data represent mean ± SD. *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001, and ****p&lt;0.0001.</p><p><supplementary-material id="fig1s1sdata1"><label>Figure 1—figure supplement 1—source data 1.</label><caption><title>Full western blot images for <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1B,E</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-73245-fig1-figsupp1-data1-v2.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-73245-fig1-figsupp1-v2.tif"/></fig><fig id="fig1s2" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 2.</label><caption><title>Metabolic effect of GOT2 KD in vitro in pancreatic cancer cell lines.</title><p>(<bold>A</bold>) Heatmaps of the relative abundances of metabolites significantly (p&lt;0.05) different between −Dox (n=3) and +Dox (n=3) PaTu-8902 (left) and MIAPaCa-2 (right) ishGOT2.1 cells. (<bold>B</bold>) Metabolic pathway analysis of the data presented in (A). (<bold>C</bold>) Ion abundances of aspartate (Asp) in normal media or media with 10 mM Asp (left) and intracellular abundances in PaTu-8902 and MIAPaCa-2 cultured in normal media or media with 10 mM Asp (right). (<bold>D</bold>) Relative abundances of tricarboxylic acid (TCA) cycle metabolites in PaTu-8902 (top) or MIAPaCa-2 (bottom) ishGOT2.1 −Dox (n=3) or +Dox (n=3). For all panels, data represent mean ± SD. *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001, and ****p&lt;0.0001.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-73245-fig1-figsupp2-v2.tif"/></fig></fig-group></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Loss of GOT2 impairs PDA cell proliferation in vitro</title><p>To expand on our previous work studying GOT2 in PDA (<xref ref-type="bibr" rid="bib55">Son et al., 2013</xref>) and to evaluate GOT2 as a potential therapeutic target, we generated a panel of PDA cell lines with doxycycline-inducible expression of either a control non-targeting shRNA (shNT) or two independent shRNAs (sh1, sh2) targeting the <italic>GOT2</italic> transcript. Cells cultured in media containing doxycycline (+Dox) exhibited a marked decrease in GOT2 protein expression compared to cells cultured in media without doxycycline (−Dox) (<xref ref-type="fig" rid="fig1">Figure 1B</xref>; <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A</xref>). This knockdown (KD) was specific for GOT2, relative to the cytosolic aspartate aminotransaminase GOT1 (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1B</xref>). Having validated GOT2 KD, we tested the importance of GOT2 for cellular proliferation. In general, GOT2 KD in PDA cells impaired colony formation (<xref ref-type="fig" rid="fig1">Figure 1C and D</xref>; <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1C</xref>) and proliferation (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1D</xref>). Consistent with our previous report (<xref ref-type="bibr" rid="bib55">Son et al., 2013</xref>), GOT2 was not required for the proliferation of non-transformed pancreatic cell types (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1E,F</xref>).</p><p>Since GOT2 has several vital metabolic roles in a cell (<xref ref-type="fig" rid="fig1">Figure 1A</xref>), the changes caused by decreased GOT2 expression in PDA cells were examined using liquid chromatography-coupled tandem mass spectroscopy (LC-MS/MS). Numerous changes in the intracellular metabolome of GOT2 KD cells were observed (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2A,B</xref>). Of note, the products of the GOT2-catalyzed reaction, aspartate (Asp) and α-ketoglutarate (αKG), were decreased (<xref ref-type="fig" rid="fig1">Figure 1E</xref>), and supplementation of these metabolites rescued growth of GOT2 KD (<xref ref-type="fig" rid="fig1">Figure 1F</xref>). While these PDAC cell lines do not express Asp transporters, we confirmed that supraphysiological levels of Asp (20-fold excess) led to an increase in intracellular Asp (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2C</xref>). In addition to reduced αKG, there was a disruption in tricarboxylic acid (TCA) cycle intermediates, consistent with a role for GOT2 in facilitating glutamine anaplerosis (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2D</xref>).</p></sec><sec id="s2-2"><title>GOT2 KD perturbs redox homeostasis in PDA cells</title><p>Aside from the expected decrease in Asp and αKG, and the perturbation of the TCA cycle, closer examination of the GOT2 KD metabolomics dataset revealed an impairment in glycolysis with a node at glyceraldehyde 3-phosphate dehydrogenase (GAPDH), indicative of NADH reductive stress (<xref ref-type="fig" rid="fig2">Figure 2A</xref>). Examination of glycolytic rate via Seahorse Flux Analysis confirmed that glycolysis was indeed impaired in GOT2 KD cells (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A</xref>). The GAPDH reduces NAD+ to produce NADH, where a buildup of NADH product inhibits GAPDH activity. Indeed, metabolite pools in upstream glycolysis and branch pathways like the pentose phosphate pathway are increased, and those in downstream glycolysis are decreased (<xref ref-type="fig" rid="fig2">Figure 2B</xref>). In cultured PDA cells, the MAS transfers glycolytic reducing potential to drive the electron transport chain (ETC) and support the maintenance of cytosolic redox balance (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). We thus hypothesized that GOT2 KD interrupted this shuttle, preventing the proper transfer of electron potential in the form of NADH between these two compartments. In support of this, GOT2 KD increased the intracellular ratio of NADH to NAD+ (<xref ref-type="fig" rid="fig2">Figure 2C</xref>).</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Glutamate-oxaloacetate transaminase 2 (GOT2) knockdown (KD) induces reductive stress, which can be ameliorated by NADH turnover.</title><p>(<bold>A</bold>) Schematic of glycolytic signature induced by GOT2 KD-mediated NADH buildup and reductive stress. G6<italic>P</italic>: glucose-6-phosphate; F6<italic>P</italic>: fructose-6-phosphate; FBP: fructose-1,6-bisphosphate; DHAP: dihydroxyacetone phosphate; GA3<italic>P</italic>: glyceraldehyde-3-phosphate; PEP: phosphoenol pyruvate; oxPPP: oxidative pentose phosphate pathway; non-oxPPP: non-oxidative pentose phosphate pathway; X5<italic>P</italic>: xylulose-5-phosphate; R5<italic>P</italic>: ribose-5-phosphate; S7<italic>P</italic>: seduoheptulose-7-phosphate; HBP: hexosamine biosynthesis pathway; and GlcNAc-1<italic>P</italic>: N-acetylglucosamine 1-phosphate. (<bold>B</bold>) Relative fold changes in the indicated metabolites between PaTu-8902 ishGOT2.1 −Dox (n=3) and +Dox (n=3). 2PG: 2-phosphoglycerate; Pyr: pyruvate; and Lac: lactate. (<bold>C</bold>) Relative NADH/NAD+ ratio in PaTu-8902 ishGOT2.1 −Dox (n=3) and +Dox (n=3). (<bold>D</bold>) Relative colony formation of MIAPaCa-2 ishRNA −Dox (n=3) or +Dox (n=3) cultured in normal media (Dulbecco’s modified Eagle medium, DMEM) or DMEM with 1 mM pyruvate, normalized to −Dox for each condition. (<bold>E</bold>) Relative colony formation of MIAPaCa-2 ishGOT2.1 −Dox (n=3) or +Dox (n=3) cultured in normal media (DMEM) or DMEM with the indicated concentrations of pyruvate (mM), normalized to −Dox for each condition. (<bold>F</bold>) Relative proliferation of PaTu-8902 (left) and MIAPaCa-2 (right) ishGOT2.1 −Dox (n=3) or +Dox (n=3) cultured in normal media (DMEM) or DMEM with 1 mM Pyr or α-ketobutyrate (αKB), normalized to Day 0 for each condition. (<bold>G</bold>) Relative proliferation of PaTu-8902 (left) and MIAPaCa-2 (right) ishGOT2.1 −Dox (n=3) or +Dox (n=3) expressing doxycycline-inducible empty vector (EV), cytosolic <italic>Lactobacillus</italic> NADH oxidase (LbNOX), or mitochondrial LbNOX (mLbNOX), normalized to Day 0 for each condition. (<bold>H</bold>) Relative NADH/NAD+ ratio of PaTu-8902 (left) and MIAPaCa-2 (right) ishGOT2.1 −Dox (n=3) or +Dox (n=3) expressing EV, LbNOX, or mLbNOX. (<bold>I</bold>) Schematic of 13C3-pyruvate into relevant metabolic pathways. 13C-carbon labels in blue, non-labeled carbon in gray. LDH: lactate dehydrogenase; GPT: glutamate-pyruvate transaminase; MPC: mitochondrial pyruvate carrier; and PC: pyruvate carboxylase. (<bold>J–K</bold>) Fractional labeling of intracellular pyruvate (J) or lactate (K) in PaTu-8902 and MIAPaCa-2 ishGOT2.1 −Dox (n=3) or +Dox (n=3) cultured in 1 mM 13C3-pyruvate and treated with DMSO vehicle control or 5 µM UK5099 (MPC inhibitor). Unlabeled controls presented at right. For all panels, data represent mean ± SD. *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001, and ****p&lt;0.0001.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-73245-fig2-v2.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>GOT2 loss in vitro slows glycolysis and can be rescued by exogenous electron acceptors.</title><p>(<bold>A</bold>) Glycolytic rate assay showing the proton efflux rate (PER) of PaTu-8902 ishGOT2.1 −Dox (n=4) or +Dox (n=4). (<bold>B–C</bold>) Relative proliferation (B) and ATP levels (C) of PaTu-8902 ishGOT2.1 −Dox (n=3) or +Dox (n=3) cultured in normal Dulbecco’s modified Eagle medium (DMEM) or DMEM with 1 mM pyruvate (Pyr). (<bold>D</bold>) Immunoblots of GOT2 and VINCULIN loading control in PaTu-8902 (top) and MIAPaCa-2 (bottom) parental (<bold>P</bold>), empty vector (EV), or two sgRNAs targeting GOT2 (sg1, sg2). (<bold>E</bold>) Relative colony formation of PaTu-8902 (left) and MIAPaCa-2 (right) P, EV, sgGOT2.1, or sgGOT2.2 cultured in normal DMEM (−Pyr, n=3) or DMEM with 1 mM pyruvate (+Pyr, n=3), normalized to +Pyr for each condition. (<bold>F</bold>) Relative colony formation of PaTu-8902 (left) and MIAPaCa-2 (right) ishGOT2.1 −Dox (n=3) or +Dox (n=3) cultured in normal media (DMEM) or DMEM with 1 mM α-ketobutyrate (αKB), normalized to −Dox for each condition. (<bold>G</bold>) Relative colony formation of MIAPaCa-2 ishGOT2.1 −Dox (n=3) or +Dox (n=3) cultured in normal media (DMEM) or DMEM with 1 mM Pyr, αKB, or nicotinaminde mononucleotide (NMN), normalized to −Dox for each condition. For all panels, data represent mean ± SD. *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001, and ****p&lt;0.0001.</p><p><supplementary-material id="fig2s1sdata1"><label>Figure 2—figure supplement 1—source data 1.</label><caption><title>Full western blot images for <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1D</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-73245-fig2-figsupp1-data1-v2.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-73245-fig2-figsupp1-v2.tif"/></fig><fig id="fig2s2" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 2.</label><caption><title>GOT2 KD can be rescued by cytosolic, but not mitochondrial, expression of LbNOX.</title><p>(<bold>A</bold>) Immunoblots of glutamate-oxaloacetate transaminase 2 (GOT2), FLAG, and VINCULIN loading controls from PaTu-8902 (left) or MIAPaCa-2 (right) ishNT or GOT2.1 cells expressing doxycycline-inducible expression of empty vector (EV) or FLAG-tagged cytosolic <italic>Lactobacillus</italic> NADH oxidase (LbNOX) or mitochondrial LbNOX (mLbNOX). (<bold>B</bold>) Relative colony formation of PaTu-8902 (left) and MIAPaCa-2 (right) ishGOT2.1 −Dox (n=3) or +Dox (n=3) expressing EV, LbNOX, or mLbNOX, normalized to −Dox for each condition. (<bold>C</bold>) Relative proliferation of PaTu-8902 (top) and MIAPaCa-2 (bottom) ishNT −Dox (n=3) or +Dox (n=3) expressing EV, LbNOX, or mLbNOX and treated with dimethyl sulfoxide (DMSO) vehicle control (left) or 1 µM piericidin (right), normalized to Day 0 for each condition. (<bold>D</bold>) Ion abundances of NAD+ (left) and NADH (right) in PaTu-8902 (top) and MIAPaCa-2 (bottom) ishGOT2.1 −Dox (n=3) and +Dox (n=3). (<bold>E</bold>) Relative extracellular pyruvate/lactate ratios in PaTu-8902 (left) and MIAPaCa-2 (right) ishGOT2.1 −Dox (n=3) and +Dox (n=3). (<bold>F</bold>) Ion abundances of extracellular pyruvate (left) and lactate (right) in PaTu-8902 (top) and MIAPaCa-2 (bottom) ishGOT2.1 −Dox (n=3) and +Dox (n=3). (<bold>G</bold>) Heatmap of log2 fold changes in metabolite abundances between PaTu-8902 (left) and MIAPaCa-2 (right) ishGOT2.1 −Dox (n=3) and +Dox (n=3) expressing EV, LbNOX, or mLbNOX. G6<italic>P</italic>: glucose-6-phosphate; F6<italic>P</italic>: fructose-6-phosphate; FBP: fructose-1,6-bisphosphate; DHAP: dihydroxyacetone phosphate; 2PG: 2-phosphoglycerate; PEP: phosphoenol pyruvate; X5<italic>P</italic>: xylulose-5-phosphate; R5<italic>P</italic>: ribose-5-phosphate; S7<italic>P</italic>: seduoheptulose-7-phosphate; αKG: α-ketoglutarate; and <italic>P</italic>: pentose phosphate pathway. For all panels, data represent mean ± SD. *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001, and ****p&lt;0.0001.</p><p><supplementary-material id="fig2s2sdata1"><label>Figure 2—figure supplement 2—source data 1.</label><caption><title>Full western blot images for <xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2A</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-73245-fig2-figsupp2-data1-v2.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-73245-fig2-figsupp2-v2.tif"/></fig><fig id="fig2s3" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 3.</label><caption><title>Cytosolic reduction of pyruvate to lactate is necessary for GOT2 KD.</title><p>(<bold>A</bold>) Relative proliferation of PaTu-8902 (left) and MIAPaCa-2 (right) ishGOT2.1 −Dox (n=3) or +Dox (n=3) cultured in 1 mM glucose Dulbecco’s modified Eagle medium (DMEM) with 1 mM pyruvate (Pyr) normalized to Day 0 for each condition. (<bold>B–D</bold>) Fractional labeling of intracellular citrate (<bold>B</bold>), aspartate (<bold>C</bold>), or alanine (<bold>D</bold>) from 13C3-pyruvate (1 mM) in PaTu-8902 and MIAPaCa-2 ishGOT2.1 −Dox (n=3) or +Dox (n=3) treated with DMSO vehicle control or 5 µM UK5099 (mitochondrial pyruvate carrier (MPC) inhibitor). Unlabeled controls presented at right. (<bold>E</bold>) Relative cell number of MIAPaCa-2 ishGOT2.1 −Dox (n=3) or +Dox (n=3) cultured in normal DMEM or DMEM with 1 mM Pyr, treated with DMSO vehicle control or 5 µM UK5099, and normalized to DMSO for each condition. (<bold>F</bold>) Relative colony formation of MIAPaCa-2 ishGOT2.1 −Dox (n=3) or +Dox (n=3) cultured in normal DMEM or DMEM with 1 mM Pyr or lactate (Lac), normalized to −Dox for each condition. (<bold>G</bold>) Relative colony formation of PaTu-8902 (left) and MIAPaCa-2 (right) ishGOT2.1 −Dox (n=3) or +Dox (n=3) cultured in normal DMEM or DMEM with 1 mM alanine, normalized to −Dox for each condition. (<bold>H</bold>) Relative colony formation of MIAPaCa-2 ishGOT2.1 −Dox (n=3) or +Dox (n=3) cultured in normal DMEM or DMEM with either 1 mM Pyr or 100 µM of the indicated combinations of adenine (<bold>A</bold>), guanine (<bold>G</bold>), thymidine (<bold>T</bold>), and cytidine (<bold>C</bold>), normalized to −Dox for each condition. For all panels, data represent mean ± SD. *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001, and ****p&lt;0.0001.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-73245-fig2-figsupp3-v2.tif"/></fig></fig-group><p>NADH accumulation leads to reductive stress, which can be relieved if the cell has access to electron acceptors (<xref ref-type="bibr" rid="bib13">Gui et al., 2016</xref>). Pyruvate is a notable metabolite in this regard, as it can accept electrons from NADH, producing lactate and regenerating NAD+, in a reaction catalyzed by lactate dehydrogenase (LDH). Therefore, we hypothesized that pyruvate could rescue the defect in cellular proliferation mediated by GOT2 KD. Indeed, culturing GOT2 KD cells in pyruvate rescued proliferation in a dose-dependent manner (<xref ref-type="fig" rid="fig2">Figure 2D and E</xref>; <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1B</xref>). Additionally, cells expressing a genetically encoded, fluorescent ATP sensor indicated that ATP levels dropped with GOT2 KD and were restored with pyruvate supplementation (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1C</xref>), reflecting the link between TCA cycle activity, respiration, and oxidative phosphorylation. Furthermore, having identified a metabolite that permits in vitro proliferation of PDA cells without GOT2, we engineered CRISPR-Cas9 <italic>GOT2</italic> knockout (KO) cells for further investigation (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1D</xref>). In support of the data generated using the doxycycline-inducible shRNA, <italic>GOT2</italic> KO impaired colony formation of PDA cells, which was similarly restored through extracellular pyruvate supplementation (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1E,F</xref>).</p><p>The α-ketobutyrate (αKB) is another electron acceptor that turns over NADH in a mechanism analogous to pyruvate but without entering downstream metabolism in the same fashion as pyruvate (<xref ref-type="bibr" rid="bib59">Sullivan et al., 2015</xref>). The αKB also rescued proliferation after GOT2 KD (<xref ref-type="fig" rid="fig2">Figure 2F</xref>; <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1F</xref>). This mechanism is dependent on NADH turnover and not NAD+ synthesis, as the NAD+ precursor nicotinamide mononucleotide (NMN) failed to rescue GOT2 KD (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1G</xref>).</p><p>To test this further, GOT2 KD cells were engineered to express either doxycycline-inducible cytosolic or mitochondrial <italic>Lactobacillus brevis</italic> NADH oxidase (LbNOX), which uses molecular oxygen to oxidize NADH and produce water and NAD+ (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2A</xref>; <xref ref-type="bibr" rid="bib12">Goodman et al., 2020</xref>; <xref ref-type="bibr" rid="bib64">Titov et al., 2016</xref>). Cytosolic LbNOX, but not mitochondrial LbNOX (mLbNOX), rescued proliferation of GOT2 KD cells (<xref ref-type="fig" rid="fig2">Figure 2G</xref>; <xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2B</xref>). We confirmed the mLbNOX construct encoded a functional enzyme as defects in proliferation incurred by treatment with complex I inhibitor piericidin could be rescued with mLbNOX as reported previously (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2C</xref>; <xref ref-type="bibr" rid="bib64">Titov et al., 2016</xref>). LbNOX reversed the increased NADH/NAD+ ratio induced by GOT2 KD via an overall decrease in NADH levels (<xref ref-type="fig" rid="fig2">Figure 2H</xref>; <xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2D</xref>). Furthermore, the secreted pyruvate/lactate ratios in the media of LbNOX-expressing cells dramatically increased, indicating a resolution of the cytosolic NADH stress induced by GOT2 KD (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2E,F</xref>). Moreover, the metabolic defects observed following GOT2 KD were ameliorated by cytosolic LbNOX activity, including an increase in Asp and αKG, normalization of TCA cycle metabolites, and the release of the glycolytic block at GAPDH (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2G</xref>). The spatial control of the LbNOX system indicated that KD of mitochondrial GOT2 could be rescued by balancing the cytosolic NADH/NAD+ pool.</p><p>Next, we traced the metabolic fate of U13C-pyruvate in cells with GOT2 KD. Importantly, we also assessed the impact and metabolism of pyruvate in this system following inhibition of the mitochondrial pyruvate carrier (MPC) inhibitor UK5099, which blocks entry of pyruvate into the mitochondria. (<xref ref-type="fig" rid="fig2">Figure 2I</xref>). Media containing equimolar unlabeled glucose and U13C-pyruvate was used to prevent dilution of the pyruvate label by unlabeled pyruvate generated via glycolysis from the high glucose concentration used in normal media. This media formulation had no impact on the pyruvate GOT2 KD rescue phenotype (<xref ref-type="fig" rid="fig2s3">Figure 2—figure supplement 3A</xref>). In this experiment, roughly 50% of the intracellular pyruvate was labeled (<xref ref-type="fig" rid="fig2">Figure 2J</xref>), in line with the other half of the unlabeled pyruvate coming from glucose, and most of the labeled pyruvate was converted to lactate (<xref ref-type="fig" rid="fig2">Figure 2K</xref>). We observed modest labeling of citrate, Asp, and alanine from pyruvate (<xref ref-type="fig" rid="fig2s3">Figure 2—figure supplement 3B-D</xref>). While the labeled TCA cycle and branching pathway intermediates decreased dramatically with UK5099, this MPC inhibition had no effect on the pyruvate GOT2 KD rescue phenotype (<xref ref-type="fig" rid="fig2s3">Figure 2—figure supplement 3E</xref>).</p><p>Both lactate and alanine can fuel oxidation via the TCA cycle (<xref ref-type="bibr" rid="bib23">Hui et al., 2017</xref>; <xref ref-type="bibr" rid="bib56">Sousa et al., 2016</xref>), and Asp is critical for nucleotide production. Pyruvate can be converted into all three of these metabolites, yet supplementation with exogenous lactate, alanine, or nucleoside bases failed to rescue GOT2 KD (<xref ref-type="fig" rid="fig2s3">Figure 2—figure supplement 3F-H</xref>). These data collectively suggest a redox role for pyruvate-mediated rescue of GOT2 KD, as opposed to entering the mitochondria for ATP production or biosynthesis. These findings provide clear evidence using several orthogonal strategies that GOT2 KD results in accumulation of NADH pools and reductive stress in PDA cells.</p></sec><sec id="s2-3"><title>GOT2 is not required for PDA tumor growth in vivo</title><p>To test the effect of GOT2 KD on in vivo tumor growth, PDA cell lines were injected subcutaneously into the flanks of immunocompromised (non-obese diabetic (NOD) <italic>scid</italic> gamma; NSG) mice. We allowed the tumors to establish for 7 days, after which the mice were fed normal chow or doxycycline chow (Dox chow) ad libitum. Surprisingly, despite the inhibitory in vitro phenotype, and robust suppression of GOT2 expression in vivo, PDA tumors from five different cell lines grew unimpeded with GOT2 KD (<xref ref-type="fig" rid="fig3">Figure 3A and B</xref>; <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1A,B</xref>). Nuclear Ki67 staining confirmed that tumors lacking GOT2 were proliferative and actually displayed a modest, but significant, increase in Ki67-positive nuclei (<xref ref-type="fig" rid="fig3">Figure 3C and D</xref>). To further examine the role of GOT2 in the proper tissue context, PDA cells were injected orthotopically into the pancreas of NSG mice, and tumors were allowed to establish for 7 days before feeding the mice regular or Dox chow. Similar to the flank model, GOT2 KD had no effect on the growth of orthotopic tumors (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1C</xref>).</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Glutamate-oxaloacetate transaminase 2 (GOT2) is not required for in vivo growth of pancreatic ductal adenocarcinoma (PDA) xenografts.</title><p>(<bold>A</bold>) Tumor volumes of PaTu-8902 ishRNA flank xenografts in NOD scid gamma (NSG) mice fed normal chow (−Dox, n=6) or doxycycline chow (+Dox, n=6). Arrows indicate administration of Dox chow 1 week after PDA cell injection. (<bold>B</bold>) Tumor volumes of four additional PDA cell line ishGOT2.1 flank xenografts in NSG mice fed normal chow (−Dox, n=6) or doxycycline chow (+Dox, n=6). Arrows indicate administration of Dox chow 1 week after PDA cell injection. (<bold>C</bold>) Immunohistochemistry for Ki67 in flank xenograft tissue from PaTu-8902 ishRNA −Dox (n=6) or +Dox (n=6). Scale bar is 100 µm. (<bold>D</bold>) Quantification of Ki67+ cells in tissue depicted in (C). (<bold>E</bold>) Relative abundances of Asp and αKG in PaTu-8902 ishGOT2.1 −Dox (n=6) or +Dox (n=6) flank xenografts. (<bold>F</bold>) Relative fold changes in the indicated metabolites between PaTu-8902 ishGOT2.1 −Dox (n=6) and +Dox (n=6) flank xenografts. G6<italic>P</italic>: glucose-6-phosphate; F6<italic>P</italic>: fructose-6-phosphate; FBP: fructose-1,6-bisphosphate; DHAP: dihydroxyacetone phosphate; GA3<italic>P</italic>: glyceraldehyde-3-phosphate; 2PG: 2-phosphoglycerate; PEP: phosphoenol pyruvate; Pyr: pyruvate; Lac: Lactate; X5<italic>P</italic>: xylulose-5-phosphate; R5<italic>P</italic>: ribose-5-phosphate; S7<italic>P</italic>: seduoheptulose-7-phosphate; and <italic>P</italic>: pentose phosphate pathway. For all panels, data represent mean ± SD. *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001, and ****p&lt;0.0001.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-73245-fig3-v2.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>GOT2 KD does not impede tumor growth or metabolism in vivo.</title><p>(<bold>A</bold>) Tumor volumes of pancreatic ductal adenocarcinoma (PDA) cell line ishNT flank xenografts in NOD scid gamma (NSG) mice fed normal chow (−Dox, n=6) or doxycycline chow (+Dox, n=6). Arrows indicate administration of Dox chow 1 week after PDA cell injection. (<bold>B</bold>) Immunoblots for glutamate-oxaloacetate transaminase 2 (GOT2) and VINCULIN loading control in PDA ishRNA −Dox or +Dox xenografts at endpoint. Each lane represents an independent xenograft. (<bold>C</bold>) Bioluminescence of MIAPaCa-2 GFP-Luc ishGOT2.1 −Dox (n=3) or +Dox (n=3) orthotopic xenografts. (<bold>D</bold>) Heatmaps of the relative abundances of metabolites significantly (p&lt;0.05) different between PaTu-8902 ishGOT2.1 −Dox (n=6) and +Dox (n=6) flank xenografts. (<bold>E</bold>) Metabolic pathway analysis of the data presented in (D). (<bold>F</bold>) Relative abundances of tricarboxylic acid cycle metabolites in PaTu-8902 ishGOT2.1 −Dox (n=6) or +Dox (n=6) flank xenografts. (<bold>G</bold>) Immunoblots for GOT2, GOT1, GLUD1, IDH1, and VINCULIN in PaTu-8902 ishGOT2.1 −Dox or +Dox flank xenografts at endpoint. For all panels, data represent mean ± SD. *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001, and ****p&lt;0.0001.</p><p><supplementary-material id="fig3s1sdata1"><label>Figure 3—figure supplement 1—source data 1.</label><caption><title>Full western blot images for <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1B,G</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-73245-fig3-figsupp1-data1-v2.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-73245-fig3-figsupp1-v2.tif"/></fig></fig-group><p>Having observed a discrepancy between in vitro and in vivo dependence on GOT2 for proliferation, the relative abundances of intracellular metabolites from flank tumors were analyzed via LC-MS/MS to compare the metabolic changes between cell lines and tumors following loss of GOT2. While GOT2 KD induced some changes in tumor metabolite levels, the affected metabolic pathways were distinct from those observed in vitro, bearing in mind we were comparing homogenous cell lines with heterocellular xenografts (<xref ref-type="fig" rid="fig3">Figure 3E and F</xref>; <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1D-F</xref>). Asp abundance was significantly decreased, yet αKG levels remained constant (<xref ref-type="fig" rid="fig3">Figure 3E</xref>), and TCA cycle intermediates were unaffected (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1F</xref>). This led us to initially hypothesize that PDA cells rewire their metabolism in vivo to maintain αKG levels when GOT2 is knocked down. However, upon examination of the expression of other αKG-producing enzymes in GOT2 KD tumors, we did not observe a compensatory increase in expression (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1G</xref>). Certainly, expression does not always dictate metabolic flux, but these data led us to adopt an alternative, cell-extrinsic hypothesis to explain the different in vitro and in vivo GOT2 KD phenotypes. Finally, the glycolytic signature indicative of NADH stress was not observed in the metabolomics analysis from flank GOT2 KD tumors, further illustrating the differential dependence on GOT2 in PDA in vitro and in vivo (<xref ref-type="fig" rid="fig3">Figure 3F</xref>).</p><p>To evaluate the role of GOT2 in an immunocompetent model, we crossed the LSL-Kras<sup>G12D</sup>;Ptf1a-Cre (KC) mouse with Got2<sup>f/f</sup> mice to generate an LSL-Kras<sup>G12D</sup>;Got2<sup>f/f</sup>;Ptf1a-Cre mouse (KC-Got2) (<xref ref-type="fig" rid="fig4">Figure 4A</xref>, <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A</xref>). Loss of <italic>Got2</italic> had no observable effect on the architecture of the healthy, non-transformed pancreas (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1B,C</xref>). This is in support of our data demonstrating loss of GOT2 was not deleterious in human, non-malignant pancreatic cell types (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1F</xref>).</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Glutamate-oxaloacetate transaminase 2 (GOT2) deletion does not impact on pancreatic ductal adenocarcinoma (PDA) tumorigenesis in an autochthonous model.</title><p>(<bold>A</bold>) Got2 deletion (floxed exon 2) with expression of mutant Kras (LSL-Kras<sup>G12D</sup>) driven by epithelial pancreas-specific Cre recombinase (p48-Cre) on an immunocompetent (C57B/6) background (KC-Got2). (<bold>B</bold>) Representative immunohistochemistry (IHC) for Got2 in pancreata from 3-month-old KC-Got2 or age-matched KC historic controls. Scale bar is 50 µM. (<bold>C</bold>) Representative hematoxylin and eosin (H&amp;E) staining of pancreata from 3-month KC (n=4) or KC-Got2 (n=6) mice. Scale bar is 200 µM. (<bold>D</bold>) Pancreas weights of 3-month KC (n=4) or KC-Got2 (n=6) mice. (<bold>E</bold>) Quantitation of H&amp;E staining from (C) of tissue area with healthy acinar cells, acinar-ductal metaplasia (ADM), or pancreatic intraepithelial (PanIN) lesion severity. (<bold>F</bold>) Representative H&amp;E staining of pancreata from 6-month KC (n=5) or KC-Got2 (n=4) mice. Scale bar is 200 µM. (<bold>G</bold>) Pancreas weights of 6-month KC (n=4) or KC-Got2 (n=4) mice. (<bold>H</bold>) Quantitation of H&amp;E staining from (F) of tissue area with healthy acinar cells, ADM, or PanIN lesion severity. (<bold>I</bold>) Representative H&amp;E staining of pancreata from 1-year KC (n=3) or KC-Got2 (n=7) mice. Scale bar is 100 µM. (<bold>J</bold>) Number of KC or KC-Got2 tissue that had progressed to carcinoma at 1 year. For all panels, data represent mean ± SD. *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001, and ****p&lt;0.0001.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-73245-fig4-v2.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>Validation of Got2 loss in an autochthonous model of pancreatic tumorigenesis.</title><p>(<bold>A</bold>) DNA gel showing representative genotyping of DNA isolated from tails of Got2<sup>f/f</sup> mice or wild-type (WT) control. (<bold>B</bold>) Representative hematoxylin and eosin (H&amp;E) staining of pancreata from 3 month WT (Got2 f/f, n=2) or p48-Got2 f/f (n=2) mice. Scale bar is 200 µM. (<bold>C</bold>) Pancreas weights of 3 month Got2 f/f (n=2) or p48-Got2 f/f (n=2) mice. For all panels, data represent mean ± SD. *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001, and ****p&lt;0.0001.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-73245-fig4-figsupp1-v2.tif"/></fig></fig-group><p>KC-Got2 and KC controls were aged to 3, 6, and 12 months, at which point pancreata were harvested. We confirmed loss of GOT2 in the epithelial compartment via immunohistochemistry (IHC; <xref ref-type="fig" rid="fig4">Figure 4B</xref>). No differences were observed in the weights of pancreata between 3-month KC-Got2 and KC mice (<xref ref-type="fig" rid="fig4">Figure 4C</xref>). Scoring the hematoxylin and eosin (H&amp;E) stained tissues from these groups by a blinded pathologist revealed that KC-Got2 mice had a significantly greater percentage of healthy acinar cells compared to KC controls (<xref ref-type="fig" rid="fig4">Figure 4D and E</xref>). However, no differences were observed in the percentages of acinar-ductal metaplasia or pancreatic intraepithelial grade between KC-Got2 and KC mice (<xref ref-type="fig" rid="fig4">Figure 4E</xref>). Additionally, we aged KC-Got2 mice to 6 months and compared the pancreata to matched 6-month KC historic controls, observing a slight decrease in weight for KC-Got2 pancreatic (<xref ref-type="fig" rid="fig4">Figure 4F and G</xref>). A histological analysis by a blinded pathologist did not identify a difference in number or severity of lesions (<xref ref-type="fig" rid="fig4">Figure 4H</xref>). In addition, both KC and KC-Got2 mice had progressed to carcinoma after aging for 1 year (<xref ref-type="fig" rid="fig4">Figure 4I and J</xref>). This suggests that loss of <italic>Got2</italic> does not affect the progression of PDA following transformation by oncogenic Kras.</p></sec><sec id="s2-4"><title>Cancer-associated fibroblast conditioned media supports colony formation in GOT2 KD cells in vitro</title><p>Human PDA tumors develop a complex microenvironment composed of a tumor-promoting immune compartment, a robust fibrotic response consisting of diverse stromal cell types, and a dense extracellular matrix (ECM; <xref ref-type="bibr" rid="bib72">Zhang et al., 2019</xref>). While the flank tumor milieu in immunocompromised mice is less complex than that of a human PDA tumor, α-smooth muscle actin (αSMA) staining revealed that activated mouse fibroblasts comprised a substantial portion of the microenvironment in tumors regardless of GOT2 status (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1A</xref>). Additionally, we and others have previously reported mechanisms by which cancer-associated fibroblasts (CAFs) in the stroma engage in cooperative metabolic crosstalk with pancreatic cancer cells (<xref ref-type="bibr" rid="bib56">Sousa et al., 2016</xref>; <xref ref-type="bibr" rid="bib73">Zhao et al., 2016</xref>; <xref ref-type="bibr" rid="bib2">Bertero et al., 2019</xref>). So, we hypothesized that CAFs supported PDA metabolism following GOT2 KD. To investigate potential metabolic crosstalk in a simplified setting, PDA cells were cultured in vitro with CM from human CAFs (hCAFs). In support of our hypothesis, hCAF CM promoted colony formation in PDA cells with GOT2 KD in a dose-dependent manner (<xref ref-type="fig" rid="fig5">Figure 5A and B</xref>; <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1B</xref>). Furthermore, hCAF CM displayed a more pronounced colony formation rescue phenotype compared to CM from tumor-educated macrophages (TEMs) or from PDA cells (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1C</xref>).</p><fig-group><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Pancreatic cancer-associated fibroblasts (CAFs) release pyruvate and compensate for loss of glutamate-oxaloacetate transaminase 2 (GOT2) in vitro.</title><p>(<bold>A</bold>) Relative colony formation of MIAPaCa-2 ishGOT2.1 −Dox (n=3) or +Dox (n=3) cultured in normal media (Dulbecco’s modified Eagle medium, DMEM) or human CAF (hCAF) conditioned media (CM) generated after 72 hr of conditioning, normalized to −Dox for each condition. (<bold>B</bold>) Relative colony formation of MIAPaCa-2 ishGOT2.1 −Dox (n=3) or +Dox (n=3) cultured in DMEM or indicated dilutions of hCAF CM, normalized to −Dox for each condition. (<bold>C</bold>) Relative colony formation of MIAPaCa-2 ishGOT2.1 −Dox (n=3) or +Dox (n=3) cultured in DMEM, mock-treated hCAF CM, boiled, 3 kDa filtered, or that subjected to freeze/thaw cycles. Data normalized to −Dox for each condition. (<bold>D</bold>) Ranked log2 fold changes of metabolite abundances in hCAF CM compared to pyruvate-free normal DMEM. (<bold>E</bold>) Absolute quantitation of pyruvate concentrations (mM) in three independently generated batches of hCAF or mouse CAF (mCAF) CM, including a pyruvate-free DMEM control. (<bold>F</bold>) Relative colony formation of MIAPaCa-2 ishGOT2.1 −Dox (n=3) or +Dox (n=3) cultured in normal media (DMEM) or mCAF CM, normalized to −Dox for each condition. (<bold>G</bold>) Ion abundance of extracellular (EX) or intracellular (IN) pyruvate (left) or lactate (right) isotopologues from hCAFs cultured with 25 mM 13C6-glucose. (<bold>H</bold>) Fractional labeling of intracellular glycolysis (left), tricarboxylic acid (TCA) cycle (middle), and pentose phosphate pathway (PPP, right) metabolites in hCAFs cultured with 25 mM 13C6-glucose. F6<italic>P</italic>: fructose-6-phosphate; FBP: fructose-1,6-bisphosphate; DHAP: dihydroxyacetone phosphate; G3<italic>P</italic> : glyceraldehyde-3-phosphate; 2PG: 2-phosphoglycerate; 3PG: 3-phosphoglycerate; PEP: phosphoenol pyruvate; Cit: citrate; αKG: α-ketoglutarate; Suc: succinate; Fum: fumarate; Mal: malate; Gln: glutamine; Asp: aspartate; S7<italic>P</italic>: seduoheptulose-7-phosphate; and R5<italic>P</italic>: ribose-5-phosphate. For all panels, data represent mean ± SD. *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001, and ****p&lt;0.0001.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-73245-fig5-v2.tif"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 1.</label><caption><title>CAF metabolism supports GOT2 KD pancreatic cancer cells in vitro.</title><p>(<bold>A</bold>) Immunohistochemistry (IHC) for α-smooth muscle actin (αSMA) in PaTu-8902 ishGOT2.1 −Dox or +Dox flank xenografts. Scale bar is 200 µM. (<bold>B</bold>) Relative colony formation of PaTu-8902 ishGOT2.1 −Dox (n=3) or +Dox (n=3) cultured in normal media (Dulbecco’s modified Eagle medium, DMEM) or human cancer-associated fibroblasts (hCAF) conditioned media (CM), normalized to −Dox for each condition. (<bold>C</bold>) Relative colony formation of PaTu-8902 ishGOT2.1 −Dox (n=3) or +Dox (n=3) cultured in DMEM, hCAF CM, pancreatic ductal adenocarcinoma (PDA) CM, or tumor-educated macrophage (TEM) CM, normalized to −Dox for each condition. (<bold>D</bold>) Relative colony formation of PaTu-8902 ishGOT2.1 −Dox (n=3) or +Dox (n=3) cultured in DMEM, hCAF CM, or hCAF CM boiled, 3 kDa filtered, or subjected to freeze/thaw cycles, normalized to −Dox for each condition. (<bold>E</bold>) Heatmap of the relative abundances of metabolites significantly (p&lt;0.05) different between normal pyruvate-free DMEM and three independently generated batches of hCAF CM. Black arrows highlight Asp and αKG. (<bold>F</bold>) Ion abundances of intracellular pyruvate in MIAPaCa-2 (left) or PaTu-8902 (right) cultured in normal DMEM media or hCAF CM. (<bold>G</bold>) Relative colony formation of PaTu-8902 ishGOT2.1 −Dox (n=3) or +Dox (n=3) cultured in normal media (DMEM) or mCAF CM, normalized to −Dox for each condition. For all panels, data represent mean ± SD. *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001, and ****p&lt;0.0001.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-73245-fig5-figsupp1-v2.tif"/></fig><fig id="fig5s2" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 2.</label><caption><title>CAF-derived pyruvate confers resistance to complex I inhibitors in vitro.</title><p>(<bold>A</bold>) Absolute quantitation of aspartate (Asp) (left) and α-ketoglutarate concentrations (µM) in human cancer-associated fibroblasts (hCAF) or mouse CAF (mCAF) conditioned media (CM), relative to Dulbecco’s modified Eagle medium (DMEM) control. (<bold>B</bold>) Relative proliferation of MIAPaCa-2 ishGOT2.1 −Dox (n=3) or +Dox (n=3) cultured in normal DMEM, 250 µM pyruvate, or a combination of 50 µM Asp and 500 µM dimethyl-α-ketoglutarate (dmαKG). (<bold>C</bold>) Relative cell number of PaTu-8902 treated with the indicated concentrations of rotenone (left), phenformin (middle), or IACS-010759 (right), and cultured in normal DMEM, hCAF CM, or 1 mM pyruvate. For all panels, data represent mean ± SD. *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001, and ****p&lt;0.0001.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-73245-fig5-figsupp2-v2.tif"/></fig></fig-group><p>To begin to identify the factors in hCAF CM responsible for this effect, hCAF CM was boiled, filtered through a 3 kDa cut-off membrane, or subjected to cycles of freezing and thawing. In each of these conditions, hCAF CM supported colony formation in GOT2 KD cells, suggesting the relevant factor(s) was a metabolite (<xref ref-type="fig" rid="fig5">Figure 5C</xref>; <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1D</xref>). Therefore, the relative abundances of metabolites in hCAF CM were analyzed via LC-MS/MS (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1E</xref>). Interestingly, when the metabolites were ranked in order of relative abundance, compared to the media control, pyruvate was one of the most differentially abundant metabolites released by hCAFs into the CM (<xref ref-type="fig" rid="fig5">Figure 5D</xref>). Since we used pyruvate-free Dulbecco’s modified Eagle medium (DMEM) to culture hCAFs, to avoid overinterpreting this finding, we quantified the absolute concentration of pyruvate in hCAF CM at 250 µM, with some variability between batches (<xref ref-type="fig" rid="fig5">Figure 5E</xref>). This is a physiologically relevant concentration of pyruvate in serum collected from mice harboring pancreatic tumors (<xref ref-type="bibr" rid="bib61">Sullivan et al., 2019</xref>), and 250 µM pyruvate rescued GOT2 KD in vitro (<xref ref-type="fig" rid="fig2">Figure 2E</xref>). Consistent with the idea of metabolite exchange, PDA cells cultured in hCAF CM had elevated levels of intracellular pyruvate (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1F</xref>).</p><p>In the in vivo flank model, mouse fibroblasts infiltrate the pancreatic xenografts and engage in crosstalk with cancer cells. Therefore, we tested whether our findings with hCAFs were also applicable in mouse cancer-associated fibroblasts (mCAFs). The mCAFs isolated from a pancreatic flank xenograft in an NSG mouse also secreted pyruvate at similar levels to hCAFs in vitro (<xref ref-type="fig" rid="fig5">Figure 5E</xref>). Furthermore, mCAF CM promoted PDA colony formation following GOT2 KD (<xref ref-type="fig" rid="fig5">Figure 5F</xref>, <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1G</xref>). Since these mCAFs are the same CAFs encountered by PDA cells in our in vivo model, these data further support a mechanism by which CAFs compensate for loss of GOT2, by providing pyruvate to PDA cells lacking GOT2.</p><p>To better understand the production and release of pyruvate in CAFs, we traced glucose metabolism using uniformly carbon-labeled (U13C) glucose and LC-MS metabolomics. We demonstrate that the pyruvate released by CAFs was produced from glucose (<xref ref-type="fig" rid="fig5">Figure 5G</xref>), and, in support of previous studies (<xref ref-type="bibr" rid="bib71">Zhang et al., 2015</xref>; <xref ref-type="bibr" rid="bib34">Lemons et al., 2010</xref>), these CAFs displayed labeling patterns indicative of glycolytic metabolism (<xref ref-type="fig" rid="fig5">Figure 5H</xref>).</p><p>Aside from pyruvate, we also detected significantly elevated levels of Asp and αKG in CAF CM (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1E</xref>). Since these are metabolites produced by GOT2, we next asked whether they were present at sufficient concentrations in CAF CM to compensate for loss of GOT2 in vitro. However, we quantified Asp at 15 µM and αKG at 50 µM in CAF CM (<xref ref-type="fig" rid="fig5s2">Figure 5—figure supplement 2A</xref>), well below the reported values from mouse serum (<xref ref-type="bibr" rid="bib61">Sullivan et al., 2019</xref>). Furthermore, millimolar levels of Asp are required to impact intracellular levels, as PDA cell lines do not express an Asp transporter (<xref ref-type="bibr" rid="bib3">Birsoy et al., 2015</xref>), and dimethyl-αKG must be used as αKG has limited membrane permeablility (<xref ref-type="bibr" rid="bib43">Parker et al., 2021</xref>). Nevertheless, we tested the rescue activity of reported serum levels of Asp and αKG (50 µM and 500 µM, respectively; <xref ref-type="bibr" rid="bib61">Sullivan et al., 2019</xref>), again utilizing the dimethyl-αKG and compared this to serum levels of pyruvate (250 µM). Here we found that pyruvate rescued proliferation of GOT2 KD to a greater extent than the combination of Asp and αKG (<xref ref-type="fig" rid="fig5s2">Figure 5—figure supplement 2B</xref>). Therefore, we conclude that pyruvate, and not Asp or αKG, is responsible for the GOT2 KD rescue activity of CAF CM in vitro.</p><p>Like GOT2 inhibition, it is well established that inhibiting the activity of complex I of the ETC also results in an increase in NADH, which can be counteracted with extracellular pyruvate (<xref ref-type="bibr" rid="bib13">Gui et al., 2016</xref>; <xref ref-type="bibr" rid="bib59">Sullivan et al., 2015</xref>; <xref ref-type="bibr" rid="bib64">Titov et al., 2016</xref>; <xref ref-type="bibr" rid="bib3">Birsoy et al., 2015</xref>). Therefore, since pyruvate is highly abundant in hCAF CM, we hypothesized that PDA cells cultured in hCAF CM would be protected from complex I inhibitors. Indeed, both hCAF CM and extracellular pyruvate conferred resistance to PDA cells against the complex I inhibitors rotenone, phenformin, and IACS-010759 (<xref ref-type="fig" rid="fig5s2">Figure 5—figure supplement 2C</xref>; <xref ref-type="bibr" rid="bib40">Molina et al., 2018</xref>). This points to a potential mechanism by which the TME could affect sensitivity to complex I inhibition, though more in depth studies are needed to test this finding further.</p></sec><sec id="s2-5"><title>Inhibiting pyruvate uptake and metabolism blocks rescue of GOT2 KD in vitro</title><p>According to our model, PDA cells are more vulnerable to GOT2 KD or complex I inhibitors in a pyruvate-depleted environment or if pyruvate uptake were blocked. Pyruvate can be transported by four monocarboxylate transporter (MCT) isoforms (<xref ref-type="bibr" rid="bib18">Halestrap, 2013</xref>; <xref ref-type="bibr" rid="bib16">Halestrap, 2012a</xref>; <xref ref-type="bibr" rid="bib17">Halestrap and Wilson, 2012b</xref>), and an analysis of the CCLE database suggests that PDA cell lines primarily express MCT1 and MCT4 (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1A</xref>). Since MCT1 has a higher affinity for pyruvate than MCT4 (<xref ref-type="bibr" rid="bib16">Halestrap, 2012a</xref>), we decided to focus on MCT1 as the transporter by which PDA cells import pyruvate (<xref ref-type="bibr" rid="bib47">Rao et al., 2020</xref>; <xref ref-type="bibr" rid="bib48">Rao et al., 2021</xref>). Indeed, PDA cells express significantly higher levels of MCT1, as compared to hCAFs (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1B</xref>). Similarly, examining expression of MCT1 from a recently published single-cell analysis of a murine syngeneic orthotopic pancreatic tumor (<xref ref-type="bibr" rid="bib57">Steele et al., 2020</xref>) indicated that PDA cells express high levels of MCT1 (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1C</xref>).</p><p>Import/export of pyruvate and lactate through MCT1, as well as the intracellular redox state, is affected by extracellular concentrations of pyruvate and lactate. The absolute concentrations of pyruvate and lactate were measured in hCAF and mCAF CM to calculate the relative pyruvate/lactate ratio from in vitro GOT2 KD rescue experiments (<xref ref-type="fig" rid="fig6">Figure 6A</xref>). In parallel, the absolute levels of pyruvate and lactate, and the relative ratio, were measured in tumor interstitial fluid (TIF) from flank xenografts and in serum from host mice (<xref ref-type="fig" rid="fig6">Figure 6B</xref>). When the measured pyruvate and lactate levels from each of these permutations were added back to regular media, the pyruvate/lactate ratios mimicking CAF CM, serum, or TIF promoted the growth of GOT2 KD cells in vitro (<xref ref-type="fig" rid="fig6">Figure 6C</xref>). These data indicate the pyruvate/lactate ratios in CAF CM in vitro and in the in vivo TME are favorable for pyruvate import, possibly through MCT1.</p><fig-group><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>MCT1 inhibition prevents pyruvate-mediated restoration of redox balance in vitro after loss of glutamate-oxaloacetate transaminase 2 (GOT2).</title><p>(<bold>A</bold>) Absolute quantitation of pyruvate (left) and lactate (middle), and the relative pyruvate/lactate ratio (right) in normal Dulbecco’s modified Eagle medium (DMEM), human cancer-associated fibroblasts (hCAF) conditioned media (CM), and mouse CAF (mCAF) CM. (<bold>B</bold>) Absolute quantitation of pyruvate (left) and lactate (middle), and the relative pyruvate/lactate ratio (right) in serum or the tumor interstitial fluid (TIF) from NOD scid gamma (NSG) mice harboring PaTu-8902 ishGOT2.1 −Dox (n=8 tumors, 4 mice) or +Dox (n=8 tumors, 4 mice) flank xenografts. (<bold>C</bold>) Relative proliferation of MIAPaCa-2 ishGOT2.1 −Dox (n=3) or +Dox (n=3) cultured with the absolute levels and relative ratios of pyruvate/lactate in hCAF and mCAF CM (left) or serum/TIF (right) from (A) and (B), normalized to Day 0 for each condition. (<bold>D</bold>) Relative colony formation of MIAPaCa-2 ishGOT2.1 −Dox (n=3) or +Dox (n=3) cultured in normal media (DMEM), 1 mM pyruvate, or hCAF CM, and treated with DMSO control or 100 nM AZD3965, normalized to −Dox for each condition. (<bold>E</bold>) Immunoblots of GOT2, MCT1, and VINCULIN loading control in PaTu-8902 ishGOT2.1 expressing empty vector (EV), or two sgRNAs targeting MCT1 (sg1, sg2). (<bold>F</bold>) Relative colony formation of PaTu-8902 ishGOT2.1 −Dox (n=3) or +Dox (n=3) expressing EV, or two sgRNAs targeting MCT1 (sg1, sg2) and cultured in the indicated doses of pyruvate, normalized to −Dox for each condition. (<bold>G</bold>) Ion counts of intracellular m+3 pyruvate (top) and lactate (bottom) in PaTu-8902 expressing EV, or two sgRNAs targeting MCT1 (sg1, sg2) and cultured in 1 mM 13C3-pyruvate for the indicated time points. (<bold>H</bold>) Relative proliferation of PaTu-8902 (top) and MIAPaCa-2 (bottom) ishGOT2.1 −Dox (n=3) or +Dox (n=3) cultured in normal DMEM or 0.25 mM pyruvate and treated with DMSO vehicle control or 25 µM FX11, normalized to Day 0 for each condition. For all panels, data represent mean ± SD. *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001, and ****p&lt;0.0001.</p><p><supplementary-material id="fig6sdata1"><label>Figure 6—source data 1.</label><caption><title>Full western blot images for <xref ref-type="fig" rid="fig6">Figure 6E</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-73245-fig6-data1-v2.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-73245-fig6-v2.tif"/></fig><fig id="fig6s1" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 1.</label><caption><title>MCT1 and LDHA inhibition dampen pyruvate rescue of GOT2 KD in vitro.</title><p>(<bold>A</bold>) Relative Cancer Cell Line Encyclopedia (CCLE) mRNA expression of the indicated SLC16 family members in PaTu-8902 and MIAPaCa-2. (<bold>B</bold>) Immunoblot for MCT1 and VINCULIN loading control the indicated cell lines. (<bold>C</bold>) Single-cell RNA sequencing data from murine syngeneic orthotopic tumors showing expression of Slc16a1 (MCT1) and Slc16a3 (MCT4) in cancer-associated fibroblasts (CAF; marked by CDH11 expression) and epithelial (marked by Krt18 expression) populations. (<bold>D,F</bold>) Immunoblots for glutamate-oxaloacetate transaminase 2 (GOT2), MCT1, and VINCULIN in PaTu-8902 (D) and MIAPaCa-2 (F) ishGOT2.1 −Dox or +Dox expressing the indicated control (CTR) or constitutive MCT1-targeting shRNAs (sh1, sh2). (<bold>E,G</bold>) Relative proliferation of PaTu-8902 (E) and MIAPaCa-2 (G) ishGOT2.1 −Dox (n=3) or +Dox (n=3) expressing the indicated shRNAs and cultured in normal Dulbecco’s modified Eagle medium (DMEM; left), 0.25 mM pyruvate (middle), or human CAF (hCAF) CM (right), normalized to Day 0 for each condition. (<bold>H</bold>) Relative colony formation of MIAPaCa-2 ishGOT2.1 −Dox (n=3) or +Dox (n=3) cultured in normal media (DMEM) or the indicated doses of pyruvate, and treated with DMSO control or 100 nM AZD3965, normalized to −Dox for each condition. (<bold>I</bold>) Relative viability of MIAPaCa-2 cultured in normal media (DMEM), 0.25 mM pyruvate (left), or hCAF CM (right) and treated with DMSO vehicle control or 100 nM IACS-010759, alone or in combination with 100 nM AZD3965, normalized to −Dox for each condition. (<bold>J</bold>) Immunoblots for GOT2, LDHA, LDHB, and VINCULIN in PaTu-8902 and MIAPaCa-2 ishRNA. (<bold>K</bold>) Relative number of PaTu-8902 (left) and MIAPaCa-2 (right) ishGOT2.1 −Dox (n=3) or +Dox (n=3) cultured in normal DMEM, 0.25 mM pyruvate, or hCAF CM, and treated with DMSO vehicle control or 25 µM FX11, normalized to −Dox for each condition. For all panels, data represent mean ± SD. *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001, and ****p&lt;0.0001.</p><p><supplementary-material id="fig6s1sdata1"><label>Figure 6—figure supplement 1—source data 1.</label><caption><title>Full western blot images for <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1B,D,F,J</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-73245-fig6-figsupp1-data1-v2.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-73245-fig6-figsupp1-v2.tif"/></fig><fig id="fig6s2" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 2.</label><caption><title>MCT1 inhibition does not sensitize tumors to GOT2 KD in vivo.</title><p>(<bold>A,B</bold>) Tumor volume (left) and weight (right) of PaTu-8902 (A) and tumor volume of MIAPaCa-2 (B) ishGOT2.1 flank xenografts in NOD scid gamma (NSG) mice fed normal chow (−Dox, n=6) or doxycycline chow (+Dox, n=6) expressing control (shNT) or shMCT1.1. (<bold>C,D</bold>) Immunoblots for GOT2, MCT1, and VINCULIN in representative tumors from PaTu-8902 (C) or MIAPaCa-2 (D) ishGOT2.1 −Dox (n=3) or +Dox (n=3) flank xenografts with shNT or shMCT1.1. Each lane represents an individual tumor. (<bold>E</bold>) Tumor volume (left) and weight (right) of PaTu-8902 flank xenografts in NSG mice fed normal chow (−Dox, n=6) or doxycycline chow (+Dox, n=6) expressing control (sgEV) or sgMCT1.1. (<bold>F</bold>) Immunoblot for GOT2, MCT1, MCT4, and VINCULIN in representative, independent tumors from PaTu-8902 ishGOT2.1 −Dox (n=3) or +Dox (n=3) flank xenografts with sgEV or sgMCT1.1. (<bold>G</bold>) Immunoblot for GOT2, MCT1, MCT4, and VINCULIN in PaTu-8902 ishGOT2.1 −Dox or +Dox cell lines with sgEV or sgMCT1.1. For (F, G) blots, arrow = MCT1 band, asterisk = non-specific band. (<bold>H</bold>) Tumor volume (left) and weight (right) of PaTu-8902 flank xenografts in NSG mice fed normal chow (−Dox, n=6) or doxycycline chow (+Dox, n=6) treated with PBS control or 100 mg/kg AZD3965. (<bold>I</bold>) Immunoblot for GOT2, MCT1, and VINCULIN in representative, independent tumors of PaTu-8902 ishGOT2.1 −Dox (n=3) or +Dox (n=3) flank xenografts. (<bold>J</bold>) Weights of mice treated in (H). For all panels, data represent mean ± SD. *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001, and ****p&lt;0.0001.</p><p><supplementary-material id="fig6s2sdata1"><label>Figure 6—figure supplement 2—source data 1.</label><caption><title>Full western blot images for <xref ref-type="fig" rid="fig6s2">Figure 6—figure supplement 2C,D,F,G,I</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-73245-fig6-figsupp2-data1-v2.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-73245-fig6-figsupp2-v2.tif"/></fig><fig id="fig6s3" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 3.</label><caption><title>LDHA inhibition does not sensitize tumors to GOT2 KD in vivo.</title><p>(<bold>A,B</bold>) Tumor volume (left) and weight (right) of PaTu-8902 (<bold>A</bold>) and MIAPaCa-2 (<bold>B</bold>) ishGOT2.1 flank xenografts in NOD scid gamma (NSG) mice fed normal chow (−Dox, n=6) or doxycycline chow (+Dox, n=6) and treated with PBS control or 2 mg/kg FX11. (<bold>C</bold>) Relative proliferation of PaTu-8902 (top) and MIAPaCa-2 (bottom) ishRNA −Dox (n=3) or +Dox (n=3) cultured in normal Dulbecco’s modified Eagle medium (DMEM), 0.25 mM pyruvate, or 2% BSA, normalized to Day 0 for each condition.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-73245-fig6-figsupp3-v2.tif"/></fig></fig-group><p>Therefore, we hypothesized that blocking pyruvate import through MCT1 would render cells vulnerable to GOT2 KD. The small molecule AZD3965 has specificity for MCT1 over MCT4 (<xref ref-type="bibr" rid="bib45">Polański et al., 2014</xref>; <xref ref-type="bibr" rid="bib21">Hong et al., 2016</xref>; <xref ref-type="bibr" rid="bib63">Tasdogan et al., 2020</xref>), therefore GOT2 KD cells were cultured in pyruvate or hCAF CM in the presence of AZD3965. In support of our hypothesis, MCT1 chemical inhibition reduced the pyruvate and hCAF CM rescue of GOT2 KD (<xref ref-type="fig" rid="fig6">Figure 6D</xref>).</p><p>For a genetic approach, MCT1 was knocked down in doxycycline-inducible GOT2 KD cells (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1D,F</xref>). MCT1 KD modestly slowed the growth of GOT2 KD cells cultured in pyruvate or hCAF CM (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1E,G</xref>). We reasoned that partial KD could explain why MCT1 KD had a more modest effect than chemical inhibition of MCT1. Therefore, we next generated MCT1 KO clones in GOT2 KD cells (<xref ref-type="fig" rid="fig6">Figure 6E</xref>). Indeed, MCT1 KO in GOT2 KD cells blocked pyruvate rescue (<xref ref-type="fig" rid="fig6">Figure 6F</xref>). We also demonstrate that MCT1 inhibition was most effective at physiological levels of pyruvate (250 µM; <xref ref-type="fig" rid="fig6">Figure 6F</xref>, <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1H</xref>). Furthermore, MCT1 KO cells cultured with U13C-pyruvate demonstrated reduced uptake of pyruvate, as measured by intracellular labeled pyruvate (<xref ref-type="fig" rid="fig6">Figure 6G</xref>). Since pyruvate is rapidly imported and converted to lactate, the reduced pyruvate uptake was observed more clearly in dramatically reduced levels of labeled lactate in MCT1 KO cells (<xref ref-type="fig" rid="fig6">Figure 6G</xref>). Lastly, MCT1 blockade was tested in combination with complex I inhibitors in PDA cells cultured in pyruvate or hCAF CM. The AZD3965 also reversed the rescue activity of pyruvate or hCAF CM in PDA cells treated with IACS-010759 (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1I</xref>).</p><p>The reduction of pyruvate to lactate by LDH is the central mechanism in our model by which NAD+ is regenerated to support proliferation in GOT2 inhibited cells. Thus, we next asked whether inhibiting LDH activity could also prevent GOT2 KD rescue by pyruvate or hCAF CM. Our PDA cell lines highly expressed the LDHA isoform of LDH, as determined by western blotting (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1J</xref>). As such, we utilized the LDHA-specific chemical inhibitor FX11 in this study (<xref ref-type="bibr" rid="bib33">Le et al., 2010</xref>). In further support of our model, inhibiting LDHA with FX11 slowed the in vitro proliferation of GOT2 KD cells cultured in pyruvate or hCAF CM, relative to single agent controls (<xref ref-type="fig" rid="fig6">Figure 6H</xref>, <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1K</xref>).</p><p>Cumulatively, these data support an in vitro model whereby perturbation of mitochondrial metabolism with GOT2 KD or complex I inhibition disrupts redox balance in PDA cells. This can be restored through import of pyruvate from the extracellular environment and reduction to lactate to regenerate NAD+.</p></sec><sec id="s2-6"><title>Metabolic plasticity in vivo supports adaptation to combined GOT2 KD and inhibition of pyruvate metabolism</title><p>This proposed in vitro mechanism suggests that the unhampered growth of GOT2-inhibited tumors (<xref ref-type="fig" rid="fig3">Figure 3A and B</xref>) could be explained by uptake of pyruvate from the TME. In vitro, MCT1 KD had a modest effect on the proliferation of GOT2 KD cells cultured in pyruvate or hCAF CM. In contrast, we found that MCT1 KD had no effect on the growth of GOT2 KD subcutaneous xenografts (<xref ref-type="fig" rid="fig6s2">Figure 6—figure supplement 2A,B</xref>). A caveat of this finding was the observed detectable levels of MCT1 at endpoint (<xref ref-type="fig" rid="fig6s2">Figure 6—figure supplement 2C,D</xref>). However, MCT1 KO similarly did not impact the growth of GOT2 KD tumors in vivo, which is in stark contrast to the results observed in vitro whereby MCT1 KO blocked the rescue of colony formation in GOT2 KD cells by pyruvate (<xref ref-type="fig" rid="fig6s2">Figure 6—figure supplement 2E</xref>). In these tumors, MCT1 was not detectable at endpoint and we did not observe a compensatory increase in MCT4 expression in either cell lines or xenografts with MCT1 KO (<xref ref-type="fig" rid="fig6s2">Figure 6—figure supplement 2F,G</xref>). Similarly, administration of AZD3965 did not impact the growth of GOT2 KD xenografts, again contrasting our in vitro data showing strong blockade of GOT2 KD rescue by pyruvate or hCAF CM with MCT1 chemical inhibition (<xref ref-type="fig" rid="fig6s2">Figure 6—figure supplement 2E-G</xref>). Lastly, unlike in vitro, FX11 had no effect on GOT2 KD growth in vivo (<xref ref-type="fig" rid="fig6s3">Figure 6—figure supplement 3A,B</xref>).</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>GOT2 is an essential component of the MAS (<xref ref-type="bibr" rid="bib5">Borst, 2020</xref>), which we now demonstrate is required for redox homeostasis in PDA cells in vitro. KD of GOT2 in vitro disrupts the MAS and renders PDA cells incapable of transferring reducing equivalents between the cytosol and mitochondria, leading to a cytosolic accumulation of NADH. This predominantly impacts the rate of glycolysis, an NAD+-coupled pathway, with secondary impacts on mitochondrial metabolism that together slow the proliferation of PDA cells in vitro. For instance, GOT2 feeds into the ME1 shunt, which we demonstrated previously also produces pyruvate and sustains intracellular NADPH levels (<xref ref-type="bibr" rid="bib55">Son et al., 2013</xref>). Extracellular supplementation of electron acceptors like pyruvate and αKB, or the expression of a cytosolic NADH oxidase, relieves this NADH reductive stress and the associated pathway feedback inhibition.</p><p>In striking contrast to the in vitro data presented here, we also illustrate that GOT2 KD does not affect the growth of PDA tumors in vivo, potentially because electron acceptors in the TME can restore redox homeostasis. Indeed, pyruvate is present in mouse serum at 250 µM (<xref ref-type="bibr" rid="bib61">Sullivan et al., 2019</xref>), a concentration which is sufficient to compensate for GOT2 KD in vitro. Furthermore, we also demonstrate that pancreatic CAFs release pyruvate in vitro, which can be utilized by PDA cells. This is supported by previous findings in CAFs from other cancers (<xref ref-type="bibr" rid="bib50">Sakamoto et al., 2019</xref>). Therefore, a source of pyruvate is available to PDA tumors, either from circulation or potentially from the CAFs.</p><p>This led us to hypothesize that blocking pyruvate uptake and metabolism would deprive PDA cells of a critical means to relieve the NADH stress mediated by GOT2 KD. In vitro, this hypothesis was supported by data illustrating that either inhibition of MCT1 or LDHA blocked the GOT2 KD rescue activity of pyruvate and CAF CM. However, this proved to be more complicated in vivo, as neither approach successfully sensitized tumors to GOT2 KD. We believe this could be explained by several mechanisms. First, previous work in KRAS*-driven non-small cell lung cancer reported differential dependencies on glutaminolysis in vitro in cell lines versus in vivo in lung tumors. Glutaminase inhibition was ineffective in vivo in these models as lung tumors primarily utilized glucose as a carbon source for the TCA cycle instead of glutamine. If this mechanism is active in our models, glucose, and not glutamine catabolism through GOT2, would fuel the TCA cycle. Second, while MCT4 has a lower affinity for pyruvate than MCT1, it can transport pyruvate (<xref ref-type="bibr" rid="bib16">Halestrap, 2012a</xref>). It is also highly expressed in the cell lines used here (<xref ref-type="fig" rid="fig6s2">Figure 6—figure supplement 2F,G</xref>) and has been shown to confer resistance to cancer cells against MCT1 inhibition (<xref ref-type="bibr" rid="bib4">Bonglack et al., 2021</xref>; <xref ref-type="bibr" rid="bib21">Hong et al., 2016</xref>). Thus, dual inhibition of MCT1 and MCT4 may be required to effectively block pyruvate uptake. Third, even with sufficient MCT blockade, PDA cells could still obtain pyruvate through other processes, such as macropinocytosis (<xref ref-type="bibr" rid="bib30">Kamphorst et al., 2015</xref>; <xref ref-type="bibr" rid="bib6">Commisso et al., 2013</xref>). Fourth, while our study focuses on pyruvate, numerous circulating metabolites can function as electron acceptors and could relieve the intracellular accumulation of NADH if cancer cells are unable to import pyruvate (<xref ref-type="bibr" rid="bib24">Hui et al., 2020</xref>). Fifth, reduction of pyruvate to lactate by LDH is not the only reaction by which NAD+ is regenerated. Recent studies have identified how serine pathway modulation, polyunsaturated fatty acid synthesis, and the glycerol-phosphate shunt all contribute to NADH turnover (<xref ref-type="bibr" rid="bib69">Yang et al., 2020</xref>; <xref ref-type="bibr" rid="bib32">Kim et al., 2019</xref>; <xref ref-type="bibr" rid="bib36">Liu et al., 2021</xref>). Future work remains to assess these mechanisms in PDA cells in vivo and if they compensate for an impaired MAS. Nevertheless, our data emphasize that redox homeostasis is a vital aspect of cancer cell metabolism and is maintained through a complex web of intracellular compensatory pathways and extracellular interactions.</p><p>Aside from its broader role in redox balance, GOT2 is also a prominent source of Asp in PDA cells, and we demonstrate that GOT2 inhibition dramatically decreases Asp levels both in vitro and in vivo. Previous studies have shown that Asp availability is rate limiting in rapidly proliferating cells (<xref ref-type="bibr" rid="bib59">Sullivan et al., 2015</xref>; <xref ref-type="bibr" rid="bib3">Birsoy et al., 2015</xref>; <xref ref-type="bibr" rid="bib60">Sullivan et al., 2018</xref>; <xref ref-type="bibr" rid="bib10">Garcia-Bermudez et al., 2018</xref>). In our models, in contrast to physiological pyruvate concentrations simultaneous treatment with supraphysiological doses of both Asp and membrane-permeable dimethyl-αKG were required to provide a rescue of PDA cell proliferation in the absence of GOT2. Additionally, free Asp is available at low micromolar concentrations and has limited uptake capacity of PDA cells (<xref ref-type="bibr" rid="bib61">Sullivan et al., 2019</xref>). Supplementation of physiologically relevant concentrations of Asp and αKG afforded a modest rescue compared to physiological pyruvate. Furthermore, exogenous protein supplementation with bovine serum albumin, another potential source for Asp, failed to rescue GOT2 KD in vitro (<xref ref-type="fig" rid="fig6s3">Figure 6—figure supplement 3C</xref>). While non-specific engulfment of ECM via macropinocytosis in vivo could supply PDA cells with Asp (<xref ref-type="bibr" rid="bib11">Garcia-Bermudez et al., 2022</xref>), meeting a vital requirement for biosynthesis, we propose this does not address overall redox imbalance. Pyruvate, on the other hand, regenerates NAD+ allowing broader metabolic processes to resume, including Asp production and nucleotide biosynthesis. In support of this, recent work in myoblasts demonstrated that while complex I inhibition with piericidin increased the NADH/NAD+ ratio leading to depletion of Asp, adding Asp back to the system neither restored redox balance nor induced proliferation (<xref ref-type="bibr" rid="bib39">Mick et al., 2020</xref>).</p><p>Our work also highlights the emerging metabolic role of CAFs in PDA. Recent studies have shown that CAFs engage in cooperative metabolic crosstalk with cancer cells in many different tumor types (<xref ref-type="bibr" rid="bib37">Lyssiotis and Kimmelman, 2017</xref>; <xref ref-type="bibr" rid="bib56">Sousa et al., 2016</xref>; <xref ref-type="bibr" rid="bib73">Zhao et al., 2016</xref>; <xref ref-type="bibr" rid="bib51">Sanford-Crane et al., 2019</xref>; <xref ref-type="bibr" rid="bib53">Schwörer et al., 2019</xref>). We add to this body of literature by demonstrating that CAFs release pyruvate, which is taken up and utilized by PDA cells. However, much remains to be discovered about CAF metabolism how they contribute to redox homeostasis in tumors. Some types of activated fibroblasts are known to be highly glycolytic (<xref ref-type="bibr" rid="bib71">Zhang et al., 2015</xref>; <xref ref-type="bibr" rid="bib34">Lemons et al., 2010</xref>), an observation supported by our data. Yet the advent of single-cell RNA sequencing in murine and human pancreatic tumor models has led to a recent appreciation for the heterogeneity of CAFs (<xref ref-type="bibr" rid="bib8">Elyada et al., 2019</xref>; <xref ref-type="bibr" rid="bib42">Ohlund et al., 2017</xref>; <xref ref-type="bibr" rid="bib41">Neuzillet et al., 2019</xref>; <xref ref-type="bibr" rid="bib22">Hosein et al., 2019</xref>; <xref ref-type="bibr" rid="bib19">Helms et al., 2022</xref>; <xref ref-type="bibr" rid="bib26">Hutton et al., 2021</xref>). The newly identified iCAF, myCAF, and apCAF populations have distinct functions in a pancreatic tumor (<xref ref-type="bibr" rid="bib8">Elyada et al., 2019</xref>) and likely employ distinct metabolism to carry out these functions. Much more remains to be uncovered regarding competitive or cooperative interactions between PDA cells and the various CAF subpopulations, including which subtype(s) are responsible for pyruvate release.</p><p>Lastly, this work suggests that the role of the TME should be considered when targeting cancer metabolism. Indeed, approaches like disrupting the MAS shuttle via GOT2 KD or blocking complex I with small molecule inhibitors were less effective in vitro when PDA cells were cultured in supplemental pyruvate or CAF CM. These data are relevant since numerous mitochondrial inhibitors are currently in clinical trials against solid tumor types (NCT03291938, NCT03026517, NCT03699319, and NCT02071862). Previous studies have also shown that complex I inhibitors are more effective in combination with AZD3965 (<xref ref-type="bibr" rid="bib1">Beloueche-Babari et al., 2017</xref>), a selective inhibitor of MCT1, though our work and others indicate that the status of other MCT isoforms should also be considered. Furthermore, the abundance of CAFs present in a tumor, as well as the level of circulating pyruvate in the patient, could predict outcomes for treatment with metabolic therapies that lead to redox imbalance. Targeting pancreatic cancer metabolism is an alluring approach, and a more detailed understanding of the metabolic crosstalk occurring in a pancreatic tumor can shed light on potential resistance mechanisms and inform more effective metabolic therapies.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><sec id="s4-1"><title>Cell culture</title><p>MIAPaCa-2, BxPC-3, Capan-1, Panc03.27, Panc10.05, PL45, and HPNE cell lines were obtained from ATCC. PaTu-8902, PaTu-8988T, and YAPC cells lines were obtained from DSMZ. UM6, UM19, UM28, UM32, UM53, and UM76 were generated from primary patient tumors at the University of Michigan. Human pancreatic stellate cells (also described here as hCAFs) were a generous gift from Rosa Hwang (<xref ref-type="bibr" rid="bib27">Hwang et al., 2008</xref>). The mCAFs were isolated as described below. All cell lines were cultured in high-glucose DMEM (Gibco) without pyruvate and supplemented with 10% fetal bovine serum (Corning). A 0.25% trypsin (Gibco) was used to detach and passage cells. Cell lines were tested regularly for mycoplasma contamination using MycoAlert (Lonza). All cell lines in this study were validated for authentication using STR profiling via the University of Michigan Advanced Genomics Core. L-Aspartic acid (Sigma), dimethyl-α-kG (Sigma), adenine (Sigma), guanine (Sigma), thymine (Sigma), cytosine (Sigma), sodium pyruvate (Invitrogen), αKB (Sigma), NMN (Sigma), L-alanine (Sigma), and sodium lactate (Sigma) were used at the indicated concentrations. UK5099, AZD3965, and phenformin were purchased from Cayman chemical, Rotenone from Sigma, FX11 from MedChem Express, and IACS-010759 was generously provided by Dr Giulio Draetta, University of Texas MD Anderson Cancer Center.</p></sec><sec id="s4-2"><title>Doxy-inducible shGOT2 cells</title><p>The tet-pLKO-puro plasmid was obtained from Dmitri Wiederschain via Addgene (#21915). Oligonucleotides encoding sense and antisense shRNAs (shGOT2.1-TRCN0000034824, shGOT2.2-TRCN0000034825) targeting <italic>GOT2</italic> (NM_002080.4) were synthesized (Integrated DNA Technologies), annealed, and cloned at AgeI and EcoRI sites according to the Wiederschain protocol (<xref ref-type="bibr" rid="bib68">Wiederschain et al., 2009</xref>). A tet-pLKO non-targeting control vector (<named-content content-type="sequence">shNT-ccggcaacaagatgaagagcaccaactcgagttggtgctcttcatcttgttgttttt</named-content>) was constructed using the same strategy. The tet-pLKO-shGOT2 and tet-pLKO-shNT lentiviruses were produced by the University of Michigan Vector Core using purified plasmid DNA. Stable cell lines were generated through transduction with optimized viral titers and selection with 1.5 µg/mL puromycin for 7 days.</p></sec><sec id="s4-3"><title>GOT2 or MCT1 KO cells</title><p><italic>GOT2</italic> or <italic>SLC16A1</italic> (MCT1) KO PDA cell lines were generated using a CRISPR-Cas9 method described previously (<xref ref-type="bibr" rid="bib46">Ran et al., 2013</xref>). Briefly, sgRNA oligonucleotide pairs were obtained from the Human GeCKO Library (v2, 3/9/2015). For <italic>GOT2</italic> KO (sg1 (Fwd), <named-content content-type="sequence">5’-CACCgAAGCTCACCTTGCGGACGCT-3’</named-content>, (Rev) <named-content content-type="sequence">5’-AAACAGCGTCCGCAAGGTGAGCTTc</named-content>; sg2 (Fwd) <named-content content-type="sequence">5’-CACCgCGTTCTGCCTAGCGTCCGCA-3’</named-content>, (Rev) <named-content content-type="sequence">5’-AAACTGCGGACGCTAGGCAGAACGc-3’</named-content>), and for MCT1 KO (sg1 (Fwd) <named-content content-type="sequence">5’- CACCgTGGGCCCGATTGGTCGCATG-3’</named-content>, (Rev) <named-content content-type="sequence">5’- AAACCATGCGACCAATCGGGCCCAc</named-content>; sg2 (Fwd) <named-content content-type="sequence">5’- CACCgTTTCTACAAGAGGCGACCAT-3’</named-content>, (Rev) <named-content content-type="sequence">5’- AAACATGGTCGCCTCTTGTAGAAAc-3’</named-content>) were cloned into the pSpCas9(BB)–2A-Puro plasmid (PX459, v2.0; Addgene, #62988), transfected in PDA cell lines, and selected in puromycin for 7 days. Cells were then seeded into 96 well plates at a density of 1 cell per well, and individual clones were expanded. <italic>GOT2</italic> KO cells were maintained in 1 mM pyruvate for this entire process. The <italic>GOT2</italic> KO was verified via western blot. Cells transfected with the empty PX459 vector were used as controls.</p></sec><sec id="s4-4"><title>MCT1 KD cells</title><p>Cells were transduced with 8 µg/mL polybrene and lentivirus containing the pGFP-C-shLenti plasmid (Origine, #TR30023) containing an shCTR sequence, shMCT1.1 (TL309405A [<named-content content-type="sequence">5′-GAGGAAGAGACCAGTATAGATGTTGCTGG-3′</named-content>]), or shMCT1.2 (TL309405B [<named-content content-type="sequence">5′-ATCCAGCTCTGACCATGATTGGCAAGTAT-3′</named-content>]). These plasmids were a generous gift from Dr Sean Morrison (<xref ref-type="bibr" rid="bib63">Tasdogan et al., 2020</xref>). The cells were then centrifuged at 1000× g for 60 min at room temperature. Transduced cells were then expanded and sorted on the MoFlo Astrios (Beckman-Coulter). The GFP+ cells were collected and expanded before verification of MCT1 KD via western blotting.</p></sec><sec id="s4-5"><title>Transduction of LbNOX/mLbNOX</title><p>pINDUCER (Addgene, #44014) plasmids containing GFP, LbNOX, or mitoLbNOX were obtained from Dr Haoqing Ying, MD Anderson. Plasmids were sequenced and transfected along with lentiviral packaging plasmids into HEK293FT cells with Lipofectamine 3000 (Thermo Fisher) per manufacturer’s instructions. Virus was collected after 48 hr and filtered through a 0.2 µm filter. PaTu-8902 and MIAPaCa-2 iDox-shGOT2.1 cells were seeded in 6 well plates at 250,000 cells/well, transduced with the indicated vectors, and selected in G418 at 500 µg/mL for 7 days. Expression of Flag-tagged LbNOX or mitoLbNOX was confirmed by western blot with a Flag antibody after culturing cells in 1 µg/mL doxycycline for 3 days.</p></sec><sec id="s4-6"><title>Luciferase-expressing cells</title><p>MIAPaCa-2 iDox-shGOT2.1 cells were transduced with the FUGW-FL (EF1a-luc-UBC6-EGFP) lentiviral vector constructed previously (<xref ref-type="bibr" rid="bib54">Smith et al., 2004</xref>), and GFP+ cells were selected via flow cytometry. Luciferase activity was confirmed following transduction and selection with an in vitro luciferase assay and detection on a SpectraMax M3 microplate reader (Molecular Devices).</p></sec><sec id="s4-7"><title>ATP fluorescent sensor/Incucyte growth assays</title><p>PaTu-8902 and MIAPaCa-2 iDox-GOT2.1 cells were transduced with CytoATP or CytoATP non-binding control vectors using the CytoATP Lentivirus Reagent Kit (Sartorious, #4772) and polybrene transfection reagent (Thermo Fisher) and selected for 7 days in 2 µg/mL puromycin. For proliferation and rescue experiments, cells were incubated in an Incucyte (Sartorious) equipped with a Metabolism Optical Module, where the ratio of ATP binding was detected and normalized to the non-binding control cells. Proliferation rate was determined by the percent confluence detected in the phase channel of the Incucyte normalized to Day 0 for each condition.</p></sec><sec id="s4-8"><title>Isolating mouse CAFs</title><p>UM2 subcutaneous xenografts from NSG mice were isolated and prepared in the laboratory of Dr Diane Simeone, as reported previously (<xref ref-type="bibr" rid="bib35">Li et al., 2007</xref>), and single-cell suspensions were plated and cultured in vitro. Mouse CAFs were separated from human pancreatic UM2 cancer cells using the Mouse Cell Depletion Kit (MACS Miltenyi Biotec) according to the manufacturer’s instructions.</p></sec><sec id="s4-9"><title>Conditioned media</title><p>CM was generated by splitting cells at ~90% confluence in a 10 cm<sup>2</sup> plate into four 15 cm<sup>2</sup> plates containing a final volume of 27 mL of growth media and incubating for 72 hr at 37°C, 5% CO<sub>2</sub>. Afterward, the media was collected in 50 mL conical tubes, centrifuged at 1000 rpm for 5 min to remove any detached cells or debris, and divided into fresh 15 mL conical tubes in 10 mL aliquots for long-term storage at –80°C. For all CM experiments, unless indicated otherwise, growth media was mixed with CM for a final ratio of 75% CM to 25% fresh growth media.</p><p>For the experiments in <xref ref-type="fig" rid="fig5">Figure 5C</xref> and <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1D</xref>, CM was manipulated as follows. For boiling, the CM tubes were placed in a water bath at 100°C for 10 min. To filter out factors &gt;3 kDa, the CM were transferred to a 3 kDa filter (Millipore) and centrifuged at 15,000 rpm in 30 min increments until all the CM had passed through the filter. To expose the CM to freeze-thaw cycles, the tubes containing the CM were thawed for 30 min in a 60°C water bath, and then frozen at –80°C for 30 min. This was repeated two more times for a total of three freeze-thaw cycles.</p></sec><sec id="s4-10"><title>Colony formation assays</title><p>Cells were seeded in 6 well plates at 200–400 cells per well in 2 mL of growth media and incubated overnight at 37°C, 5% CO<sub>2</sub>. The next day, the growth media was aspirated and fresh media containing the indicated compounds was added to the cells. Doxycycline was used at 1 µg/mL for all assays. For each assay, cells were incubated in the indicated conditions for 10 days, with the media and doxycycline changed every 3 days. After 10 days, the media was aspirated, the wells were washed once with PBS, and the cells were fixed in 100% methanol for 10 min. Next, the methanol was removed, and the cells were stained with 0.4% crystal violet for 10 min. Finally, the crystal violet was removed, the plates were washed under running water and dried on the benchtop overnight. The next day, images were taken of the plates with a Chemidoc BioRad imager and quantified using the ColonyArea plugin in ImageJ, as described previously (<xref ref-type="bibr" rid="bib14">Guzmán et al., 2014</xref>).</p></sec><sec id="s4-11"><title>Proliferation assays</title><p>Cells were pre-treated for 3 days with 1 µg/mL doxycycline before seeding in 96 well plates at 1000 cells/well in 80 µL of media and incubated overnight at 37°C, 5% CO<sub>2</sub>. The next day, 150 µL of the indicated treatment media was added to the appropriate wells, and the cells were incubated for 6–7 more days, with a media change on day 3. Cell proliferation was determined by live cell imaging for the duration of the assay, or using CyQUANT (Invitrogen) at endpoint according to the manufacturer’s instructions, and detecting fluorescence on a SpectraMax M3 microplate reader (Molecular Devices).</p></sec><sec id="s4-12"><title>Glycolytic rate assay</title><p>PaTu-8902 iDox-shGOT2.1 cells that had been cultured in 1 µg/mL doxycycline for 3 days were seeded at 2 × 10<sup>4</sup> cells/well in 80 μL/well of normal growth media in an Agilent XF96 V3 PS Cell Culture microplate (Agilent). To achieve an even distribution of cells within wells, plates were incubated on the bench top at room temperature for 1 hr before incubating at 37°C, 5% CO<sub>2</sub> overnight. To hydrate the XF96 FluxPak (Agilent), 200 μL/well of sterile water was added and the entire cartridge was incubated at 37°C, CO<sub>2</sub>-free incubator overnight. The following day, 1 hr prior to running the assay, 60 µL of media was removed, and the cells were washed twice with 200 μL/well of assay medium (XF DMEM Base Medium, pH 7.4 containing 25 mM glucose and 4 mM glutamine; Agilent). After washing, 160 μL/well of assay medium was added to the cell culture plate for a final volume of 180 μL/well. Cells were then incubated at 37°C, in a CO<sub>2</sub>-free incubator until analysis. In parallel, 1 hr prior to the assay, water from the FluxPak hydration was exchanged for 200 μL/well of XF Calibrant 670 (Agilent), and the cartridge was returned to 37°C, CO<sub>2</sub>-free incubator until analysis. Rotenone/Antimycin (50 μM, Agilent) and 2DG (500 mM, Agilent) were re-constituted in assay medium to make the indicated stock concentrations. 20 μL of rotenone/antimycin was loaded into Port A for each well of the FluxPak and 22 μL of 2DG into Port B, for a final concentration of 0.5 μM and 50 mM, respectively. The Glycolytic Rate Assay was conducted on an XF96 Extracellular Flux Analyzer (Agilent) and PER was calculated using Wave 2.6 software (Agilent). Following the assay, PER was normalized to cell number with the CyQUANT NF Cell Proliferation Assay (Invitrogen) according to manufacturer’s instructions.</p></sec><sec id="s4-13"><title>Protein lysates</title><p>Cell lines cultured in 6 well plates in vitro were washed with ice-cold PBS on ice and incubated in 250 µL of RIPA buffer (Sigma) containing protease (Roche) and phosphatase (Sigma) inhibitors on ice for 10 min. Next, cells were scraped with a pipet tip, and the resulting lysate was transferred to a 1.5 mL tube also on ice. The lysate was centrifuged at 15,000 rpm for 10 min at 4°C. After, the supernatant was transferred to a fresh 1.5 mL tube and stored at –80°C.</p><p>In vivo, tumor tissue was placed in a 1.5 mL tube containing a metal ball and 300 µL RIPA buffer with protease and phosphatase inhibitors. The tissue was homogenized using a tissue lyser machine. Then, the resulting lysate was centrifuged at 15,000 rpm for 10 min at 4°C. After, the supernatant was transferred to a fresh 1.5 mL tube and stored at –80°C.</p></sec><sec id="s4-14"><title>Western blotting</title><p>Protein levels were determined using a BCA assay (Thermo Fisher), according to manufacturer’s instructions. Following quantification, the necessary volume of lysate containing 30 µg of protein was added to a mixture of loading dye (Invitrogen) and reducing agent (Invitrogen) and incubated at 90°C for 5 min. Next, the lysate was separated on a 4–12% Bis-Tris gradient gel (Invitrogen) along with a protein ladder (Invitrogen) at 150 V until the dye reached the bottom of the gel (about 90 min). Then, the protein was transferred to a methanol-activated PVDF membrane (Millipore) at 25 V for 1 hr. After that, the membrane was blocked in 5% blocking reagent (Biorad) dissolved in TBS-T on a plate rocked for &gt;1 hr. The membrane was then incubated overnight at 4°C rocking in the indicated primary antibody diluted in blocking buffer. The next day, the primary antibody was removed, and the membrane was washed three times in TBS-T rocking for 5 min. Then, the membrane was incubated for 1 hr rocking at room temperature in the appropriate secondary antibody diluted in TBS-T. Finally, the membrane was washed as before and incubated in Clarity ECL reagent (Biorad) according to manufacturer’s instructions before imaging on a Biorad Chemidoc. The following primary antibodies were used in this study: GOT2 (Atlas, HPA018139), GOT1 (Abcam, ab171939), GLUD1 (Abcam, ab166618), IDH1 (Cell Signaling, 3997 S), MCT1 (Abcam, ab85021), MCT4 (Sigma, AB3316P), anti-Flag (Sigma, F3165), VINCULIN (Cell Signaling, 13,901 S), LDHA (Cell Signaling, 3582), LDHB (Abcam, ab53292), and the anti-rabbit-HRP secondary antibody (Cell Signaling, 7074 S).</p></sec><sec id="s4-15"><title>Isolating polar metabolites</title><p>For intracellular metabolome analyses, cells were seeded at 10,000 cells in 2 mL of growth media per well of a 6 well plate and incubated overnight. The next day, the growth media was removed, and cells were incubated in media containing the indicated compounds for 6 days, with the media being changed every 3 days. On day 6, the media was removed, and the cells were fixed and metabolites extracted into 1 mL/well of ice-cold 80% methanol on dry ice for 10 min. Following the incubation, the wells were scraped with a pipet tip and transferred to a 1.5 mL tube on dry ice.</p><p>To analyze extracellular metabolomes, 0.8 mL of ice-cold 100% methanol was added to 0.2 mL of media, mixed well, and incubated on dry ice for 10 min.</p><p>Mouse serum and TIF were isolated and analyzed as described previously (<xref ref-type="bibr" rid="bib61">Sullivan et al., 2019</xref>).</p><p>The tubes were then centrifuged at 15,000 rpm for 10 min at 4°C to pellet insoluble material, and the resulting metabolite supernatant was transferred to a fresh 1.5 mL tube. The metabolites were then dried on a SpeedVac until the methanol/water had evaporated, and the resulting pellet was re-suspended in a 50:50 mixture of methanol and water.</p></sec><sec id="s4-16"><title>Snapshot metabolomics</title><p>Samples were run on an Agilent 1290 Infinity II LC –6470 Triple Quadrupole (QqQ) tandem mass spectrometer (MS/MS) system with the following parameters: Agilent Technologies Triple Quad 6470 LC-MS/MS system consists of the 1290 Infinity II LC Flexible Pump (Quaternary Pump), the 1290 Infinity II Multisampler, the 1290 Infinity II Multicolumn Thermostat with 6 port valves, and the 6470 triple quad mass spectrometer. Agilent Masshunter Workstation Software LC/MS Data Acquisition for 6400 Series Triple Quadrupole MS with Version B.08.02 is used for compound optimization, calibration, and data acquisition.</p><p>Solvent A is 97% water and 3% methanol 15 mM acetic acid and 10 mM tributylamine at pH of 5. Solvent C is 15 mM acetic acid and 10 mM tributylamine in methanol. Washing Solvent D is acetonitrile. LC system seal washing solvent 90% water and 10% isopropanol, needle wash solvent 75% methanol, 25% water. GC-grade Tributylamine 99% (ACROS ORGANICS), LC/MS grade acetic acid Optima (Fisher Chemical), InfinityLab Deactivator additive, ESI–L Low concentration Tuning mix (Agilent Technologies), LC-MS grade solvents of water, and acetonitrile, methanol (Millipore), isopropanol (Fisher Chemical).</p><p>An Agilent ZORBAX RRHD Extend-C18, 2.1 × 150 mm and a 1.8 µm and ZORBAX Extend Fast Guards for ultra high performance liquid chromatography (UHPLC) are used in the separation. LC gradient profile is: at 0.25 mL/min, 0–2.5 min, 100% A; 7.5 min, 80% A and 20% C; 13 min 55% A and 45% C; 20 min, 1% A and 99% C; 24 min, 1% A and 99% C; 24.05 min, 1% A and 99% D; 27 min, 1% A and 99% D; at 0.8 mL/min, 27.5–31.35 min, 1% A and 99% D; at 0.6 mL/min, 31.50 min, 1% A and 99% D; at 0.4 mL/min, 32.25–39.9 min, 100% A; and at 0.25 mL/min, 40 min, 100% A. Column temperature is kept at 35°C, samples are at 4°C, injection volume is 2 µL.</p><p>The 6470 Triple Quad MS is calibrated with the Agilent ESI-L Low concentration Tuning mix. Source parameters: gas temperature 150°C, gas flow 10 L/min, nebulizer 45 psi, sheath gas temperature 325°C, sheath gas flow 12 L/min, capillary –2000 V, and delta EMV –200 V. Dynamic multiple reaction monitoring (dMRM) scan type is used with 0.07 min peak width, acquisition time is 24 min. dMRM transitions and other parameters for each compounds are list in a separate sheets. Delta retention time of plus and minus 1 min, fragmentor of 40 eV, and cell accelerator of 5 eV are incorporated in the method.</p><p>The MassHunter Metabolomics Dynamic MRM Database and method was used for target identification. The QqQ data were pre-processed with Agilent MassHunter Workstation QqQ Quantitative Analysis Software (B0700). Each metabolite abundance level in each sample was divided by the median of all abundance levels across all samples for proper comparisons, statistical analyses, and visualizations among metabolites. Metabolites with values &gt;1 are higher in the experimental conditions, and metabolites with values &lt;1 are lower in the experimental condition. The statistical significance test was done by a two-tailed t-test with a significance threshold level of 0.05.</p><p>Heatmaps were generated and data clustered using Morpheus Matrix Visualization and analysis tool (<ext-link ext-link-type="uri" xlink:href="https://software.broadinstitute.org/morpheus">https://software.broadinstitute.org/morpheus</ext-link>).</p><p>Pathway analyses were conducted using MetaboAnalyst (<ext-link ext-link-type="uri" xlink:href="https://www.metaboanalyst.ca">https://www.metaboanalyst.ca</ext-link>).</p></sec><sec id="s4-17"><title>U13C-glucose, U13C-pyruvate isotope tracing</title><p>For glucose tracing, CAFs were seeded in 6 well plates at 2 × 10<sup>5</sup> cells/well and incubated for 72 hr in growth media containing U13C-glucose (Cambridge Isotope Laboratories).</p><p>For pyruvate tracing, PaTu-8902 and MIAPaCa-2 iDox-shGOT2.1 cells were cultured in media containing 1 mM unlabeled glucose and 1 mM U13C-pyruvate (Cambridge Isotope Laboratories) for 16 hr.</p><p>Polar metabolites were extracted from the media and cells according to the method described above. Isotope tracing experiments utilized the same chromatography as described in the Snapshot Metabolomics section and were conducted on two instruments with the following parameters:</p><p>Agilent Technologies Q-TOF 6530 LC/MS system consists of a 1290 Infinity II LC Flexible Pump (Quaternary Pump), 1290 Infinity II Multisampler, 1290 Infinity II Multicolumn Thermostat with 6 port valves, and a 6530 Q-TOF mass spectrometer with a dual-Assisted Jet Stream (AJI) ESI source. Agilent MassHunter Workstation Software LC/MS Data Acquisition for 6200 series TOF/6500 series Q-TOF Version B.09.00 Build 9.0.9044 .a SP1 is used for calibration and data acquisition.</p><p>Agilent 6530 Q-TOF MS is calibrated with ESI-L Low Concentration Tuning mix. Source parameters: gas temp 250°C, gas flow 13 L/min, nebulizer 35 psi, sheath gas temp 325° C, sheath gas flow 12 L/min, Vcap 3500 V, Nozzle Voltage (V) 1500, Fragmentor 140, Skimmer1 65, and OctopoleRFPeak 750. The MS acquisition mode is set in MS1 with mass range between 50 and 1200 da with collision energy of zero. The scan rate (spectra/s) is set at 1 Hz. The LC-MS acquisition time is 18 min and the total run time is 30 min. Reference masses are enabled with reference masses in negative mode of 112.9856 and 1033.9881 da.</p><p>Agilent Technologies 6545B Accurate-Mass Quadrupole Time of Flight (MS Q-TOF) LC/MS coupled with an Agilent 1290 Infinity II UHPLC. Agilent Masshunter Workstation Software LC/MS Data Acquisition for 6500 Series QTOF MS with Version 09.00, Build 9.0.9044.0 was used for tuning, calibration, and data acquisition.</p><p>In negative mode, the UHPLC was configured with 1290 Infinity II LC Flexible Pump (Quaternary Pump), 1290 Infinity II Multisampler, 1290 Infinity II Multicolumn Thermostat with 6 port valves. In negative scan mode, the Agilent G6545B Q-TOF MS with Dual AJD ESI Sources in centroid mode was configured with following parameters: acquisition range: 50–1200 da at scan rate of 1 spectra/s, gas temp 250°C, gas flow 13 L/min, nebulizer at 40 psi, sheath gas heater 325°C, sheath gas flow 12 L/min, capillary 3500 V, nozzle voltage 1000 V, Fragmentor 130 V, Skimmer1 60 V, Octopole RFPeak 750 V, Collision 0 V, auto recalibration limit of detection 150 ppm with minute height of 1000 counts, and reference ions of two at 59.0139 and 980.0164 da.</p><p>Data processing was performed in Agilent MassHunter Workstation Profinder 10.0 Build 10.0.10062.0. Isotopologue distributions were derived from a compound standard library built in Agilent MassHunter PCDL (Personal Compound and Database Library) v7.0.</p></sec><sec id="s4-18"><title>Xenograft studies</title><p>Animal experiments were conducted in accordance with the Office of Laboratory Animal Welfare and approved by the Institutional Animal Care and Use Committees of the University of Michigan. The NSG mice (Jackson Laboratory) 6–10 weeks old of both sexes were maintained in the facilities of the Unit for Laboratory Animal Medicine under specific pathogen-free conditions.</p><p>Cells expressing doxycycline-inducible shNT or doxycycline-inducible shGOT2 were injected subcutaneously into both the left and right flanks of male and female NSG mice, with 1–4 × 10<sup>6</sup> cells in a mixture of 50 µL media and 50 µL Matrigel (Corning) per injection. Tumors were established for 7 days before mice were fed either normal chow or chow containing doxycycline (BioServ). Tumors were measured with calipers two times per week, and mice were euthanized once the tumors reached a diameter of 2 cm<sup>3</sup>. Subcutaneous tumor volume (V) was calculated as V = 1/2 (length × width; <xref ref-type="bibr" rid="bib66">Vander Heiden and DeBerardinis, 2017</xref>). At endpoint, the tumors were removed, and fragments were either snap frozen in liquid nitrogen and stored at –80°C or fixed in ZFix solution (Anatech) for histology.</p><p>Cells expressing doxycycline-inducible shGOT2 and luciferase were injected into the pancreas tail of NSG mice, with 200,000 cells in a mixture of 50 µL media and 50 µL Matrigel (Corning) per injection. Tumors were established for 7 days before mice were fed either normal chow or chow containing doxycycline (BioServ). Tumor progression was monitored by weekly intraperitoneal injections of luciferin (Promega) and bioluminescence imaging (BLI) on an IVIS SpectrumCT (Perkin Elmer). BLI was analyzed with Living Image software (PerkinElmer) At endpoint, the tumors were removed, and fragments were either snap frozen in liquid nitrogen and stored at –80°C or fixed in ZFix (Anatech) solution for histology.</p><p>AZD3965 or FX11 was dissolved in DMSO and stored at –80°C in aliquots. Each day, one aliquot was thaw and mixed with a 0.5% Hypromellose (Sigma), 0.2% tween 80 (Sigma) solution such that the final DMSO concentration was 5%. Vehicle or AZD3965 was administered at 100 mg/kg by daily oral gavage. FX11 was administered at 2 mg/kg by daily intraperitoneal injection.</p></sec><sec id="s4-19"><title>Histology</title><p>Tissues were processed using a Leica ASP300S tissue processor (Leica Microsystems). Paraffin-embedded tissues were sectioned at 4 μm and stained for specific target proteins using the Discovery Ultra XT autostainer (Ventana Medical Systems), with listed antibodies, and counterstained with Mayer’s hematoxylin (Sigma). H&amp;E staining was performed using Mayer’s hematoxylin solution and Eosin Y (Thermo Fisher). IHC slides were then scanned on a Pannoramic SCAN scanner (Perkin Elmer). Scanned images were quantified using algorithms provided from Halo software version 2.0 (Indica Labs). The following antibodies were used for IHC: Ki67 (1:1000; Abcam, ab15580), αSMA (1:20,000; Abcam, ab5694), and Got2 (1:500; Atlas, HPA018139).</p></sec><sec id="s4-20"><title>KC-Got2<sup>f/f</sup> model</title><p>Mice containing loxP sites flanking exon 2 of the Got2 gene were generated by Ozgene. These mice were crossed to the LSL-Kras<sup>G12D</sup>;Ptf1a-Cre model (<xref ref-type="bibr" rid="bib20">Hingorani et al., 2003</xref>). Tails from 3-week-old mice were collected at weaning and submitted to Transnetyx for genotyping. The following primers were used: Kras<sup>G12D</sup> (<named-content content-type="sequence">Fw-GGCCTGCTGAAAATGACTGAGTATA</named-content>, <named-content content-type="sequence">Rev-CTGTATCGTCAAGGCGCTCTT</named-content>); Got2 WT (<named-content content-type="sequence">Fw- GCAGATTAAAACCACAAGGCCTGTA</named-content>, <named-content content-type="sequence">Rev-ATGTTAAAATTGTCATCCCCTTGTGC</named-content>); Got2 floxed (<named-content content-type="sequence">Fw-GCAGATTAAAACCACAAGGCCTGTA</named-content>, <named-content content-type="sequence">Rev-AGAGAATAGGAACTTCGGAATAGGAACT</named-content>); Cre (<named-content content-type="sequence">Fw-TTAATCCATATTGGCAGAACGAAAACG</named-content>, <named-content content-type="sequence">Rev-CAGGCTAAGTGCCTTCTCTACA</named-content>).</p></sec><sec id="s4-21"><title>Statistics</title><p>Statistics were performed using Graph Pad Prism 8. Groups of 2 were analyzed with two-tailed students t test, groups greater than 2 were compared using one-way ANOVA analysis with Tukey post hoc test or two-way ANOVA with Dunnett’s correction for multiple independent variables. All error bars represent mean with SD, all group numbers and explanation of significant values are presented within the figure legends. Experiments were repeated at least twice to verify results.</p></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf2"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Formal analysis, Investigation, Methodology, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con2"><p>Data curation, Formal analysis</p></fn><fn fn-type="con" id="con3"><p>Data curation, Formal analysis</p></fn><fn fn-type="con" id="con4"><p>Formal analysis, Investigation</p></fn><fn fn-type="con" id="con5"><p>Data curation, Formal analysis</p></fn><fn fn-type="con" id="con6"><p>Data curation, Formal analysis</p></fn><fn fn-type="con" id="con7"><p>Data curation, Formal analysis</p></fn><fn fn-type="con" id="con8"><p>Data curation, Formal analysis</p></fn><fn fn-type="con" id="con9"><p>Data curation, Formal analysis</p></fn><fn fn-type="con" id="con10"><p>Data curation, Formal analysis</p></fn><fn fn-type="con" id="con11"><p>Data curation, Formal analysis</p></fn><fn fn-type="con" id="con12"><p>Data curation, Formal analysis</p></fn><fn fn-type="con" id="con13"><p>Data curation, Formal analysis</p></fn><fn fn-type="con" id="con14"><p>Data curation, Formal analysis</p></fn><fn fn-type="con" id="con15"><p>Data curation, Formal analysis</p></fn><fn fn-type="con" id="con16"><p>Data curation, Formal analysis</p></fn><fn fn-type="con" id="con17"><p>Data curation, Formal analysis</p></fn><fn fn-type="con" id="con18"><p>Data curation, Formal analysis</p></fn><fn fn-type="con" id="con19"><p>Data curation</p></fn><fn fn-type="con" id="con20"><p>Data curation</p></fn><fn fn-type="con" id="con21"><p>Data curation</p></fn><fn fn-type="con" id="con22"><p>Data curation, Formal analysis</p></fn><fn fn-type="con" id="con23"><p>Resources</p></fn><fn fn-type="con" id="con24"><p>Data curation, Formal analysis</p></fn><fn fn-type="con" id="con25"><p>Resources, Project administration</p></fn><fn fn-type="con" id="con26"><p>Resources, Writing – review and editing</p></fn><fn fn-type="con" id="con27"><p>Resources</p></fn><fn fn-type="con" id="con28"><p>Resources, Project administration</p></fn><fn fn-type="con" id="con29"><p>Resources, Data curation, Formal analysis, Project administration</p></fn><fn fn-type="con" id="con30"><p>Conceptualization, Resources, Writing – original draft, Project administration, Writing – review and editing</p></fn><fn fn-type="con" id="con31"><p>Conceptualization, Resources, Formal analysis, Supervision, Funding acquisition, Investigation, Methodology, Writing – original draft, Project administration, Writing – review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Animal experiments were conducted in accordance with the Office of Laboratory Animal Welfare and approved by the Institutional Animal Care and Use Committees of the University of Michigan. ULAM: PRO00008877.</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title>Metabolomics data from <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2A</xref>, <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1D</xref>, and <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1E</xref>.</title></caption><media xlink:href="elife-73245-supp1-v2.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="transrepform"><label>Transparent reporting form</label><media xlink:href="elife-73245-transrepform1-v2.docx" mimetype="application" mime-subtype="docx"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>All data generated or analyzed during this study are included in the manuscript and supporting source data. Raw data are provided for metabolomics experiments, separated by tabs, in Supplementary file 1.</p></sec><ack id="ack"><title>Acknowledgements</title><p>This work was funded by T32AI007413, F31CA24745701, and 1F99CA264414-01 (SAK); CA148828 and CA245546 (YMS); a Pancreatic Cancer Action Network/AACR Pathway to Leadership award (13-70-25-LYSS), Junior Scholar Award from The V Foundation for Cancer Research (V2016-009), Kimmel Scholar Award from the Sidney Kimmel Foundation for Cancer Research (SKF-16–005), a 2017 AACR NextGen Grant for Transformative Cancer Research (17-20-01-LYSS), and NIH grants R37CA237421, R01CA248160, R01CA244931 (CAL). Additional funding sources include F31CA254079 (JAJ); T32-DK094775 and T32-CA009676 (BSN); R50 CA232985 (YZ), T32-GM11390 and F31-CA247076 (SBK); T32-CA009676, the American Cancer Society Postdoctoral Award PF-19-096-01, and the Michigan Institute for Clinical and Healthy Research (MICHR) Postdoctoral Translational Scholar Program fellowship award (NGS); the Michigan Postdoctoral Pioneer Program (ZCN); K99CA241357 and P30DK034933 (CJH); R01GM101171 and CA253986 (DBL); and Cancer Center support grant (P30 CA046592). Metabolomics studies performed at the University of Michigan were supported by NIH grant DK097153, the Charles Woodson Research Fund, and the UM Pediatric Brain Tumor Initiative. Research reported in this publication was supported by the National Cancer Institutes of Health under Award Number P30CA046592 by the use of the following Cancer Center Shared Resource(s): Flow Cytometry Core, Tissue and Molecular Pathology Core, Center for Molecular Imaging (P30CA046592). The University of Michigan Center for Gastrointestinal Research Core Director, Michael Mattea, provided assistance in tissue processing, sectioning, and staining.</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beloueche-Babari</surname><given-names>M</given-names></name><name><surname>Wantuch</surname><given-names>S</given-names></name><name><surname>Casals Galobart</surname><given-names>T</given-names></name><name><surname>Koniordou</surname><given-names>M</given-names></name><name><surname>Parkes</surname><given-names>HG</given-names></name><name><surname>Arunan</surname><given-names>V</given-names></name><name><surname>Chung</surname><given-names>YL</given-names></name><name><surname>Eykyn</surname><given-names>TR</given-names></name><name><surname>Smith</surname><given-names>PD</given-names></name><name><surname>Leach</surname><given-names>MO</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Mct1 inhibitor azd3965 increases mitochondrial metabolism, facilitating combination therapy and noninvasive magnetic resonance spectroscopy</article-title><source>Cancer Research</source><volume>77</volume><fpage>5913</fpage><lpage>5924</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-16-2686</pub-id><pub-id pub-id-type="pmid">28923861</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bertero</surname><given-names>T</given-names></name><name><surname>Oldham</surname><given-names>WM</given-names></name><name><surname>Grasset</surname><given-names>EM</given-names></name><name><surname>Bourget</surname><given-names>I</given-names></name><name><surname>Boulter</surname><given-names>E</given-names></name><name><surname>Pisano</surname><given-names>S</given-names></name><name><surname>Hofman</surname><given-names>P</given-names></name><name><surname>Bellvert</surname><given-names>F</given-names></name><name><surname>Meneguzzi</surname><given-names>G</given-names></name><name><surname>Bulavin</surname><given-names>DV</given-names></name><name><surname>Estrach</surname><given-names>S</given-names></name><name><surname>Feral</surname><given-names>CC</given-names></name><name><surname>Chan</surname><given-names>SY</given-names></name><name><surname>Bozec</surname><given-names>A</given-names></name><name><surname>Gaggioli</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Tumor-stroma mechanics coordinate amino acid availability to sustain tumor growth and malignancy</article-title><source>Cell Metabolism</source><volume>29</volume><fpage>124</fpage><lpage>140</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2018.09.012</pub-id><pub-id pub-id-type="pmid">30293773</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Birsoy</surname><given-names>K</given-names></name><name><surname>Wang</surname><given-names>T</given-names></name><name><surname>Chen</surname><given-names>WW</given-names></name><name><surname>Freinkman</surname><given-names>E</given-names></name><name><surname>Abu-Remaileh</surname><given-names>M</given-names></name><name><surname>Sabatini</surname><given-names>DM</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>An essential role of the mitochondrial electron transport chain in cell proliferation is to enable aspartate synthesis</article-title><source>Cell</source><volume>162</volume><fpage>540</fpage><lpage>551</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2015.07.016</pub-id><pub-id pub-id-type="pmid">26232224</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bonglack</surname><given-names>EN</given-names></name><name><surname>Messinger</surname><given-names>JE</given-names></name><name><surname>Cable</surname><given-names>JM</given-names></name><name><surname>Ch’ng</surname><given-names>J</given-names></name><name><surname>Parnell</surname><given-names>KM</given-names></name><name><surname>Reinoso-Vizcaíno</surname><given-names>NM</given-names></name><name><surname>Barry</surname><given-names>AP</given-names></name><name><surname>Russell</surname><given-names>VS</given-names></name><name><surname>Dave</surname><given-names>SS</given-names></name><name><surname>Christofk</surname><given-names>HR</given-names></name><name><surname>Luftig</surname><given-names>MA</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Monocarboxylate transporter antagonism reveals metabolic vulnerabilities of viral-driven lymphomas</article-title><source>PNAS</source><volume>118</volume><elocation-id>e2022495118</elocation-id><pub-id pub-id-type="doi">10.1073/pnas.2022495118</pub-id><pub-id pub-id-type="pmid">34161263</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Borst</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>The malate-aspartate shuttle (Borst cycle): How it started and developed into a major metabolic pathway</article-title><source>IUBMB Life</source><volume>72</volume><fpage>2241</fpage><lpage>2259</lpage><pub-id pub-id-type="doi">10.1002/iub.2367</pub-id><pub-id pub-id-type="pmid">32916028</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Commisso</surname><given-names>C</given-names></name><name><surname>Davidson</surname><given-names>SM</given-names></name><name><surname>Soydaner-Azeloglu</surname><given-names>RG</given-names></name><name><surname>Parker</surname><given-names>SJ</given-names></name><name><surname>Kamphorst</surname><given-names>JJ</given-names></name><name><surname>Hackett</surname><given-names>S</given-names></name><name><surname>Grabocka</surname><given-names>E</given-names></name><name><surname>Nofal</surname><given-names>M</given-names></name><name><surname>Drebin</surname><given-names>JA</given-names></name><name><surname>Thompson</surname><given-names>CB</given-names></name><name><surname>Rabinowitz</surname><given-names>JD</given-names></name><name><surname>Metallo</surname><given-names>CM</given-names></name><name><surname>Vander Heiden</surname><given-names>MG</given-names></name><name><surname>Bar-Sagi</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Macropinocytosis of protein is an amino acid supply route in Ras-transformed cells</article-title><source>Nature</source><volume>497</volume><fpage>633</fpage><lpage>637</lpage><pub-id pub-id-type="doi">10.1038/nature12138</pub-id><pub-id pub-id-type="pmid">23665962</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cox</surname><given-names>AD</given-names></name><name><surname>Fesik</surname><given-names>SW</given-names></name><name><surname>Kimmelman</surname><given-names>AC</given-names></name><name><surname>Luo</surname><given-names>J</given-names></name><name><surname>Der</surname><given-names>CJ</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Drugging the undruggable RAS: Mission possible?</article-title><source>Nature Reviews. Drug Discovery</source><volume>13</volume><fpage>828</fpage><lpage>851</lpage><pub-id pub-id-type="doi">10.1038/nrd4389</pub-id><pub-id pub-id-type="pmid">25323927</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elyada</surname><given-names>E</given-names></name><name><surname>Bolisetty</surname><given-names>M</given-names></name><name><surname>Laise</surname><given-names>P</given-names></name><name><surname>Flynn</surname><given-names>WF</given-names></name><name><surname>Courtois</surname><given-names>ET</given-names></name><name><surname>Burkhart</surname><given-names>RA</given-names></name><name><surname>Teinor</surname><given-names>JA</given-names></name><name><surname>Belleau</surname><given-names>P</given-names></name><name><surname>Biffi</surname><given-names>G</given-names></name><name><surname>Lucito</surname><given-names>MS</given-names></name><name><surname>Sivajothi</surname><given-names>S</given-names></name><name><surname>Armstrong</surname><given-names>TD</given-names></name><name><surname>Engle</surname><given-names>DD</given-names></name><name><surname>Yu</surname><given-names>KH</given-names></name><name><surname>Hao</surname><given-names>Y</given-names></name><name><surname>Wolfgang</surname><given-names>CL</given-names></name><name><surname>Park</surname><given-names>Y</given-names></name><name><surname>Preall</surname><given-names>J</given-names></name><name><surname>Jaffee</surname><given-names>EM</given-names></name><name><surname>Califano</surname><given-names>A</given-names></name><name><surname>Robson</surname><given-names>P</given-names></name><name><surname>Tuveson</surname><given-names>DA</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Cross-species single-cell analysis of pancreatic ductal adenocarcinoma reveals antigen-presenting cancer-associated fibroblasts</article-title><source>Cancer Discovery</source><volume>9</volume><fpage>1102</fpage><lpage>1123</lpage><pub-id pub-id-type="doi">10.1158/2159-8290.CD-19-0094</pub-id><pub-id pub-id-type="pmid">31197017</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Encarnación-Rosado</surname><given-names>J</given-names></name><name><surname>Kimmelman</surname><given-names>AC</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Harnessing metabolic dependencies in pancreatic cancers</article-title><source>Nature Reviews. Gastroenterology &amp; Hepatology</source><volume>18</volume><fpage>482</fpage><lpage>492</lpage><pub-id pub-id-type="doi">10.1038/s41575-021-00431-7</pub-id><pub-id pub-id-type="pmid">33742165</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garcia-Bermudez</surname><given-names>J</given-names></name><name><surname>Baudrier</surname><given-names>L</given-names></name><name><surname>La</surname><given-names>K</given-names></name><name><surname>Zhu</surname><given-names>XG</given-names></name><name><surname>Fidelin</surname><given-names>J</given-names></name><name><surname>Sviderskiy</surname><given-names>VO</given-names></name><name><surname>Papagiannakopoulos</surname><given-names>T</given-names></name><name><surname>Molina</surname><given-names>H</given-names></name><name><surname>Snuderl</surname><given-names>M</given-names></name><name><surname>Lewis</surname><given-names>CA</given-names></name><name><surname>Possemato</surname><given-names>RL</given-names></name><name><surname>Birsoy</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Aspartate is a limiting metabolite for cancer cell proliferation under hypoxia and in tumours</article-title><source>Nature Cell Biology</source><volume>20</volume><fpage>775</fpage><lpage>781</lpage><pub-id pub-id-type="doi">10.1038/s41556-018-0118-z</pub-id><pub-id pub-id-type="pmid">29941933</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garcia-Bermudez</surname><given-names>J</given-names></name><name><surname>Badgley</surname><given-names>MA</given-names></name><name><surname>Prasad</surname><given-names>S</given-names></name><name><surname>Baudrier</surname><given-names>L</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>La</surname><given-names>K</given-names></name><name><surname>Soula</surname><given-names>M</given-names></name><name><surname>Williams</surname><given-names>RT</given-names></name><name><surname>Yamaguchi</surname><given-names>N</given-names></name><name><surname>Hwang</surname><given-names>RF</given-names></name><name><surname>Taylor</surname><given-names>LJ</given-names></name><name><surname>de Stanchina</surname><given-names>E</given-names></name><name><surname>Rostandy</surname><given-names>B</given-names></name><name><surname>Alwaseem</surname><given-names>H</given-names></name><name><surname>Molina</surname><given-names>H</given-names></name><name><surname>Bar-Sagi</surname><given-names>D</given-names></name><name><surname>Birsoy</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Adaptive stimulation of macropinocytosis overcomes aspartate limitation in cancer cells under hypoxia</article-title><source>Nature Metabolism</source><volume>4</volume><fpage>724</fpage><lpage>738</lpage><pub-id pub-id-type="doi">10.1038/s42255-022-00583-z</pub-id><pub-id pub-id-type="pmid">35726024</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goodman</surname><given-names>RP</given-names></name><name><surname>Markhard</surname><given-names>AL</given-names></name><name><surname>Shah</surname><given-names>H</given-names></name><name><surname>Sharma</surname><given-names>R</given-names></name><name><surname>Skinner</surname><given-names>OS</given-names></name><name><surname>Clish</surname><given-names>CB</given-names></name><name><surname>Deik</surname><given-names>A</given-names></name><name><surname>Patgiri</surname><given-names>A</given-names></name><name><surname>Hsu</surname><given-names>Y-HH</given-names></name><name><surname>Masia</surname><given-names>R</given-names></name><name><surname>Noh</surname><given-names>HL</given-names></name><name><surname>Suk</surname><given-names>S</given-names></name><name><surname>Goldberger</surname><given-names>O</given-names></name><name><surname>Hirschhorn</surname><given-names>JN</given-names></name><name><surname>Yellen</surname><given-names>G</given-names></name><name><surname>Kim</surname><given-names>JK</given-names></name><name><surname>Mootha</surname><given-names>VK</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Hepatic NADH reductive stress underlies common variation in metabolic traits</article-title><source>Nature</source><volume>583</volume><fpage>122</fpage><lpage>126</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-2337-2</pub-id><pub-id pub-id-type="pmid">32461692</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gui</surname><given-names>DY</given-names></name><name><surname>Sullivan</surname><given-names>LB</given-names></name><name><surname>Luengo</surname><given-names>A</given-names></name><name><surname>Hosios</surname><given-names>AM</given-names></name><name><surname>Bush</surname><given-names>LN</given-names></name><name><surname>Gitego</surname><given-names>N</given-names></name><name><surname>Davidson</surname><given-names>SM</given-names></name><name><surname>Freinkman</surname><given-names>E</given-names></name><name><surname>Thomas</surname><given-names>CJ</given-names></name><name><surname>Vander Heiden</surname><given-names>MG</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Environment dictates dependence on mitochondrial complex i for nad+ and aspartate production and determines cancer cell sensitivity to metformin</article-title><source>Cell Metabolism</source><volume>24</volume><fpage>716</fpage><lpage>727</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2016.09.006</pub-id><pub-id pub-id-type="pmid">27746050</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guzmán</surname><given-names>C</given-names></name><name><surname>Bagga</surname><given-names>M</given-names></name><name><surname>Kaur</surname><given-names>A</given-names></name><name><surname>Westermarck</surname><given-names>J</given-names></name><name><surname>Abankwa</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>ColonyArea: an ImageJ plugin to automatically quantify colony formation in clonogenic assays</article-title><source>PLOS ONE</source><volume>9</volume><elocation-id>e92444</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0092444</pub-id><pub-id pub-id-type="pmid">24647355</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Halbrook</surname><given-names>CJ</given-names></name><name><surname>Lyssiotis</surname><given-names>CA</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Employing metabolism to improve the diagnosis and treatment of pancreatic cancer</article-title><source>Cancer Cell</source><volume>31</volume><fpage>5</fpage><lpage>19</lpage><pub-id pub-id-type="doi">10.1016/j.ccell.2016.12.006</pub-id><pub-id pub-id-type="pmid">28073003</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Halestrap</surname><given-names>AP</given-names></name></person-group><year iso-8601-date="2012">2012a</year><article-title>The monocarboxylate transporter family--Structure and functional characterization</article-title><source>IUBMB Life</source><volume>64</volume><fpage>1</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1002/iub.573</pub-id><pub-id pub-id-type="pmid">22131303</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Halestrap</surname><given-names>AP</given-names></name><name><surname>Wilson</surname><given-names>MC</given-names></name></person-group><year iso-8601-date="2012">2012b</year><article-title>The monocarboxylate transporter family--role and regulation</article-title><source>IUBMB Life</source><volume>64</volume><fpage>109</fpage><lpage>119</lpage><pub-id pub-id-type="doi">10.1002/iub.572</pub-id><pub-id pub-id-type="pmid">22162139</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Halestrap</surname><given-names>AP</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Monocarboxylic acid transport</article-title><source>Comprehensive Physiology</source><volume>3</volume><fpage>1611</fpage><lpage>1643</lpage><pub-id pub-id-type="doi">10.1002/cphy.c130008</pub-id><pub-id pub-id-type="pmid">24265240</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Helms</surname><given-names>EJ</given-names></name><name><surname>Berry</surname><given-names>MW</given-names></name><name><surname>Chaw</surname><given-names>RC</given-names></name><name><surname>DuFort</surname><given-names>CC</given-names></name><name><surname>Sun</surname><given-names>D</given-names></name><name><surname>Onate</surname><given-names>MK</given-names></name><name><surname>Oon</surname><given-names>C</given-names></name><name><surname>Bhattacharyya</surname><given-names>S</given-names></name><name><surname>Sanford-Crane</surname><given-names>H</given-names></name><name><surname>Horton</surname><given-names>W</given-names></name><name><surname>Finan</surname><given-names>JM</given-names></name><name><surname>Sattler</surname><given-names>A</given-names></name><name><surname>Makar</surname><given-names>R</given-names></name><name><surname>Dawson</surname><given-names>DW</given-names></name><name><surname>Xia</surname><given-names>Z</given-names></name><name><surname>Hingorani</surname><given-names>SR</given-names></name><name><surname>Sherman</surname><given-names>MH</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Mesenchymal lineage heterogeneity underlies nonredundant functions of pancreatic cancer-associated fibroblasts</article-title><source>Cancer Discovery</source><volume>12</volume><fpage>484</fpage><lpage>501</lpage><pub-id pub-id-type="doi">10.1158/2159-8290.CD-21-0601</pub-id><pub-id pub-id-type="pmid">34548310</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hingorani</surname><given-names>SR</given-names></name><name><surname>Petricoin</surname><given-names>EF</given-names></name><name><surname>Maitra</surname><given-names>A</given-names></name><name><surname>Rajapakse</surname><given-names>V</given-names></name><name><surname>King</surname><given-names>C</given-names></name><name><surname>Jacobetz</surname><given-names>MA</given-names></name><name><surname>Ross</surname><given-names>S</given-names></name><name><surname>Conrads</surname><given-names>TP</given-names></name><name><surname>Veenstra</surname><given-names>TD</given-names></name><name><surname>Hitt</surname><given-names>BA</given-names></name><name><surname>Kawaguchi</surname><given-names>Y</given-names></name><name><surname>Johann</surname><given-names>D</given-names></name><name><surname>Liotta</surname><given-names>LA</given-names></name><name><surname>Crawford</surname><given-names>HC</given-names></name><name><surname>Putt</surname><given-names>ME</given-names></name><name><surname>Jacks</surname><given-names>T</given-names></name><name><surname>Wright</surname><given-names>CVE</given-names></name><name><surname>Hruban</surname><given-names>RH</given-names></name><name><surname>Lowy</surname><given-names>AM</given-names></name><name><surname>Tuveson</surname><given-names>DA</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse</article-title><source>Cancer Cell</source><volume>4</volume><fpage>437</fpage><lpage>450</lpage><pub-id pub-id-type="doi">10.1016/s1535-6108(03)00309-x</pub-id><pub-id pub-id-type="pmid">14706336</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hong</surname><given-names>CS</given-names></name><name><surname>Graham</surname><given-names>NA</given-names></name><name><surname>Gu</surname><given-names>W</given-names></name><name><surname>Espindola Camacho</surname><given-names>C</given-names></name><name><surname>Mah</surname><given-names>V</given-names></name><name><surname>Maresh</surname><given-names>EL</given-names></name><name><surname>Alavi</surname><given-names>M</given-names></name><name><surname>Bagryanova</surname><given-names>L</given-names></name><name><surname>Krotee</surname><given-names>PAL</given-names></name><name><surname>Gardner</surname><given-names>BK</given-names></name><name><surname>Behbahan</surname><given-names>IS</given-names></name><name><surname>Horvath</surname><given-names>S</given-names></name><name><surname>Chia</surname><given-names>D</given-names></name><name><surname>Mellinghoff</surname><given-names>IK</given-names></name><name><surname>Hurvitz</surname><given-names>SA</given-names></name><name><surname>Dubinett</surname><given-names>SM</given-names></name><name><surname>Critchlow</surname><given-names>SE</given-names></name><name><surname>Kurdistani</surname><given-names>SK</given-names></name><name><surname>Goodglick</surname><given-names>L</given-names></name><name><surname>Braas</surname><given-names>D</given-names></name><name><surname>Graeber</surname><given-names>TG</given-names></name><name><surname>Christofk</surname><given-names>HR</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>MCT1 modulates cancer cell pyruvate export and growth of tumors that co-express MCT1 and mct4MCT1 Modulates Cancer Cell Pyruvate Export and Growth of Tumors that Co-express MCT1 and MCT4</article-title><source>Cell Reports</source><volume>14</volume><fpage>1590</fpage><lpage>1601</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2016.01.057</pub-id><pub-id pub-id-type="pmid">26876179</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hosein</surname><given-names>AN</given-names></name><name><surname>Huang</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Parmar</surname><given-names>K</given-names></name><name><surname>Du</surname><given-names>W</given-names></name><name><surname>Huang</surname><given-names>J</given-names></name><name><surname>Maitra</surname><given-names>A</given-names></name><name><surname>Olson</surname><given-names>E</given-names></name><name><surname>Verma</surname><given-names>U</given-names></name><name><surname>Brekken</surname><given-names>RA</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Cellular heterogeneity during mouse pancreatic ductal adenocarcinoma progression at single-cell resolution</article-title><source>JCI Insight</source><volume>5</volume><elocation-id>129212</elocation-id><pub-id pub-id-type="doi">10.1172/jci.insight.129212</pub-id><pub-id pub-id-type="pmid">31335328</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hui</surname><given-names>S</given-names></name><name><surname>Ghergurovich</surname><given-names>JM</given-names></name><name><surname>Morscher</surname><given-names>RJ</given-names></name><name><surname>Jang</surname><given-names>C</given-names></name><name><surname>Teng</surname><given-names>X</given-names></name><name><surname>Lu</surname><given-names>W</given-names></name><name><surname>Esparza</surname><given-names>LA</given-names></name><name><surname>Reya</surname><given-names>T</given-names></name><name><surname>Yanxiang Guo</surname><given-names>J</given-names></name><name><surname>White</surname><given-names>E</given-names></name><name><surname>Rabinowitz</surname><given-names>JD</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Glucose feeds the TCA cycle via circulating lactate</article-title><source>Nature</source><volume>551</volume><fpage>115</fpage><lpage>118</lpage><pub-id pub-id-type="doi">10.1038/nature24057</pub-id><pub-id pub-id-type="pmid">29045397</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hui</surname><given-names>S</given-names></name><name><surname>Cowan</surname><given-names>AJ</given-names></name><name><surname>Zeng</surname><given-names>X</given-names></name><name><surname>Yang</surname><given-names>L</given-names></name><name><surname>TeSlaa</surname><given-names>T</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Bartman</surname><given-names>C</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Jang</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Lu</surname><given-names>W</given-names></name><name><surname>Rojas</surname><given-names>J</given-names></name><name><surname>Baur</surname><given-names>J</given-names></name><name><surname>Rabinowitz</surname><given-names>JD</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Quantitative fluxomics of circulating metabolites</article-title><source>Cell Metabolism</source><volume>32</volume><fpage>676</fpage><lpage>688</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2020.07.013</pub-id><pub-id pub-id-type="pmid">32791100</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Humpton</surname><given-names>TJ</given-names></name><name><surname>Alagesan</surname><given-names>B</given-names></name><name><surname>DeNicola</surname><given-names>GM</given-names></name><name><surname>Lu</surname><given-names>D</given-names></name><name><surname>Yordanov</surname><given-names>GN</given-names></name><name><surname>Leonhardt</surname><given-names>CS</given-names></name><name><surname>Yao</surname><given-names>MA</given-names></name><name><surname>Alagesan</surname><given-names>P</given-names></name><name><surname>Zaatari</surname><given-names>MN</given-names></name><name><surname>Park</surname><given-names>Y</given-names></name><name><surname>Skepper</surname><given-names>JN</given-names></name><name><surname>Macleod</surname><given-names>KF</given-names></name><name><surname>Perez-Mancera</surname><given-names>PA</given-names></name><name><surname>Murphy</surname><given-names>MP</given-names></name><name><surname>Evan</surname><given-names>GI</given-names></name><name><surname>Vousden</surname><given-names>KH</given-names></name><name><surname>Tuveson</surname><given-names>DA</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Oncogenic kras induces nix-mediated mitophagy to promote pancreatic cancer</article-title><source>Cancer Discovery</source><volume>9</volume><fpage>1268</fpage><lpage>1287</lpage><pub-id pub-id-type="doi">10.1158/2159-8290.CD-18-1409</pub-id><pub-id pub-id-type="pmid">31263025</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hutton</surname><given-names>C</given-names></name><name><surname>Heider</surname><given-names>F</given-names></name><name><surname>Blanco-Gomez</surname><given-names>A</given-names></name><name><surname>Banyard</surname><given-names>A</given-names></name><name><surname>Kononov</surname><given-names>A</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Karim</surname><given-names>S</given-names></name><name><surname>Paulus-Hock</surname><given-names>V</given-names></name><name><surname>Watt</surname><given-names>D</given-names></name><name><surname>Steele</surname><given-names>N</given-names></name><name><surname>Kemp</surname><given-names>S</given-names></name><name><surname>Hogg</surname><given-names>EKJ</given-names></name><name><surname>Kelly</surname><given-names>J</given-names></name><name><surname>Jackstadt</surname><given-names>R-F</given-names></name><name><surname>Lopes</surname><given-names>F</given-names></name><name><surname>Menotti</surname><given-names>M</given-names></name><name><surname>Chisholm</surname><given-names>L</given-names></name><name><surname>Lamarca</surname><given-names>A</given-names></name><name><surname>Valle</surname><given-names>J</given-names></name><name><surname>Sansom</surname><given-names>OJ</given-names></name><name><surname>Springer</surname><given-names>C</given-names></name><name><surname>Malliri</surname><given-names>A</given-names></name><name><surname>Marais</surname><given-names>R</given-names></name><name><surname>Pasca di Magliano</surname><given-names>M</given-names></name><name><surname>Zelenay</surname><given-names>S</given-names></name><name><surname>Morton</surname><given-names>JP</given-names></name><name><surname>Jørgensen</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Single-cell analysis defines a pancreatic fibroblast lineage that supports anti-tumor immunity</article-title><source>Cancer Cell</source><volume>39</volume><fpage>1227</fpage><lpage>1244</lpage><pub-id pub-id-type="doi">10.1016/j.ccell.2021.06.017</pub-id><pub-id pub-id-type="pmid">34297917</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hwang</surname><given-names>RF</given-names></name><name><surname>Moore</surname><given-names>T</given-names></name><name><surname>Arumugam</surname><given-names>T</given-names></name><name><surname>Ramachandran</surname><given-names>V</given-names></name><name><surname>Amos</surname><given-names>KD</given-names></name><name><surname>Rivera</surname><given-names>A</given-names></name><name><surname>Ji</surname><given-names>B</given-names></name><name><surname>Evans</surname><given-names>DB</given-names></name><name><surname>Logsdon</surname><given-names>CD</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Cancer-associated stromal fibroblasts promote pancreatic tumor progression</article-title><source>Cancer Research</source><volume>68</volume><fpage>918</fpage><lpage>926</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-07-5714</pub-id><pub-id pub-id-type="pmid">18245495</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Janes</surname><given-names>MR</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>L-S</given-names></name><name><surname>Hansen</surname><given-names>R</given-names></name><name><surname>Peters</surname><given-names>U</given-names></name><name><surname>Guo</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Babbar</surname><given-names>A</given-names></name><name><surname>Firdaus</surname><given-names>SJ</given-names></name><name><surname>Darjania</surname><given-names>L</given-names></name><name><surname>Feng</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>JH</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Long</surname><given-names>YO</given-names></name><name><surname>Thach</surname><given-names>C</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Zarieh</surname><given-names>A</given-names></name><name><surname>Ely</surname><given-names>T</given-names></name><name><surname>Kucharski</surname><given-names>JM</given-names></name><name><surname>Kessler</surname><given-names>LV</given-names></name><name><surname>Wu</surname><given-names>T</given-names></name><name><surname>Yu</surname><given-names>K</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Yao</surname><given-names>Y</given-names></name><name><surname>Deng</surname><given-names>X</given-names></name><name><surname>Zarrinkar</surname><given-names>PP</given-names></name><name><surname>Brehmer</surname><given-names>D</given-names></name><name><surname>Dhanak</surname><given-names>D</given-names></name><name><surname>Lorenzi</surname><given-names>MV</given-names></name><name><surname>Hu-Lowe</surname><given-names>D</given-names></name><name><surname>Patricelli</surname><given-names>MP</given-names></name><name><surname>Ren</surname><given-names>P</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Targeting kras mutant cancers with a covalent g12c-specific inhibitor</article-title><source>Cell</source><volume>172</volume><fpage>578</fpage><lpage>589</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2018.01.006</pub-id><pub-id pub-id-type="pmid">29373830</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jänne</surname><given-names>PA</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Adagrasib in non-small-cell lung cancer harboring a KRAS(G12C) mutationAdagrasib in Non-Small-Cell Lung Cancer Harboring a KRAS(G12C) Mutation</article-title><source>The New England Journal of Medicine</source><volume>387</volume><fpage>120</fpage><lpage>131</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2204619</pub-id><pub-id pub-id-type="pmid">35658005</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kamphorst</surname><given-names>JJ</given-names></name><name><surname>Nofal</surname><given-names>M</given-names></name><name><surname>Commisso</surname><given-names>C</given-names></name><name><surname>Hackett</surname><given-names>SR</given-names></name><name><surname>Lu</surname><given-names>W</given-names></name><name><surname>Grabocka</surname><given-names>E</given-names></name><name><surname>Vander Heiden</surname><given-names>MG</given-names></name><name><surname>Miller</surname><given-names>G</given-names></name><name><surname>Drebin</surname><given-names>JA</given-names></name><name><surname>Bar-Sagi</surname><given-names>D</given-names></name><name><surname>Thompson</surname><given-names>CB</given-names></name><name><surname>Rabinowitz</surname><given-names>JD</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Human pancreatic cancer tumors are nutrient poor and tumor cells actively scavenge extracellular protein</article-title><source>Cancer Research</source><volume>75</volume><fpage>544</fpage><lpage>553</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-14-2211</pub-id><pub-id pub-id-type="pmid">25644265</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kerk</surname><given-names>SA</given-names></name><name><surname>Papagiannakopoulos</surname><given-names>T</given-names></name><name><surname>Shah</surname><given-names>YM</given-names></name><name><surname>Lyssiotis</surname><given-names>CA</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Metabolic networks in mutant KRAS-driven tumours: tissue specificities and the microenvironment</article-title><source>Nature Reviews. Cancer</source><volume>21</volume><fpage>510</fpage><lpage>525</lpage><pub-id pub-id-type="doi">10.1038/s41568-021-00375-9</pub-id><pub-id pub-id-type="pmid">34244683</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>W</given-names></name><name><surname>Deik</surname><given-names>A</given-names></name><name><surname>Gonzalez</surname><given-names>C</given-names></name><name><surname>Gonzalez</surname><given-names>ME</given-names></name><name><surname>Fu</surname><given-names>F</given-names></name><name><surname>Ferrari</surname><given-names>M</given-names></name><name><surname>Churchhouse</surname><given-names>CL</given-names></name><name><surname>Florez</surname><given-names>JC</given-names></name><name><surname>Jacobs</surname><given-names>SBR</given-names></name><name><surname>Clish</surname><given-names>CB</given-names></name><name><surname>Rhee</surname><given-names>EP</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Polyunsaturated fatty acid desaturation is a mechanism for glycolytic NAD<sup>+</sup> recycling</article-title><source>Cell Metabolism</source><volume>29</volume><fpage>856</fpage><lpage>870</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2018.12.023</pub-id><pub-id pub-id-type="pmid">30686744</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Le</surname><given-names>A</given-names></name><name><surname>Cooper</surname><given-names>CR</given-names></name><name><surname>Gouw</surname><given-names>AM</given-names></name><name><surname>Dinavahi</surname><given-names>R</given-names></name><name><surname>Maitra</surname><given-names>A</given-names></name><name><surname>Deck</surname><given-names>LM</given-names></name><name><surname>Royer</surname><given-names>RE</given-names></name><name><surname>Vander Jagt</surname><given-names>DL</given-names></name><name><surname>Semenza</surname><given-names>GL</given-names></name><name><surname>Dang</surname><given-names>CV</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression</article-title><source>PNAS</source><volume>107</volume><fpage>2037</fpage><lpage>2042</lpage><pub-id pub-id-type="doi">10.1073/pnas.0914433107</pub-id><pub-id pub-id-type="pmid">20133848</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lemons</surname><given-names>JMS</given-names></name><name><surname>Feng</surname><given-names>X-J</given-names></name><name><surname>Bennett</surname><given-names>BD</given-names></name><name><surname>Legesse-Miller</surname><given-names>A</given-names></name><name><surname>Johnson</surname><given-names>EL</given-names></name><name><surname>Raitman</surname><given-names>I</given-names></name><name><surname>Pollina</surname><given-names>EA</given-names></name><name><surname>Rabitz</surname><given-names>HA</given-names></name><name><surname>Rabinowitz</surname><given-names>JD</given-names></name><name><surname>Coller</surname><given-names>HA</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Quiescent fibroblasts exhibit high metabolic activity</article-title><source>PLOS Biology</source><volume>8</volume><elocation-id>e1000514</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pbio.1000514</pub-id><pub-id pub-id-type="pmid">21049082</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Heidt</surname><given-names>DG</given-names></name><name><surname>Dalerba</surname><given-names>P</given-names></name><name><surname>Burant</surname><given-names>CF</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Adsay</surname><given-names>V</given-names></name><name><surname>Wicha</surname><given-names>M</given-names></name><name><surname>Clarke</surname><given-names>MF</given-names></name><name><surname>Simeone</surname><given-names>DM</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Identification of pancreatic cancer stem cells</article-title><source>Cancer Research</source><volume>67</volume><fpage>1030</fpage><lpage>1037</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-06-2030</pub-id><pub-id pub-id-type="pmid">17283135</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Fu</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>G</given-names></name><name><surname>Cao</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>N</given-names></name><name><surname>Shan</surname><given-names>Y</given-names></name><name><surname>Cao</surname><given-names>Y</given-names></name><name><surname>Ma</surname><given-names>Y</given-names></name><name><surname>Dong</surname><given-names>M</given-names></name><name><surname>Liu</surname><given-names>Q</given-names></name><name><surname>Jiang</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Glycerol-3-phosphate biosynthesis regenerates cytosolic NAD<sup>+</sup> to alleviate mitochondrial disease</article-title><source>Cell Metabolism</source><volume>33</volume><fpage>1974</fpage><lpage>1987</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2021.06.013</pub-id><pub-id pub-id-type="pmid">34270929</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lyssiotis</surname><given-names>CA</given-names></name><name><surname>Kimmelman</surname><given-names>AC</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Metabolic interactions in the tumor microenvironment</article-title><source>Trends in Cell Biology</source><volume>27</volume><fpage>863</fpage><lpage>875</lpage><pub-id pub-id-type="doi">10.1016/j.tcb.2017.06.003</pub-id><pub-id pub-id-type="pmid">28734735</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martínez-Reyes</surname><given-names>I</given-names></name><name><surname>Chandel</surname><given-names>NS</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Cancer metabolism: looking forward</article-title><source>Nature Reviews. Cancer</source><volume>21</volume><fpage>669</fpage><lpage>680</lpage><pub-id pub-id-type="doi">10.1038/s41568-021-00378-6</pub-id><pub-id pub-id-type="pmid">34272515</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mick</surname><given-names>E</given-names></name><name><surname>Titov</surname><given-names>DV</given-names></name><name><surname>Skinner</surname><given-names>OS</given-names></name><name><surname>Sharma</surname><given-names>R</given-names></name><name><surname>Jourdain</surname><given-names>AA</given-names></name><name><surname>Mootha</surname><given-names>VK</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Distinct mitochondrial defects trigger the integrated stress response depending on the metabolic state of the cell</article-title><source>eLife</source><volume>9</volume><elocation-id>e49178</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.49178</pub-id><pub-id pub-id-type="pmid">32463360</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Molina</surname><given-names>JR</given-names></name><name><surname>Sun</surname><given-names>Y</given-names></name><name><surname>Protopopova</surname><given-names>M</given-names></name><name><surname>Gera</surname><given-names>S</given-names></name><name><surname>Bandi</surname><given-names>M</given-names></name><name><surname>Bristow</surname><given-names>C</given-names></name><name><surname>McAfoos</surname><given-names>T</given-names></name><name><surname>Morlacchi</surname><given-names>P</given-names></name><name><surname>Ackroyd</surname><given-names>J</given-names></name><name><surname>Agip</surname><given-names>A-NA</given-names></name><name><surname>Al-Atrash</surname><given-names>G</given-names></name><name><surname>Asara</surname><given-names>J</given-names></name><name><surname>Bardenhagen</surname><given-names>J</given-names></name><name><surname>Carrillo</surname><given-names>CC</given-names></name><name><surname>Carroll</surname><given-names>C</given-names></name><name><surname>Chang</surname><given-names>E</given-names></name><name><surname>Ciurea</surname><given-names>S</given-names></name><name><surname>Cross</surname><given-names>JB</given-names></name><name><surname>Czako</surname><given-names>B</given-names></name><name><surname>Deem</surname><given-names>A</given-names></name><name><surname>Daver</surname><given-names>N</given-names></name><name><surname>de Groot</surname><given-names>JF</given-names></name><name><surname>Dong</surname><given-names>J-W</given-names></name><name><surname>Feng</surname><given-names>N</given-names></name><name><surname>Gao</surname><given-names>G</given-names></name><name><surname>Gay</surname><given-names>J</given-names></name><name><surname>Do</surname><given-names>MG</given-names></name><name><surname>Greer</surname><given-names>J</given-names></name><name><surname>Giuliani</surname><given-names>V</given-names></name><name><surname>Han</surname><given-names>J</given-names></name><name><surname>Han</surname><given-names>L</given-names></name><name><surname>Henry</surname><given-names>VK</given-names></name><name><surname>Hirst</surname><given-names>J</given-names></name><name><surname>Huang</surname><given-names>S</given-names></name><name><surname>Jiang</surname><given-names>Y</given-names></name><name><surname>Kang</surname><given-names>Z</given-names></name><name><surname>Khor</surname><given-names>T</given-names></name><name><surname>Konoplev</surname><given-names>S</given-names></name><name><surname>Lin</surname><given-names>Y-H</given-names></name><name><surname>Liu</surname><given-names>G</given-names></name><name><surname>Lodi</surname><given-names>A</given-names></name><name><surname>Lofton</surname><given-names>T</given-names></name><name><surname>Ma</surname><given-names>H</given-names></name><name><surname>Mahendra</surname><given-names>M</given-names></name><name><surname>Matre</surname><given-names>P</given-names></name><name><surname>Mullinax</surname><given-names>R</given-names></name><name><surname>Peoples</surname><given-names>M</given-names></name><name><surname>Petrocchi</surname><given-names>A</given-names></name><name><surname>Rodriguez-Canale</surname><given-names>J</given-names></name><name><surname>Serreli</surname><given-names>R</given-names></name><name><surname>Shi</surname><given-names>T</given-names></name><name><surname>Smith</surname><given-names>M</given-names></name><name><surname>Tabe</surname><given-names>Y</given-names></name><name><surname>Theroff</surname><given-names>J</given-names></name><name><surname>Tiziani</surname><given-names>S</given-names></name><name><surname>Xu</surname><given-names>Q</given-names></name><name><surname>Zhang</surname><given-names>Q</given-names></name><name><surname>Muller</surname><given-names>F</given-names></name><name><surname>DePinho</surname><given-names>RA</given-names></name><name><surname>Toniatti</surname><given-names>C</given-names></name><name><surname>Draetta</surname><given-names>GF</given-names></name><name><surname>Heffernan</surname><given-names>TP</given-names></name><name><surname>Konopleva</surname><given-names>M</given-names></name><name><surname>Jones</surname><given-names>P</given-names></name><name><surname>Di Francesco</surname><given-names>ME</given-names></name><name><surname>Marszalek</surname><given-names>JR</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>An inhibitor of oxidative phosphorylation exploits cancer vulnerability</article-title><source>Nature Medicine</source><volume>24</volume><fpage>1036</fpage><lpage>1046</lpage><pub-id pub-id-type="doi">10.1038/s41591-018-0052-4</pub-id><pub-id pub-id-type="pmid">29892070</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Neuzillet</surname><given-names>C</given-names></name><name><surname>Tijeras-Raballand</surname><given-names>A</given-names></name><name><surname>Ragulan</surname><given-names>C</given-names></name><name><surname>Cros</surname><given-names>J</given-names></name><name><surname>Patil</surname><given-names>Y</given-names></name><name><surname>Martinet</surname><given-names>M</given-names></name><name><surname>Erkan</surname><given-names>M</given-names></name><name><surname>Kleeff</surname><given-names>J</given-names></name><name><surname>Wilson</surname><given-names>J</given-names></name><name><surname>Apte</surname><given-names>M</given-names></name><name><surname>Tosolini</surname><given-names>M</given-names></name><name><surname>Wilson</surname><given-names>AS</given-names></name><name><surname>Delvecchio</surname><given-names>FR</given-names></name><name><surname>Bousquet</surname><given-names>C</given-names></name><name><surname>Paradis</surname><given-names>V</given-names></name><name><surname>Hammel</surname><given-names>P</given-names></name><name><surname>Sadanandam</surname><given-names>A</given-names></name><name><surname>Kocher</surname><given-names>HM</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Inter- and intra-tumoural heterogeneity in cancer-associated fibroblasts of human pancreatic ductal adenocarcinoma</article-title><source>The Journal of Pathology</source><volume>248</volume><fpage>51</fpage><lpage>65</lpage><pub-id pub-id-type="doi">10.1002/path.5224</pub-id><pub-id pub-id-type="pmid">30575030</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ohlund</surname><given-names>D</given-names></name><name><surname>Handly-Santana</surname><given-names>A</given-names></name><name><surname>Biffi</surname><given-names>G</given-names></name><name><surname>Elyada</surname><given-names>E</given-names></name><name><surname>Almeida</surname><given-names>AS</given-names></name><name><surname>Ponz-Sarvise</surname><given-names>M</given-names></name><name><surname>Corbo</surname><given-names>V</given-names></name><name><surname>Oni</surname><given-names>TE</given-names></name><name><surname>Hearn</surname><given-names>SA</given-names></name><name><surname>Lee</surname><given-names>EJ</given-names></name><name><surname>Chio</surname><given-names>IIC</given-names></name><name><surname>Hwang</surname><given-names>CI</given-names></name><name><surname>Tiriac</surname><given-names>H</given-names></name><name><surname>Baker</surname><given-names>LA</given-names></name><name><surname>Engle</surname><given-names>DD</given-names></name><name><surname>Feig</surname><given-names>C</given-names></name><name><surname>Kultti</surname><given-names>A</given-names></name><name><surname>Egeblad</surname><given-names>M</given-names></name><name><surname>Fearon</surname><given-names>DT</given-names></name><name><surname>Crawford</surname><given-names>JM</given-names></name><name><surname>Clevers</surname><given-names>H</given-names></name><name><surname>Park</surname><given-names>Y</given-names></name><name><surname>Tuveson</surname><given-names>DA</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer</article-title><source>The Journal of Experimental Medicine</source><volume>214</volume><fpage>579</fpage><lpage>596</lpage><pub-id pub-id-type="doi">10.1084/jem.20162024</pub-id><pub-id pub-id-type="pmid">28232471</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parker</surname><given-names>SJ</given-names></name><name><surname>Encarnación-Rosado</surname><given-names>J</given-names></name><name><surname>Hollinshead</surname><given-names>KER</given-names></name><name><surname>Hollinshead</surname><given-names>DM</given-names></name><name><surname>Ash</surname><given-names>LJ</given-names></name><name><surname>Rossi</surname><given-names>JAK</given-names></name><name><surname>Lin</surname><given-names>EY</given-names></name><name><surname>Sohn</surname><given-names>ASW</given-names></name><name><surname>Philips</surname><given-names>MR</given-names></name><name><surname>Jones</surname><given-names>DR</given-names></name><name><surname>Kimmelman</surname><given-names>AC</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Spontaneous hydrolysis and spurious metabolic properties of α-ketoglutarate esters</article-title><source>Nature Communications</source><volume>12</volume><elocation-id>4905</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-021-25228-9</pub-id><pub-id pub-id-type="pmid">34385458</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pavlova</surname><given-names>NN</given-names></name><name><surname>Thompson</surname><given-names>CB</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>The emerging hallmarks of cancer metabolism</article-title><source>Cell Metabolism</source><volume>23</volume><fpage>27</fpage><lpage>47</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2015.12.006</pub-id><pub-id pub-id-type="pmid">26771115</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Polański</surname><given-names>R</given-names></name><name><surname>Hodgkinson</surname><given-names>CL</given-names></name><name><surname>Fusi</surname><given-names>A</given-names></name><name><surname>Nonaka</surname><given-names>D</given-names></name><name><surname>Priest</surname><given-names>L</given-names></name><name><surname>Kelly</surname><given-names>P</given-names></name><name><surname>Trapani</surname><given-names>F</given-names></name><name><surname>Bishop</surname><given-names>PW</given-names></name><name><surname>White</surname><given-names>A</given-names></name><name><surname>Critchlow</surname><given-names>SE</given-names></name><name><surname>Smith</surname><given-names>PD</given-names></name><name><surname>Blackhall</surname><given-names>F</given-names></name><name><surname>Dive</surname><given-names>C</given-names></name><name><surname>Morrow</surname><given-names>CJ</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Activity of the monocarboxylate transporter 1 inhibitor AZD3965 in small cell lung cancer</article-title><source>Clinical Cancer Research</source><volume>20</volume><fpage>926</fpage><lpage>937</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-13-2270</pub-id><pub-id pub-id-type="pmid">24277449</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ran</surname><given-names>FA</given-names></name><name><surname>Hsu</surname><given-names>PD</given-names></name><name><surname>Wright</surname><given-names>J</given-names></name><name><surname>Agarwala</surname><given-names>V</given-names></name><name><surname>Scott</surname><given-names>DA</given-names></name><name><surname>Zhang</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Genome engineering using the CRISPR-Cas9 system</article-title><source>Nature Protocols</source><volume>8</volume><fpage>2281</fpage><lpage>2308</lpage><pub-id pub-id-type="doi">10.1038/nprot.2013.143</pub-id><pub-id pub-id-type="pmid">24157548</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rao</surname><given-names>Y</given-names></name><name><surname>Gammon</surname><given-names>S</given-names></name><name><surname>Zacharias</surname><given-names>NM</given-names></name><name><surname>Liu</surname><given-names>T</given-names></name><name><surname>Salzillo</surname><given-names>T</given-names></name><name><surname>Xi</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Bhattacharya</surname><given-names>P</given-names></name><name><surname>Piwnica-Worms</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Hyperpolarized [1-<sup>13</sup>C]pyruvate-to-[1-<sup>13</sup>C]lactate conversion is rate-limited by monocarboxylate transporter-1 in the plasma membrane</article-title><source>PNAS</source><volume>117</volume><fpage>22378</fpage><lpage>22389</lpage><pub-id pub-id-type="doi">10.1073/pnas.2003537117</pub-id><pub-id pub-id-type="pmid">32839325</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rao</surname><given-names>Y</given-names></name><name><surname>Gammon</surname><given-names>ST</given-names></name><name><surname>Sutton</surname><given-names>MN</given-names></name><name><surname>Zacharias</surname><given-names>NM</given-names></name><name><surname>Bhattacharya</surname><given-names>P</given-names></name><name><surname>Piwnica-Worms</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Excess exogenous pyruvate inhibits lactate dehydrogenase activity in live cells in an MCT1-dependent manner</article-title><source>The Journal of Biological Chemistry</source><volume>297</volume><elocation-id>100775</elocation-id><pub-id pub-id-type="doi">10.1016/j.jbc.2021.100775</pub-id><pub-id pub-id-type="pmid">34022218</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ryan</surname><given-names>DP</given-names></name><name><surname>Hong</surname><given-names>TS</given-names></name><name><surname>Bardeesy</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Pancreatic adenocarcinoma</article-title><source>The New England Journal of Medicine</source><volume>371</volume><fpage>1039</fpage><lpage>1049</lpage><pub-id pub-id-type="doi">10.1056/NEJMra1404198</pub-id><pub-id pub-id-type="pmid">25207767</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sakamoto</surname><given-names>A</given-names></name><name><surname>Kunou</surname><given-names>S</given-names></name><name><surname>Shimada</surname><given-names>K</given-names></name><name><surname>Tsunoda</surname><given-names>M</given-names></name><name><surname>Aoki</surname><given-names>T</given-names></name><name><surname>Iriyama</surname><given-names>C</given-names></name><name><surname>Tomita</surname><given-names>A</given-names></name><name><surname>Nakamura</surname><given-names>S</given-names></name><name><surname>Hayakawa</surname><given-names>F</given-names></name><name><surname>Kiyoi</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Pyruvate secreted from patient-derived cancer-associated fibroblasts supports survival of primary lymphoma cells</article-title><source>Cancer Science</source><volume>110</volume><fpage>269</fpage><lpage>278</lpage><pub-id pub-id-type="doi">10.1111/cas.13873</pub-id><pub-id pub-id-type="pmid">30426593</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sanford-Crane</surname><given-names>H</given-names></name><name><surname>Abrego</surname><given-names>J</given-names></name><name><surname>Sherman</surname><given-names>MH</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Fibroblasts as modulators of local and systemic cancer metabolism</article-title><source>Cancers</source><volume>11</volume><elocation-id>E619</elocation-id><pub-id pub-id-type="doi">10.3390/cancers11050619</pub-id><pub-id pub-id-type="pmid">31058816</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Santana-Codina</surname><given-names>N</given-names></name><name><surname>Roeth</surname><given-names>AA</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>A</given-names></name><name><surname>Mashadova</surname><given-names>O</given-names></name><name><surname>Asara</surname><given-names>JM</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Bronson</surname><given-names>RT</given-names></name><name><surname>Lyssiotis</surname><given-names>CA</given-names></name><name><surname>Ying</surname><given-names>H</given-names></name><name><surname>Kimmelman</surname><given-names>AC</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Oncogenic KRAS supports pancreatic cancer through regulation of nucleotide synthesis</article-title><source>Nature Communications</source><volume>9</volume><elocation-id>4945</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-018-07472-8</pub-id><pub-id pub-id-type="pmid">30470748</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schwörer</surname><given-names>S</given-names></name><name><surname>Vardhana</surname><given-names>SA</given-names></name><name><surname>Thompson</surname><given-names>CB</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Cancer metabolism drives a stromal regenerative response</article-title><source>Cell Metabolism</source><volume>29</volume><fpage>576</fpage><lpage>591</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2019.01.015</pub-id><pub-id pub-id-type="pmid">30773467</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>MCP</given-names></name><name><surname>Luker</surname><given-names>KE</given-names></name><name><surname>Garbow</surname><given-names>JR</given-names></name><name><surname>Prior</surname><given-names>JL</given-names></name><name><surname>Jackson</surname><given-names>E</given-names></name><name><surname>Piwnica-Worms</surname><given-names>D</given-names></name><name><surname>Luker</surname><given-names>GD</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>CXCR4 regulates growth of both primary and metastatic breast cancer</article-title><source>Cancer Research</source><volume>64</volume><fpage>8604</fpage><lpage>8612</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-04-1844</pub-id><pub-id pub-id-type="pmid">15574767</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Son</surname><given-names>J</given-names></name><name><surname>Lyssiotis</surname><given-names>CA</given-names></name><name><surname>Ying</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Hua</surname><given-names>S</given-names></name><name><surname>Ligorio</surname><given-names>M</given-names></name><name><surname>Perera</surname><given-names>RM</given-names></name><name><surname>Ferrone</surname><given-names>CR</given-names></name><name><surname>Mullarky</surname><given-names>E</given-names></name><name><surname>Shyh-Chang</surname><given-names>N</given-names></name><name><surname>Kang</surname><given-names>Y</given-names></name><name><surname>Fleming</surname><given-names>JB</given-names></name><name><surname>Bardeesy</surname><given-names>N</given-names></name><name><surname>Asara</surname><given-names>JM</given-names></name><name><surname>Haigis</surname><given-names>MC</given-names></name><name><surname>DePinho</surname><given-names>RA</given-names></name><name><surname>Cantley</surname><given-names>LC</given-names></name><name><surname>Kimmelman</surname><given-names>AC</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway</article-title><source>Nature</source><volume>496</volume><fpage>101</fpage><lpage>105</lpage><pub-id pub-id-type="doi">10.1038/nature12040</pub-id><pub-id pub-id-type="pmid">23535601</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sousa</surname><given-names>CM</given-names></name><name><surname>Biancur</surname><given-names>DE</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Halbrook</surname><given-names>CJ</given-names></name><name><surname>Sherman</surname><given-names>MH</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Kremer</surname><given-names>D</given-names></name><name><surname>Hwang</surname><given-names>RF</given-names></name><name><surname>Witkiewicz</surname><given-names>AK</given-names></name><name><surname>Ying</surname><given-names>H</given-names></name><name><surname>Asara</surname><given-names>JM</given-names></name><name><surname>Evans</surname><given-names>RM</given-names></name><name><surname>Cantley</surname><given-names>LC</given-names></name><name><surname>Lyssiotis</surname><given-names>CA</given-names></name><name><surname>Kimmelman</surname><given-names>AC</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Pancreatic stellate cells support tumour metabolism through autophagic alanine secretion</article-title><source>Nature</source><volume>536</volume><fpage>479</fpage><lpage>483</lpage><pub-id pub-id-type="doi">10.1038/nature19084</pub-id><pub-id pub-id-type="pmid">27509858</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Steele</surname><given-names>NG</given-names></name><name><surname>Carpenter</surname><given-names>ES</given-names></name><name><surname>Kemp</surname><given-names>SB</given-names></name><name><surname>Sirihorachai</surname><given-names>VR</given-names></name><name><surname>The</surname><given-names>S</given-names></name><name><surname>Delrosario</surname><given-names>L</given-names></name><name><surname>Lazarus</surname><given-names>J</given-names></name><name><surname>Amir</surname><given-names>E-AD</given-names></name><name><surname>Gunchick</surname><given-names>V</given-names></name><name><surname>Espinoza</surname><given-names>C</given-names></name><name><surname>Bell</surname><given-names>S</given-names></name><name><surname>Harris</surname><given-names>L</given-names></name><name><surname>Lima</surname><given-names>F</given-names></name><name><surname>Irizarry-Negron</surname><given-names>V</given-names></name><name><surname>Paglia</surname><given-names>D</given-names></name><name><surname>Macchia</surname><given-names>J</given-names></name><name><surname>Chu</surname><given-names>AKY</given-names></name><name><surname>Schofield</surname><given-names>H</given-names></name><name><surname>Wamsteker</surname><given-names>E-J</given-names></name><name><surname>Kwon</surname><given-names>R</given-names></name><name><surname>Schulman</surname><given-names>A</given-names></name><name><surname>Prabhu</surname><given-names>A</given-names></name><name><surname>Law</surname><given-names>R</given-names></name><name><surname>Sondhi</surname><given-names>A</given-names></name><name><surname>Yu</surname><given-names>J</given-names></name><name><surname>Patel</surname><given-names>A</given-names></name><name><surname>Donahue</surname><given-names>K</given-names></name><name><surname>Nathan</surname><given-names>H</given-names></name><name><surname>Cho</surname><given-names>C</given-names></name><name><surname>Anderson</surname><given-names>MA</given-names></name><name><surname>Sahai</surname><given-names>V</given-names></name><name><surname>Lyssiotis</surname><given-names>CA</given-names></name><name><surname>Zou</surname><given-names>W</given-names></name><name><surname>Allen</surname><given-names>BL</given-names></name><name><surname>Rao</surname><given-names>A</given-names></name><name><surname>Crawford</surname><given-names>HC</given-names></name><name><surname>Bednar</surname><given-names>F</given-names></name><name><surname>Frankel</surname><given-names>TL</given-names></name><name><surname>Pasca di Magliano</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Multimodal mapping of the tumor and peripheral blood immune landscape in human pancreatic cancer</article-title><source>Nature Cancer</source><volume>1</volume><fpage>1097</fpage><lpage>1112</lpage><pub-id pub-id-type="doi">10.1038/s43018-020-00121-4</pub-id><pub-id pub-id-type="pmid">34296197</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Storz</surname><given-names>P</given-names></name><name><surname>Crawford</surname><given-names>HC</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Carcinogenesis of pancreatic ductal adenocarcinoma</article-title><source>Gastroenterology</source><volume>158</volume><fpage>2072</fpage><lpage>2081</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2020.02.059</pub-id><pub-id pub-id-type="pmid">32199881</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sullivan</surname><given-names>LB</given-names></name><name><surname>Gui</surname><given-names>DY</given-names></name><name><surname>Hosios</surname><given-names>AM</given-names></name><name><surname>Bush</surname><given-names>LN</given-names></name><name><surname>Freinkman</surname><given-names>E</given-names></name><name><surname>Vander Heiden</surname><given-names>MG</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Supporting aspartate biosynthesis is an essential function of respiration in proliferating cells</article-title><source>Cell</source><volume>162</volume><fpage>552</fpage><lpage>563</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2015.07.017</pub-id><pub-id pub-id-type="pmid">26232225</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sullivan</surname><given-names>LB</given-names></name><name><surname>Luengo</surname><given-names>A</given-names></name><name><surname>Danai</surname><given-names>LV</given-names></name><name><surname>Bush</surname><given-names>LN</given-names></name><name><surname>Diehl</surname><given-names>FF</given-names></name><name><surname>Hosios</surname><given-names>AM</given-names></name><name><surname>Lau</surname><given-names>AN</given-names></name><name><surname>Elmiligy</surname><given-names>S</given-names></name><name><surname>Malstrom</surname><given-names>S</given-names></name><name><surname>Lewis</surname><given-names>CA</given-names></name><name><surname>Vander Heiden</surname><given-names>MG</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Aspartate is an endogenous metabolic limitation for tumour growth</article-title><source>Nature Cell Biology</source><volume>20</volume><fpage>782</fpage><lpage>788</lpage><pub-id pub-id-type="doi">10.1038/s41556-018-0125-0</pub-id><pub-id pub-id-type="pmid">29941931</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sullivan</surname><given-names>MR</given-names></name><name><surname>Danai</surname><given-names>LV</given-names></name><name><surname>Lewis</surname><given-names>CA</given-names></name><name><surname>Chan</surname><given-names>SH</given-names></name><name><surname>Gui</surname><given-names>DY</given-names></name><name><surname>Kunchok</surname><given-names>T</given-names></name><name><surname>Dennstedt</surname><given-names>EA</given-names></name><name><surname>Vander Heiden</surname><given-names>MG</given-names></name><name><surname>Muir</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Quantification of microenvironmental metabolites in murine cancers reveals determinants of tumor nutrient availability</article-title><source>eLife</source><volume>8</volume><elocation-id>e44235</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.44235</pub-id><pub-id pub-id-type="pmid">30990168</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tape</surname><given-names>CJ</given-names></name><name><surname>Ling</surname><given-names>S</given-names></name><name><surname>Dimitriadi</surname><given-names>M</given-names></name><name><surname>McMahon</surname><given-names>KM</given-names></name><name><surname>Worboys</surname><given-names>JD</given-names></name><name><surname>Leong</surname><given-names>HS</given-names></name><name><surname>Norrie</surname><given-names>IC</given-names></name><name><surname>Miller</surname><given-names>CJ</given-names></name><name><surname>Poulogiannis</surname><given-names>G</given-names></name><name><surname>Lauffenburger</surname><given-names>DA</given-names></name><name><surname>Jørgensen</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Oncogenic kras regulates tumor cell signaling via stromal reciprocation</article-title><source>Cell</source><volume>165</volume><fpage>910</fpage><lpage>920</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2016.03.029</pub-id><pub-id pub-id-type="pmid">27087446</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tasdogan</surname><given-names>A</given-names></name><name><surname>Faubert</surname><given-names>B</given-names></name><name><surname>Ramesh</surname><given-names>V</given-names></name><name><surname>Ubellacker</surname><given-names>JM</given-names></name><name><surname>Shen</surname><given-names>B</given-names></name><name><surname>Solmonson</surname><given-names>A</given-names></name><name><surname>Murphy</surname><given-names>MM</given-names></name><name><surname>Gu</surname><given-names>Z</given-names></name><name><surname>Gu</surname><given-names>W</given-names></name><name><surname>Martin</surname><given-names>M</given-names></name><name><surname>Kasitinon</surname><given-names>SY</given-names></name><name><surname>Vandergriff</surname><given-names>T</given-names></name><name><surname>Mathews</surname><given-names>TP</given-names></name><name><surname>Zhao</surname><given-names>Z</given-names></name><name><surname>Schadendorf</surname><given-names>D</given-names></name><name><surname>DeBerardinis</surname><given-names>RJ</given-names></name><name><surname>Morrison</surname><given-names>SJ</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Metabolic heterogeneity confers differences in melanoma metastatic potential</article-title><source>Nature</source><volume>577</volume><fpage>115</fpage><lpage>120</lpage><pub-id pub-id-type="doi">10.1038/s41586-019-1847-2</pub-id><pub-id pub-id-type="pmid">31853067</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Titov</surname><given-names>DV</given-names></name><name><surname>Cracan</surname><given-names>V</given-names></name><name><surname>Goodman</surname><given-names>RP</given-names></name><name><surname>Peng</surname><given-names>J</given-names></name><name><surname>Grabarek</surname><given-names>Z</given-names></name><name><surname>Mootha</surname><given-names>VK</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Complementation of mitochondrial electron transport chain by manipulation of the NAD+/NADH ratio</article-title><source>Science</source><volume>352</volume><fpage>231</fpage><lpage>235</lpage><pub-id pub-id-type="doi">10.1126/science.aad4017</pub-id><pub-id pub-id-type="pmid">27124460</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vander Heiden</surname><given-names>MG</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Targeting cancer metabolism: a therapeutic window opens</article-title><source>Nature Reviews. Drug Discovery</source><volume>10</volume><fpage>671</fpage><lpage>684</lpage><pub-id pub-id-type="doi">10.1038/nrd3504</pub-id><pub-id pub-id-type="pmid">21878982</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vander Heiden</surname><given-names>MG</given-names></name><name><surname>DeBerardinis</surname><given-names>RJ</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Understanding the intersections between metabolism and cancer biology</article-title><source>Cell</source><volume>168</volume><fpage>657</fpage><lpage>669</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2016.12.039</pub-id><pub-id pub-id-type="pmid">28187287</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Viale</surname><given-names>A</given-names></name><name><surname>Pettazzoni</surname><given-names>P</given-names></name><name><surname>Lyssiotis</surname><given-names>CA</given-names></name><name><surname>Ying</surname><given-names>H</given-names></name><name><surname>Sánchez</surname><given-names>N</given-names></name><name><surname>Marchesini</surname><given-names>M</given-names></name><name><surname>Carugo</surname><given-names>A</given-names></name><name><surname>Green</surname><given-names>T</given-names></name><name><surname>Seth</surname><given-names>S</given-names></name><name><surname>Giuliani</surname><given-names>V</given-names></name><name><surname>Kost-Alimova</surname><given-names>M</given-names></name><name><surname>Muller</surname><given-names>F</given-names></name><name><surname>Colla</surname><given-names>S</given-names></name><name><surname>Nezi</surname><given-names>L</given-names></name><name><surname>Genovese</surname><given-names>G</given-names></name><name><surname>Deem</surname><given-names>AK</given-names></name><name><surname>Kapoor</surname><given-names>A</given-names></name><name><surname>Yao</surname><given-names>W</given-names></name><name><surname>Brunetto</surname><given-names>E</given-names></name><name><surname>Kang</surname><given-names>Y</given-names></name><name><surname>Yuan</surname><given-names>M</given-names></name><name><surname>Asara</surname><given-names>JM</given-names></name><name><surname>Wang</surname><given-names>YA</given-names></name><name><surname>Heffernan</surname><given-names>TP</given-names></name><name><surname>Kimmelman</surname><given-names>AC</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Fleming</surname><given-names>JB</given-names></name><name><surname>Cantley</surname><given-names>LC</given-names></name><name><surname>DePinho</surname><given-names>RA</given-names></name><name><surname>Draetta</surname><given-names>GF</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function</article-title><source>Nature</source><volume>514</volume><fpage>628</fpage><lpage>632</lpage><pub-id pub-id-type="doi">10.1038/nature13611</pub-id><pub-id pub-id-type="pmid">25119024</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wiederschain</surname><given-names>D</given-names></name><name><surname>Wee</surname><given-names>S</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Loo</surname><given-names>A</given-names></name><name><surname>Yang</surname><given-names>G</given-names></name><name><surname>Huang</surname><given-names>A</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Caponigro</surname><given-names>G</given-names></name><name><surname>Yao</surname><given-names>YM</given-names></name><name><surname>Lengauer</surname><given-names>C</given-names></name><name><surname>Sellers</surname><given-names>WR</given-names></name><name><surname>Benson</surname><given-names>JD</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Single-vector inducible lentiviral RNAi system for oncology target validation</article-title><source>Cell Cycle</source><volume>8</volume><fpage>498</fpage><lpage>504</lpage><pub-id pub-id-type="doi">10.4161/cc.8.3.7701</pub-id><pub-id pub-id-type="pmid">19177017</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>L</given-names></name><name><surname>Garcia Canaveras</surname><given-names>JC</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Liang</surname><given-names>L</given-names></name><name><surname>Jang</surname><given-names>C</given-names></name><name><surname>Mayr</surname><given-names>JA</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Ghergurovich</surname><given-names>JM</given-names></name><name><surname>Zhan</surname><given-names>L</given-names></name><name><surname>Joshi</surname><given-names>S</given-names></name><name><surname>Hu</surname><given-names>Z</given-names></name><name><surname>McReynolds</surname><given-names>MR</given-names></name><name><surname>Su</surname><given-names>X</given-names></name><name><surname>White</surname><given-names>E</given-names></name><name><surname>Morscher</surname><given-names>RJ</given-names></name><name><surname>Rabinowitz</surname><given-names>JD</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Serine catabolism feeds nadh when respiration is impaired</article-title><source>Cell Metabolism</source><volume>31</volume><fpage>809</fpage><lpage>821</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2020.02.017</pub-id><pub-id pub-id-type="pmid">32187526</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ying</surname><given-names>H</given-names></name><name><surname>Kimmelman</surname><given-names>AC</given-names></name><name><surname>Lyssiotis</surname><given-names>CA</given-names></name><name><surname>Hua</surname><given-names>S</given-names></name><name><surname>Chu</surname><given-names>GC</given-names></name><name><surname>Fletcher-Sananikone</surname><given-names>E</given-names></name><name><surname>Locasale</surname><given-names>JW</given-names></name><name><surname>Son</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Coloff</surname><given-names>JL</given-names></name><name><surname>Yan</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Chen</surname><given-names>S</given-names></name><name><surname>Viale</surname><given-names>A</given-names></name><name><surname>Zheng</surname><given-names>H</given-names></name><name><surname>Paik</surname><given-names>J</given-names></name><name><surname>Lim</surname><given-names>C</given-names></name><name><surname>Guimaraes</surname><given-names>AR</given-names></name><name><surname>Martin</surname><given-names>ES</given-names></name><name><surname>Chang</surname><given-names>J</given-names></name><name><surname>Hezel</surname><given-names>AF</given-names></name><name><surname>Perry</surname><given-names>SR</given-names></name><name><surname>Hu</surname><given-names>J</given-names></name><name><surname>Gan</surname><given-names>B</given-names></name><name><surname>Xiao</surname><given-names>Y</given-names></name><name><surname>Asara</surname><given-names>JM</given-names></name><name><surname>Weissleder</surname><given-names>R</given-names></name><name><surname>Wang</surname><given-names>YA</given-names></name><name><surname>Chin</surname><given-names>L</given-names></name><name><surname>Cantley</surname><given-names>LC</given-names></name><name><surname>DePinho</surname><given-names>RA</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism</article-title><source>Cell</source><volume>149</volume><fpage>656</fpage><lpage>670</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2012.01.058</pub-id><pub-id pub-id-type="pmid">22541435</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>D</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Shi</surname><given-names>Z</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Sun</surname><given-names>P</given-names></name><name><surname>Hou</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Zhao</surname><given-names>S</given-names></name><name><surname>Zhou</surname><given-names>BP</given-names></name><name><surname>Mi</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Metabolic reprogramming of cancer-associated fibroblasts by IDH3α downregulation</article-title><source>Cell Reports</source><volume>10</volume><fpage>1335</fpage><lpage>1348</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2015.02.006</pub-id><pub-id pub-id-type="pmid">25732824</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Crawford</surname><given-names>HC</given-names></name><name><surname>Pasca di Magliano</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Epithelial-stromal interactions in pancreatic cancer</article-title><source>Annual Review of Physiology</source><volume>81</volume><fpage>211</fpage><lpage>233</lpage><pub-id pub-id-type="doi">10.1146/annurev-physiol-020518-114515</pub-id><pub-id pub-id-type="pmid">30418798</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>H</given-names></name><name><surname>Yang</surname><given-names>L</given-names></name><name><surname>Baddour</surname><given-names>J</given-names></name><name><surname>Achreja</surname><given-names>A</given-names></name><name><surname>Bernard</surname><given-names>V</given-names></name><name><surname>Moss</surname><given-names>T</given-names></name><name><surname>Marini</surname><given-names>JC</given-names></name><name><surname>Tudawe</surname><given-names>T</given-names></name><name><surname>Seviour</surname><given-names>EG</given-names></name><name><surname>San Lucas</surname><given-names>FA</given-names></name><name><surname>Alvarez</surname><given-names>H</given-names></name><name><surname>Gupta</surname><given-names>S</given-names></name><name><surname>Maiti</surname><given-names>SN</given-names></name><name><surname>Cooper</surname><given-names>L</given-names></name><name><surname>Peehl</surname><given-names>D</given-names></name><name><surname>Ram</surname><given-names>PT</given-names></name><name><surname>Maitra</surname><given-names>A</given-names></name><name><surname>Nagrath</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Tumor microenvironment derived exosomes pleiotropically modulate cancer cell metabolism</article-title><source>eLife</source><volume>5</volume><elocation-id>e10250</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.10250</pub-id><pub-id pub-id-type="pmid">26920219</pub-id></element-citation></ref></ref-list></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.73245.sa0</article-id><title-group><article-title>Editor's evaluation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Finley</surname><given-names>Lydia WS</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02yrq0923</institution-id><institution>Memorial Sloan Kettering Cancer Center</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><related-object id="sa0ro1" object-id-type="id" object-id="10.1101/2020.08.07.238766" link-type="continued-by" xlink:href="https://sciety.org/articles/activity/10.1101/2020.08.07.238766"/></front-stub><body><p>This paper provides evidence that the environmental redox state shapes metabolic liabilities in pancreatic cancer cells. In vitro, pancreatic cancer cells rely on the malate-aspartate shuttle to regenerate oxidized electron acceptors in the cytosol that are required for cell proliferation; stromal cells within tumors secrete metabolites that serve as alternate electron acceptors, thereby reducing cancer cell reliance on the malate-aspartate shuttle.</p></body></sub-article><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.73245.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Finley</surname><given-names>Lydia WS</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02yrq0923</institution-id><institution>Memorial Sloan Kettering Cancer Center</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group></front-stub><body><boxed-text id="sa2-box1"><p>Our editorial process produces two outputs: i) <ext-link ext-link-type="uri" xlink:href="https://sciety.org/articles/activity/10.1101/2020.08.07.238766">public reviews</ext-link> designed to be posted alongside <ext-link ext-link-type="uri" xlink:href="https://www.biorxiv.org/content/10.1101/2020.08.07.238766v3">the preprint</ext-link> for the benefit of readers; ii) feedback on the manuscript for the authors, including requests for revisions, shown below. We also include an acceptance summary that explains what the editors found interesting or important about the work.</p></boxed-text><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;GOT2 is Dispensable for Pancreatic Tumor Growth&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by 3 peer reviewers, one of whom is a member of our Board of Reviewing Editors, and the evaluation has been overseen by Richard White as the Senior Editor. The reviewers have opted to remain anonymous.</p><p>The reviewers have discussed their reviews with one another, and the Reviewing Editor has drafted this to help you prepare a revised submission.</p><p>Essential revisions:</p><p>1. The authors should restructure the manuscript. The major issue is that all experiments to probe the role of pyruvate import and reduction to lactate in vivo provide negative results. While all reviewers commended the authors for including the data, and agreed that other factors could contribute to these negative results, at present there is no reason to conclude that environmental pyruvate and/or changes in redox state enable tumors to grow in vivo without GOT2. If anything, MCT1 depletion seems to promote tumor growth, arguing against the favored hypothesis. Alternative explanations, such as a potentially reduced reliance on glutamine for TCA cycle anaplerosis in vivo, are not considered. Therefore, the central conclusion of the manuscript remains largely unsupported. Absent supportive evidence, the manuscript should be largely restructured to remove any claims as to the role of the TME supporting redox homeostasis in cells lacking GOT2 in vivo. The authors perhaps could refocus the manuscript to show how their data provide a striking example of how the metabolic dependencies identified in culture may not translate to the complex microenvironment of tumors, as suggested by Reviewer #2. All reviewers agreed that it is very important that the authors ensure it is clear in abstract and other places that it remains unresolved whether CAFs actually contribute to redox balance in the tumor, even though they hold this potential as shown in the cell culture experiments.</p><p>2. Overall, alternative explanations are not often tested. For example, the experiments showing that pyruvate and LbNOX rescue GOT2 deficiency are interesting and certainly support the notion that cytosolic redox is limiting for proliferation following GOT2 deficiency. However, an important control is assessing whether these interventions rescue any metabolic consequences of GOT2 loss (e.g. aspartate, glutamine anaplerosis, etc). This point is important as Extended Data 4d shows a nearly identical rescue between pyruvate and αKG+asp, aside from one replicate being higher. Similarly, the conditioned medium and pyruvate rescues are very clear, but the aKB and LbNOX are more partial and the LDH inhibitor effect is fairly modest. Is pyruvate doing something more in addition to impacting redox homeostasis?</p><p>3. Related, the authors should also test whether macropinocytosis, known to be important in PDAC tumors in vivo, can compensate for GOT2 loss. Perhaps macropinocytosis is impaired in culture due to lack of protein availability (or other environmental causes) rendering cells sensitive to GOT2 loss, but activation of macropinocytosis in vivo may cause GOT2 to be dispensable. Have the authors investigated if macropinocytosis and GOT2 metabolism are two parallel paths of nutrient sufficiency? For example, would additional BSA rescue GOT2-deficient cells in vitro? Linking the phenotypes of GOT2 deficient cells with the pancreatic cancer macropinocytosis literature would considerably increase the impact of this work.</p><p>4. What is the relative concentration of pyr/lac in conditioned medium in vitro, and in the serum/TME in vivo? Of note, authors mention that mouse plasma has ~250 μm pyruvate, but the same study (Sullivan et al. 2019) found that tumor interstitial fluid had quite a bit less pyruvate than plasma. It is possible that lactate is much more abundant than pyruvate, and so the relative degree to which the pyruvate/lactate exposure in CM can be net oxidizing remains untested. This becomes even more important given the finding that MCT1 depletion seems to enhance tumor growth. To address this point, the authors could measure pyruvate and lactate in CAF conditioned media and test if adding pyr/lac at these relevant levels is sufficient to rescue GOT2 loss.</p><p>5. To what extent does MCT1 KO block pyruvate uptake? Are there any changes in MCT4 expression upon MCT1 KO? If feasible, it would be nice to see whether a double MCT1/4 KO would prevent tumor growth in the context of GOT2 KD, but this latter experiment is not necessary for publication.</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.73245.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential revisions:</p><p>1. The authors should restructure the manuscript. The major issue is that all experiments to probe the role of pyruvate import and reduction to lactate in vivo provide negative results. While all reviewers commended the authors for including the data, and agreed that other factors could contribute to these negative results, at present there is no reason to conclude that environmental pyruvate and/or changes in redox state enable tumors to grow in vivo without GOT2. If anything, MCT1 depletion seems to promote tumor growth, arguing against the favored hypothesis. Alternative explanations, such as a potentially reduced reliance on glutamine for TCA cycle anaplerosis in vivo, are not considered. Therefore, the central conclusion of the manuscript remains largely unsupported. Absent supportive evidence, the manuscript should be largely restructured to remove any claims as to the role of the TME supporting redox homeostasis in cells lacking GOT2 in vivo. The authors perhaps could refocus the manuscript to show how their data provide a striking example of how the metabolic dependencies identified in culture may not translate to the complex microenvironment of tumors, as suggested by Reviewer #2. All reviewers agreed that it is very important that the authors ensure it is clear in abstract and other places that it remains unresolved whether CAFs actually contribute to redox balance in the tumor, even though they hold this potential as shown in the cell culture experiments.</p></disp-quote><p>We agree with this important critique of the previous manuscript, and we appreciate the associated suggestions on how to reframe our work. Herein, we have restructured the manuscript to emphasize the redox mechanism involving GOT2 knockdown (KD) in vitro, and we have reframed our results to highlight differences between in vitro and in vivo metabolism. A section in the discussion on previous work investigating glutamine metabolism in vitro versus in vivo has also been added (lines 387-392). The language regarding the role of the TME in maintaining redox balance has been appropriately tempered, and, rather, we posit in the discussion that the proposed mechanism could be one of several potential mechanisms driving GOT2 independent growth in vivo. Further, we have made sure to clearly detail in the abstract, text accompanying associated experiments, as well as in the discussion (line 429-430), that the role of CAFs in redox balance in vivo remains to be investigated. Finally, we have rewritten the abstract to (i) focus on the in vitro work identifying how GOT2 KD induces NADH stress, a role we think has been previously overshadowed due to justifiable interest in aspartate metabolism, and (ii) illustrate the complexity of in vivo metabolism, especially for essential metabolic concepts like redox balance.</p><disp-quote content-type="editor-comment"><p>2. Overall, alternative explanations are not often tested. For example, the experiments showing that pyruvate and LbNOX rescue GOT2 deficiency are interesting and certainly support the notion that cytosolic redox is limiting for proliferation following GOT2 deficiency. However, an important control is assessing whether these interventions rescue any metabolic consequences of GOT2 loss (e.g. aspartate, glutamine anaplerosis, etc). This point is important as Extended Data 4d shows a nearly identical rescue between pyruvate and αKG+asp, aside from one replicate being higher. Similarly, the conditioned medium and pyruvate rescues are very clear, but the aKB and LbNOX are more partial and the LDH inhibitor effect is fairly modest. Is pyruvate doing something more in addition to impacting redox homeostasis?</p></disp-quote><p>This is absolutely an important point, and we appreciate the opportunity to include the necessary control data. Herein we provide new metabolomics data from GOT2KD + EV, LbNOX, or mLbNOX. These data illustrate that LbNOX, but not mLbNOX, resolves the NADH/NAD imbalance (Figure 2H, Figure 2—figure supplement 2D). Similarly, the secreted pyruvate/lactate ratio indicates specificity for the cytosolic pools (Figure 2—figure supplement 2E,F). In parallel, we observe that LbNOX, but not mLbNOX, rescues the metabolic defects observed with GOT2 KD. The stalled glycolytic signature is reversed, TCA cycle metabolite levels are corrected, and both Asp and αKG levels increase (Figure 2—figure supplement 2G).</p><p>To address the rescue discrepancy between the pyruvate and Asp+αKG rescues, we repeated the experiment using serum concentrations reported in mice (PMC6510537); i.e. pyruvate (250 µM), Asp (50 µM), and αKG (500 µM). For αKG, we employed the esterified dimethyl-αKG analog to increase the intracellular availability. Here, we again demonstrate that pyruvate rescued to a greater extent than Asp+αKG (Figure 5—figure supplement 2B). Considering these levels of Asp and αKG reported in mouse serum are significantly higher than those measured in CAF CM, we conclude that Asp+αKG are not the responsible components of CAF CM for rescue activity. That said, we do find that supraphysiological Asp (20 mM) and dimethyl-αKG (1 mM) rescue GOT2 KD growth (Figure 1F).</p><p>We also repeated the αKB (Figure 2F) and LbNOX GOT2 KD (Figure 2G) rescue experiments to show the extent to which these interventions promote proliferation compared to pyruvate.</p><p>Lastly, we repeated the FX11+GOT2 KD rescue experiments with pyruvate to demonstrate that FX11 strongly inhibits the pyruvate-mediated rescue of GOT2 KD in vitro (Figure 6H).</p><p>Collectively, these data continue to support our model that the primary in vitro mechanism by which pyruvate rescues GOT2 KD is via NADH turnover, through LDHA, which reverses reductive stress and allows cellular metabolism to resume. In further support of this model, our 13C3-Pyruvate tracing data presented in Figure 2I-K show that supplemented pyruvate is rapidly converted to lactate in GOT2 KD cells. Importantly, while blocking pyruvate entry to the mitochondria via MPC inhibition with UK5099 decreases pyruvate carbon incorporation into the TCA cycle (Figure 2—figure supplement 3B-D), this has no effect on the GOT2 KD rescue of pyruvate supplementation (Figure 2—figure supplement 3E). These data suggest that the activity of pyruvate is non-mitochondrial. We also show data to suggest that pyruvate conversion to lactate (Figure 2—figure supplement 3F) or alanine (Figure 2—figure supplement 3G) is not relevant for our mechanism, as these metabolites provide no rescue activity to GOT2 KD cells.</p><disp-quote content-type="editor-comment"><p>3. Related, the authors should also test whether macropinocytosis, known to be important in PDAC tumors in vivo, can compensate for GOT2 loss. Perhaps macropinocytosis is impaired in culture due to lack of protein availability (or other environmental causes) rendering cells sensitive to GOT2 loss, but activation of macropinocytosis in vivo may cause GOT2 to be dispensable. Have the authors investigated if macropinocytosis and GOT2 metabolism are two parallel paths of nutrient sufficiency? For example, would additional BSA rescue GOT2-deficient cells in vitro? Linking the phenotypes of GOT2 deficient cells with the pancreatic cancer macropinocytosis literature would considerably increase the impact of this work.</p></disp-quote><p>We recognize the importance of this suggestion. As we now discuss in lines 416-418, macropinocytosis could be an in vivo mechanism by which cells obtain Asp or pyruvate, though it should be noted that we observe significantly reduced Asp levels in vivo (Figure 3E). Indeed, we and others have demonstrated that macropinocytosis is highly active in PDA cell lines in vitro (PMC8730721, PMC3810415). In standard culture conditions, our PDA cells are maintained in 10% FBS, providing adequate protein for these purposes. Despite high basal macropinocytosis and adequate protein, we still see a strong GOT2 KD phenotype in vitro.</p><p>That said, we appreciate the spirit of suggestion, and to test this possibility, we cultured GOT2 KD cells in +/- 2% BSA, conditions that rescue glutamine deprivation in PDA cells via micropinocytosis (PMC3810415). BSA did not provide a growth rescue of GOT2 KD (Figure 6—figure supplement 3C).</p><p>We would like to reiterate that we are not ruling out the possibility that macropinocytosis could compensate for GOT2 loss in vivo. Nevertheless, we have included these BSA rescue data and the indicated section in the discussion because macropinocytosis is clearly an important mechanism for nutrient acquisition in PDA.</p><disp-quote content-type="editor-comment"><p>4. What is the relative concentration of pyr/lac in conditioned medium in vitro, and in the serum/TME in vivo? Of note, authors mention that mouse plasma has ~250 μm pyruvate, but the same study (Sullivan et al. 2019) found that tumor interstitial fluid had quite a bit less pyruvate than plasma. It is possible that lactate is much more abundant than pyruvate, and so the relative degree to which the pyruvate/lactate exposure in CM can be net oxidizing remains untested. This becomes even more important given the finding that MCT1 depletion seems to enhance tumor growth. To address this point, the authors could measure pyruvate and lactate in CAF conditioned media and test if adding pyr/lac at these relevant levels is sufficient to rescue GOT2 loss.</p></disp-quote><p>We appreciate this excellent suggestion. To test the rescue activity of pyruvate and pyruvate to lactate ratios at context relevant concentrations, we first determined the absolute concentration of pyruvate and lactate in CAF CM (Figure 6A) and mouse serum and TIF (Figure 6B). We did not observe a significant difference in pyruvate levels between TIF and serum in this model, though we did detect a significant increase in lactate, as would be expected in a tumor. Next, we supplemented growth media with the measured concentration of pyruvate and lactate in CAF CM, serum, and TIF to artificially recreate the pyruvate/lactate ratios of these environments. Each of these levels and ratios promoted growth of GOT2 KD cells in vitro, effectively in a manner akin to pyruvate alone (Figure 6C).</p><disp-quote content-type="editor-comment"><p>5. To what extent does MCT1 KO block pyruvate uptake?</p></disp-quote><p>To determine the impact of MCT1 KO on pyruvate uptake, we incubated MCT1-expressing (EV) or MCT1 KO (sg1, sg2) cells with 13C3-Pyruvate and measured intracellular pyruvate and lactate by LC-MS/MS over a 5 minute window, a well appreciated time frame for pyruvate uptake/metabolism by the hyperpolarization community (PMID: 29769199, PMID: 32466260). First, we observed a decrease in labelled pyruvate in MCT1 KO cells (Figure 6G). While we washed the cells of media (and label) prior to collection, we put forth that the modest difference in labeled pyruvate results from media contamination. Indeed, as is far more evident, we observed substantially less labelled lactate in MCT1 KO cells (Figure 6G), a reflection of both pyruvate uptake and NADH turnover. These data confirm that MCT1 KO impairs pyruvate metabolism in PDA cell lines.</p><disp-quote content-type="editor-comment"><p>Are there any changes in MCT4 expression upon MCT1 KO?</p></disp-quote><p>While GOT2 KD MCT1 KO flank xenografts do express MCT4, we did not observe a further compensatory increase in MCT4 (Figure 6—figure supplement 2F). Similarly, we also do not observe an increase in MCT4 expression in MCT1 KO cell lines in vitro (Figure 6—figure supplement 2G).</p><disp-quote content-type="editor-comment"><p>If feasible, it would be nice to see whether a double MCT1/4 KO would prevent tumor growth in the context of GOT2 KD, but this latter experiment is not necessary for publication.</p></disp-quote><p>We agree with the referee that this is an excellent experiment. While we do not test dual inhibition of MCT1 and MCT4 in GOT2 KD flank xenografts in this study, we do discuss this mechanism in lines 392-397.</p></body></sub-article></article>